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GENERAL INTRODUCTION 
Kynurenine aminotransferase (KAT) is a pyridoxal 5’-phosphate dependent enzyme, which catalyzes the 
irreversible transamination of L-kynurenine (KYN) to produce kynurenic acid (KYNA). KYN is the central 
metabolite in the Kynurenine pathway (KP), the main tryptophan degradation pathway in most living 
organisms. The scientific interest in KP is unceasing because some of its enzymes and metabolites 
(kynurenines) mediate relevant physiological functions and associated pathological states of the immune and 
nervous systems. In particular, KYNA is a neuroinhibitory metabolite of the KP, acting as a broad-spectrum 
endogenous antagonist of ionotropic excitatory amino acid receptors and 7 nicotinic acetylcholine 
receptors, which are involved in cognitive functions like learning and memory. Since these antagonistic 
effects are seen at KYNA concentrations found in the mammalian brain, elevations in the brain KYNA has 
been hypothesized as an important factor contributing to the pathogenesis and progression of neurological 
or psychiatric diseases that are associated to cognitive impairment, including schizophrenia and Alzheimer’s 
disease. In human and rodent brains four proteins named KAT I, II, III and IV, have been reported to be 
involved in KYNA synthesis. In view of its biochemical properties, KAT II is the prevalent isoform responsible 
for KYN degradation in mammalian brain to give KYNA. Therefore, human KAT II is a potential drug target in 
the treatment of neurophatological conditions characterized by a glutamatergic and cholinergic hypofunction 
related to an excess of KYNA, like Schizophrenia and Alzheimer’s disease. Despite hKAT II is considered a 
potential regulatory target for maintaining physiological concentrations of KYNA, a thorough biochemical 
characterization of this enzyme is still missing. The principal aim of this study was a detailed assessment of 
hKAT II in regards its biochemical and functional characteristics. In particular, the activity of hKAT II towards 
the natural substrates kynurenine and -aminoadipate, and the inhibitors (R)-2-amino-4-(4-(ethylsulfonyl)-4-
oxobutanoic acid and sulfinic acid was investigated. Moreover, we determined for the first time the intrinsic -
lytic activity towards the substrate analog -chloroalanine of hKAT II and a variant carrying the Y142F 
mutation, expected, on the basis of structural evaluations, to exhibit a decreased propensity for -elimination, 
a side reaction common to transaminases. The biochemical investigation has allowed us to develop two 
efficient and rapid assays to screen hKAT II inhibitors: i) a continuous assay based on the absorbance of the 
natural substrate L-KYN, that allows fast measurement of enzyme activity and determination of inhibition 
mechanisms; and ii) a 96-well plate suited, end-point assay based on the coupling of hKAT II activity to two 
reporter reactions. These assays are of interest in the high-throughput screening for specific hKAT II 
inhibitors. The availability of these assays and a detailed spectroscopic analysis allowed to demonstrate that 
(R)-2-amino-4-(4-(ethylsulfonyl)-4-oxobutanoic acid and sulfinic acid, reported to be selective and potent rat 
KAT II inhibitors, are actually substrate for the human ortholog, rather than pure competitive inhibitors. As a 
part of the activities carried out during the thesis, we carried out attemps to increase the expression yield of 
soluble hKAT II. Recombinant expression of hKAT II was investigated by a novel culture method, called 
EnBase
TM
, or enzyme-based-substrate-delivery (BioSilta). EnBase
TM
 (BioSilta) is an enhanced novel 
microbial culture system in which enzyme-based supply of glucose allows a glucose-limited growth, providing 
high cell densities and high recombinant protein yields. The avaibility of higher amounts of hKAT II, together 
with the tools developed for the high-throughput screening of hKAT II specific inhibitors will be useful in the 
development of novel drugs for cognitive dysfunction.  
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CHAPTER 1 
 
 INTRODUCTION 
 
The kynurenine pathway 
In mammalian tissues, the most important route of non proteinogenic tryptophan metabolism is the 
“Kynurenine Pathway” (1) (KP; Scheme 1), a cascade of enzymatic steps which convert tryptophan 
to nicotinamide adenine dinucleotide (NAD) (2). The term “Kynurenine Pathway” is derived from 
the central metabolite L-kynurenine (L-KYN) and is different from the use of tryptophan for the 
formation of the neurotransmitter serotonin and the related neurohormone melatonin (3). In 
humans the KP occurs both peripherally and centrally and involves many enzymes, including two 
heme-dependent enzymes, indoleamine-2,3-dioxygenase(4) (IDO; EC: 1.13.11.52) and 
tryptophan-2,3-dioxygenase(5) (TDO; EC 1.13.11.11), which catalyze the oxidative ring opening of 
tryptophan. They differ in their tissue localization and regulation(6). TDO is predominantly 
expressed in the liver, constitutes the major source of KYN in non-inflammatory conditions, and is 
activated by glucocortinoids (7). IDO is present both in brain (neurons, glial cells) and in peripheral 
tissues (8) and is stimulated by proinflammatory cytokines (9). The product of this reaction is 
formyl-kynurenine, which is further degraded  to KYN by  kynurenine formylase (10). KYN can be 
further metabolized by three different enzymes: kynurenine 3-monooxygenase (KMO), yielding 3-
hydroxykynurenine (3-HKYN), kynureninase which forms anthranilic acid (HANA) and kynurenine 
aminotransferase (KAT) which catalyzes the transamination of KYN to a side chain keto acid  
intermediate which spontaneously undergoes to an intramolecular cyclization yielding  kynurenic 
acid (KYNA) (11). The transamination reaction which forms KYNA is irreversible and constitutes a 
dead-end arm of the KP, since there is no enzyme that further metabolises KYNA. 3-HK is 
metabolized by the same KATs to yield xanthurenic acid, another metabolic inert side product of 
the pathway, or by kynureninase to give rise to 3-hydroxyanthranilic acid. 3-hydroxyanthranilic acid 
3,4 dioxygenase then converts 3-hydroxyanthranilic acid to -amino- -carboxymuconic acid 
semialdehyde, which either rearranges non enzimatically to form quinolinic acid (QUIN), or serves 
as a substrate for 2-amino-3-carboxymuconic acid semialdehyde decarboxylase yielding picolinic 
acid and its downstream metabolites. Finally, QUIN is metabolized by quinolinic acid 
phosphoribosyltransferase, yielding nicotinic acid mononucleotide and subsequent degradation 
products including the end product NAD+. 
All the enzymes required for this catabolic cascade are present in the brain (12), but their cerebral 
activity is much lower than in the peripheral organs such as the liver and kidney (13, 14). Indeed, 
the KP mainly occurs in systemic tissues, especially in the liver, while most of the tryptophan in the 
CNS is converted to indolamines or utilized in protein synthesis (15). The activities of both TDO 
and IDO in the brain are normally very low under regular physiological conditions, thus the cerebral 
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KP pathway is driven mainly by blood-derived KYN, which can readily cross the blood-brain barrier 
(BBB) by using the same tryptophan neutral amino acid transporter (12, 16). However, unlike 
tryptophan, which serves as a substrate for serotonine biosynthesis in neurons, brain KYN is 
preferentially metabolized in astrocytes and microglial cells. Indeed, in mammalian brain all 
enzymes of the KP are primarily expressed in astrocytes and/or in microglial cells, rather than in 
neurons. As brain KYN derives to a significant extent (about 60%) (17) from the peripheral 
circulation, fluctuations in peripheral KYN formation have significant influence on brain kynurenines 
formation. 
 
 
Scheme 1. Kynurenine pathway in mammalian cells. 
 
Blood-borne KYN, after entering the brain from the periphery, is sequestrated into either astrocytes 
or microglia for further degradation. In the brain, the subsequent intracellular degradation of KYN is 
primarily dictated by the differential distribution of individual KP’s enzymes in astrocytes and 
microglial cells (12, 18-20). Astrocytes do not appear to contain kynurenine 3-monooxygenase and 
therefore favour KYNA synthesis, whereas microglial cells possess very little KAT activity and 
preferentially form intermediates of the QUIN branch of the pathway (20). In the brain the formation 
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of KYNA and QUIN is therefore spatially separated: in astrocytes KYN is irreversibly transaminated 
to KYNA (the “KYNA branch” of the KP), which cannot be metabolized further intracellularly, but is 
promptly released from the cell. In contrast, 3-HK and its downstream product QUIN are 
preferentially synthesized in microglial cells and then further degraded enzymatically  (the “QUIN 
branch” of the KP). This cellular compartimentalization probably accounts for the fact that no 
functional interaction between the two KP arms are observed when either KAT or KMO are 
specifically inhibited. The independence of the two branches of the KP is maintained under both 
physiological and pathological conditions (21). 
The levels of brain kynurenines are often abnormal as a result of pathogenic events (22). Cerebral 
KP metabolism is always stimulated in response to physical injury, resulting in the rapid up-
regulation of QUIN, 3-HK and KYNA formation (12). Inflammatory conditions, such as viral 
invasion, presence of bacterial lipopolysaccarides or interferon stimulation are accompanied by an 
increased activity of indoleamine 2,3-dioxygenase and kynurenine hydroxylase, causing 
substantial increases in the production of kynurenine (18, 23). Substantial (often 100- to 1000-fold) 
elevations in 3-HK and QUIN are seen when microglial cells are activated or when macrophages 
infiltrate the brain during immunological impairment, such as viral or other infections, 
neuroinflammation or ischemic and traumatic conditions (24). Because of the very low KAT activity 
in microglia and other cells of monocyte origin, the synthesis of KYNA is less affected (13). 
Kynurenine 3-monooxygenase (KMO), which converts L-KYN to 3-hydroxykynurenine along the 
“QUIN branch” of the KP, is increasingly viewed as a major gatekeeper of the kynurenine pathway 
(25). This enzyme shows much higher activity in peripheral tissues than in the brain. Because of its 
low Km for KYN (approximately 20 μM), this microglial enzyme is more rapidly saturated by brain 
KYN concentrations than astrocytic KATs (Km values: 4 mM) (26). It follows that cerebral KMO 
exerts preferential control over the fate of KYN within the brain.  
Qualitatively, the characteristics of enzymes along the “QUIN branch” of the pathway does not 
appear to differ between the brain and the periphery. Moreover, kynurenine 3-monooxygenase, 
kynureninase, 3-hydroxyanthranilic acid oxygenase and quinolinc acid phosphoribosyltransferase 
present in the brain have been confirmed to be identical with those expressed in the periphery, 
using specific antibodies and molecular cloning (13). On the contrary, comparison of peripheral 
and central nervous system (CNS) KATs reveals a more complex picture since peripheral organs 
contains several aminotransferases capable of forming KYNA from L-KYN (27), whereas L-KYN 
transamination to produce KYNA in the CNS of mammals  is carried out by four distinct enzymes,  
KAT I, II, III and  IV, constituting the KATs family (28-32). Although all the four isoforms are present 
in the mammalian brain to a different extent, only KAT I and KAT II have been thoroughly 
characterized with regard to their role in cerebral KYNA synthesis (33, 34). This two isoforms differ, 
in particular, by substrate specificity, with KAT I showing a lower substrate specificity than KAT II 
for L-KYN (33). Moreover, the intrinsic catalytic promiscuity of KAT I is enhanced by its -lyase 
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activity (35, 36). Therefore,  KAT II  has been considered the principal isoform responsible for the 
synthesis of KYNA in the rodent and human brain (33, 34, 37).  
 
Physiological relevance of kynurenines  
In the periphery, the role of the KP appears to be primarily directed toward the maintenance of 
NAD homeostasis, with other KP metabolites excreted unchanged in high concentrations in the 
urine (13), hence the collective term “kynurenines” for KP metabolites. Although all kynurenines 
are found in high concentration in urine, none of them has so far been assigned a relevant 
physiological function in peripheral organs (13). Instead, in mammalian CNS the KP is of particular 
biological interest because it leads to four neuroactive metabolites: KYNA and QUIN, which exert 
respectively neuroinhibitory and neuroexcitatory activity through interaction with glutamate and 
nicotinic receptors, and  3-HKYN and HANA, which promote neuronal damage by generating 
neurotoxic free radicals. The synthesis of these neuroactive kynurenines within the CNS has been 
implicated not only in mediating several physiological functions of the nervous systems, but also in 
the pathogenesis of different neurological disorders (11, 14). The first indication that kynurenines 
might play a role in the brain was provided by Lapin (38) (1978), who noted convulsion after an 
intracerebral injection of QUIN in mice. Soon thereafter, ionophoretically applied QUIN was found 
to excite rat cortical neurons (39), and intracerebrally injected QUIN was shown to cause 
excitotoxic lesions in rat brain (40, 41). In the last decades the physiophatological effects of 
neuroactive kynurenines have been intensively investigated. Neuroactive metabolites of tryptophan 
along the KP have been implicated in the pathophysiology of a variety of neurological and 
psychiatric diseases (13, 42) either chronic like Alzheimer’s (43), Parkinson’s (44) and Huntington’s 
disease (45, 46), Schizophrenia and cognitive impairment (47-50), Multiple sclerosis (51), 
Amyotropic lateral sclerosis (52), or caused by acute insult like ischemia, stroke and head trauma 
(13).  
Among the neuroactive kynurenines, KYNA has recently received most of the attention. Indeed, it 
has been demonstrated by in vivo studies that KYNA participates in normal brain function as 
endogenous modulator of excitatory neurotransmission (53, 54). Most physiological effects 
associates with KYNA, including neuroprotective properties, have been attributed to its 
antagonistic activity on ionotropic glutamate and 7 nicotinic acetylcholine receptors, both of which 
are involved in regulating neuronal plasticity and cognitive functions like learning and memory (55). 
Several recent studies emphasized the effects of KYNA on the physiological functions related to 
these receptors.  
 
Glutamate and nicotinic acetylcholine receptors  
Glutamate and nicotinic acetylcholine receptors are ligand–gated channels selective for cations. 
Both these receptors are transmembrane ion channels that are opened or closed in response to 
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the binding, on an allosteric binding site, of a chemical messenger, a neurotransmitter. The ion 
channel is regulated by a ligand and is usually very selective to one or more ions like Na+, K+ or 
Ca2+. Such receptors are located at synapses and convert the chemical signal of presynaptically 
released neurotransmitter directly and very quickly into a postsynaptic electrical signal.  
Ionotropic glutamate receptors, which mediate most of the fast excitatory synaptic transmissions in 
the CNS, consists of 3 subtypes: kainate receptors, alpha-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) receptors and N-methyl-D-aspartate (NMDA) receptors. Activation of 
glutamate receptors is responsible for basal excitatory synaptic transmission and for mechanisms 
which underlie learning and memory such as long-term potentiation and long-term depression (56, 
57). However, any event or process leading to a sudden or chronic increase in the activity of 
glutamate receptors often induces the death of neurons (58). Indeed, over-activation of glutamate 
receptors leads to a rise of intracellular Ca2+ that promotes neuronal cells damage by both 
activating destructive enzymes and increasing the formation of reactive oxygen species(59). The 
neuronal damage that characterizes chronic neurodegenerative disorders such as Parkinson’s 
disease and follows cerebral insults as stroke, ischemia, trauma, hypoxia, hypoglicemia and 
hepatic encephalopathy, is believed to result, in part, from increased activity of glutamate receptors 
(60). N-Methyl-D-aspartate receptor (NMDAR) is a specific type of glutamate-gated ion channel 
ubiquitously distributed throughout the brain, fundamental to excitatory neurotransmission and 
critical for normal CNS function. Its role relates to memory functions, learning processes and 
mental performance. The activation of NMDA receptor requires co-binding by two ligands: 
glutamate and glycine (Figure 1). The co-agonist glycine binds to a “strychnine-insensitive” glycine 
modulatory site on the NMDA receptor, which must be occupied in order for glutamate to open the 
channel (61). Therefore, the availability of glycine at the co-agonist site plays a critical role in the 
optimal NMDA receptor functioning. Activation of NMDA receptor result in the opening of an ion 
channel that allows flow of Na+ and Ca2+ ions into the cells and K+ out of the cells. Calcium flux 
through NMDARs is thought to play a role in synaptic plasticy, a cellular mechanism which is 
believed to underlie memory and learning. Abnormal over-activation of MNDARs has been 
suggested to lead to neuronal cell death observed in many acute and chronic disorders such as 
ischemia, stroke, and Huntington's disease (62). 
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Figure 1. Simplified model of NMDAR activation and various types of NMDAR blockers. 
 
Nicotinic acetylcholine receptors (nAChRs) are grouped into muscle, neuronal and -
bungarotoxin– sensitive, based on pharmacology and tissue–specific expression. Neuronal 
nAChRs are trans-membrane allosteric proteins formed by five subunits (63). They can be 
holigomers as well as heteroligomers made up from the combination of different  subunits or  
and  subunits (64). Numerous type of functional neuronal nAChRs have been so far identified. As 
with all ligand-gated ion channels, opening of the nAChR channel pore requires the binding of a 
chemical messenger. Like the other type of acetylcholine receptors, muscarinic acetylcholine 
receptors (mAChRs), the nAChR is triggered by the binding of the neurotransmitter acetylcholine 
(ACh). However, whereas muscarinic receptors are activated by muscarine, nicotinic receptors are 
also opened by nicotine. Hence, the name "nicotinic". Agonist, such as endogenous acetylcholine 
or exogenous nicotine, stabilize the open conformation of the nAChR channel for several 
milliseconds. While open, the nAChRs channel transiently permeates cations before closing back; 
in particular, Na+ enters the cell and K+ exits. The net flow of positively-charged ions is inward. 
With a sufficient number of channels opening at once, the intracellular Na+ concentration rises to 
the point at which the positive charge within the cell is enough to depolarize the membrane and 
produce an intracellular ionic signal. Although sodium and potassium carry most of nAChR current, 
calcium can also make a significant contribution (55, 65, 66). Figure 2 illustrates sites on a nAChR 
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that can alter function. Competitive antagonists and partial agonists can occupy the agonist binding 
sites. Open channel blockers, such as phenylcyclidine, can bind within the pore. Moreover, there 
are multiple sites for other noncompetitive inhibitors and modulators.  
 
 
Figure 2. A representation of the allosteric sites on a nAChR, showing three of the five subunits 
that form the pentameric receptor-channel complex (67). 
The structural diversity of nicotinic receptors provides the flexibility necessary for them to play 
multiple and varied roles in synaptic transmission throughout the CNS. In particular, receptor 
channels made up entirely of the α7 subunit (α7 nAChRs), are widely distributed in the mammalian 
CNS and are characterized by high calcium permeability and rapid activation and desensitization 
kinetics (68). Cholinergic mechanisms mediated by α7 nAChRs influence a number of cognitive 
functions and modulates a wide variety of behaviours (63). Behavioural and pharmacologic studies 
carried out in rats have suggested that α7nAChRs are essential for memory (69). Nicotinic AChRs 
also have roles during development and neuronal plasticity (70). Biological changes that 
inappropriately alter nicotinic mechanisms could immediately influence the release of many 
neurotransmitters and alter excitatory neurotransmission. Nicotinic cholinergic dysfunctions in the 
brain are intimately involved in the pathogenesis of a number of neurological disorders, including 
Alzheimer’s disease, Parkinson’s disease, Down Syndrome, schizophrenia and some form of 
epilepsy (63). As example, during the progression of Alzheimer’s disease, cholinergic inputs 
decreased as well as the number of nAChRs in some brain area (71, 72). Loss of nicotinic-based 
mechanism is likely to contribute to the overall cognitive deficits associated with Alzheimer’s 
disease (67). 
 
KYNA as an endogenous antagonist of ionotropic glutamate and nicotinic acetylcholine 
receptors 
KYNA, which is produced and released by astrocytes in the brain, is unique in three aspects. First, 
the transamination reaction, where the side chain of KYN cyclizes to form KYNA, is irreversible. 
Second, there is no catabolic enzymes that further metabolizes KYNA. Third, KYNA is not taken up 
by glia cells or neurons. Thus, following its irreversible transamination from KYN in astrocytes, 
newly formed KYNA is rapidly released into the extracellular milieu (73, 74), where it has access to 
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neuronal membrane receptors. The only known mechanism that clears KYNA from the 
extracellular space in the CNS is a non specific acid transporter that eliminates KYNA from the 
brain (13, 75). Furthermore, rapid renal excretion seems to be the single most important 
mechanism of brain KYNA disposition in the rat (76). Under normal physiologic conditions, tissue 
concentration of KYNA in human brain range between 0.2 and 1.5 M (75, 77). The KYNA content 
of the rat brain is substantially lower (  20 nM) (78).  
The neuroactive properties of KYNA have long been attributed to its action as a competitive 
antagonist at the glycine site on NMDA receptors. At low micromolar concentrations (IC50  10-15 
M) (79, 80) , it specifically blocks the NMDARs activity via a competitive antagonism of glycine at 
the “strychnine-insensitive” glycine modulatory site on the NMDA receptor (81), see Figure 1.  At 
higher concentrations (IC50  200-500 M), KYNA acts as a competitive antagonist at the agonist 
recognition site of the NMDA receptor (79, 82, 83). Furthermore, in even higher dose, (IC50 0.1 – 1 
mM), this tryptophan metabolite is able to antagonize also AMPA and kainate receptors (11, 14, 
84). Therefore, KYNA is considered a broad-spectrum endogenous antagonist of ionotropic 
excitatory amino acid receptors (74, 85). More recently, it has been discovered that at 
physiologically relevant concentrations (IC 50  7 M)  )(80), KYNA non-competitively antagonizes 
7 nicotinic acetylcholine receptor ( 7nAChRs) more effectively than NMDA receptors(80). This 
action, which may play a part in the ability of KYNA to generate a deficit in the sensory system (86, 
87), has been suggested to be mediated by its binding to sites located on the N-terminal domain of 
the 7-nACh receptor subunit (63). In the light of present data, 7nAChRs could be considered a 
preferential target for endogenous KYNA in vivo (88) and it is likely that fluctuations in endogenous 
brain KYNA levels preferentially affect 7nAChRs function (80), activation of which at the 
presynaptic site is involved in regulating neuronal plasticity in the brain (68, 70, 89-91). 
Considering that KYNA levels in mammalian brains, including humans, range from low nanomolar 
to low micromolar (75), it has long been a matter of controversy whether endogenous KYNA levels 
are sufficiently high to block NMDA receptor activity with physiological or pathological relevance. 
Some lines of evidence indicate that the glycine coagonist site on NMDA receptors may not be fully 
saturated (92-94), so that even quite low KYNA concentrations under physiological conditions 
could be sufficient to maintain a partial antagonism at the glycine receptor (14). Moreover, a recent 
study (95) suggests that as KYNA is synthesized and released from brain astrocytes (96), 
especially from those in close opposition to glutamatergic synapses (97), the concentration of 
KYNA in glutamatergic boutons might be high enough  not only to block both the glycine-site of the 
NMDA receptor and the 7 nicotinic receptor, but also the agonist recognition site of the NMDA 
receptor, thus producing significant actions on brain glutamatergic and cholinergic 
neurotransmission. 
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KYNA as a ligand of GPR35 
G protein-coupled receptors (GPCRs) are seven-transmembrane domain receptors that constitute 
the largest and most diverse protein family in mammalian genomes. Their primary function is to 
transduce extracellular stimuli into intracellular signals through interaction of their intracellular 
domains with heterotrimeric G proteins. Depending on the type of G protein to which the receptor is 
coupled, a variety of downstream signalling pathways can be activated (98). GPCRs are involved 
in a wide variety of physiological processes, such as the visual sense, the sense of smell, 
behavioral and mood regulation, regulation of immune system activity and inflammation. In human, 
in addition to about 160 characterized receptors, an equal number of genes encode proteins 
belonging to this family of receptors, but their ligands and functions remain to be determined and 
they are so called “orphan” G protein-coupled receptors (99, 100). 
In a recent study, KYNA has been identified as an endogenous ligand of an orphan G protein-
coupled receptor, GPR35, that is predominantly expressed in immune cells and gastrointestinal 
tissue (98). In particular, KYNA elicited a specific rise in Ca2+ in cells expressing human GPR35, 
with a medium effective concentration (EC50) of 39 M. The reported EC50 value of KYNA on 
human GPR35 activation is comparable with the concentration required for NMDA receptor 
antagonism. The discovery of KYNA as an endogenous ligand for GPR35 further highlighted the 
importance of this kynurenine metabolite in regulating biological functions. Kynurenine metabolic 
pathway is indeed activated during inflammatory conditions, such as viral invasion, bacterial 
lipopolysaccharides (LPS), or interferon- -stimulation (101, 102). The activation of tryptophan 
metabolism causes a reduced plasma tryptophan level and an elevated KYNA concentration (42). 
The predominant expression of GPR35 in immune cells and the elevation of KYNA levels during 
inflammation, suggest that this receptor-ligand pair may play important roles in immunological 
regulation.  
 
In addition to above described physiological functions, KYNA is also involved in maintaining 
physiological arterial blood pressure. In rats, the region of the rostral and caudal medulla in the 
CNS play an important role in regulating cardiovascular function (103-105). Spontaneously 
hypertensive rats that have higher arterial blood pressure were found to have significantly lower 
KAT activity and KYNA content in their rostral and caudal medulla than the control rats (106). 
Injection of KYNA into the rostral ventrolateral medulla of these rats significantly decreased their 
arterial pressure (107), which suggest that KYNA is involved in maintaining physiological arterial 
blood pressure. 
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Other neuroactive kynurenines 
In addition to KYNA, the KP generates others three neuroactive compounds, the excitotoxic 
NMDARs agonist quinolinic acid (QUIN), and the free radical generators 3-hydroxykynurenine (3-
HK) and 3-hydroxyanthranilic acid (HANA). 
QUIN is the only known endogenous compound with the ability to selectively activate the NMDA 
subtype of glutamate receptors, causing increased neuronal firing (108). QUIN has been shown to 
enhance synaptosomal glutamate release and to inhibit the glutamate uptake into astrocytes, 
resulting in an increased glutamate concentration into the synaptic cleft and at the presynaptic 
level (109). It is documented that CNS infection and immune activation are associated with 
accumulation of QUIN in the brain and cerebral spinal fluid, as a consequence of IDO and TDO 
over-activation (18, 23). Substantial (often 100-to 1000 fold) elevations in QUIN are seen when 
microglia cells are activated or when macrophages infiltrate the brain during immunological 
compromise, such as viral or other infections, neuroinflammation or ischemic and traumatic 
conditions (24). Elevated QUIN concentrations are responsible for over-activation of NMDA 
receptors and have been shown to concur to neuronal damage occurring in CNS inflammations. 
The mechanism for QUIN neuroexcitocytotoxicity in human astrocytes and neurons has recently 
been clarified (110). QUIN-induced cytotoxic effects on neurons and astrocytes are likely to be 
mediated by an over activation of NMDA receptors with subsequent induction of nitric oxide 
synthase and excessive nitric oxide-mediated free radical damage. The concentration of QUIN in 
cerebral tissue, between 40 and 400 nM (13, 111-113), and its low receptor affinity (IC50  100 M) 
are difficult to reconcile with its high cytotoxicity. It appears that the high in vivo potency of QUIN, 
particularly as an excitotoxin, is caused by a combination of factors, including the absence of 
effective removal mechanisms for extracellular QUIN (85) and its ability to readily generate 
damage-promoting free radicals. In fact, it also induces lipid peroxidation (114) and the production 
of reactive oxygen species (115). 
3-HK, a biological precursor of QUIN, is present in the human brain at a concentration range 
between 15 and 400 nM. Also 3-HK has neurotoxic properties, but in contrast to QUIN and KYNA, 
the neurotoxicity of 3-HK is not mediated by the direct interaction with specific recognition sites, but 
by generating toxic free radicals (116), which initiate a cascade of intracellular events resulting in 
cellular oxidative damage. Applications of 3-HK at micromolar levels (1-100 μM) to striatal neuronal 
cultures causes time and dose-dependent death, which is significantly reduced by co-treatment 
with catalase, suggesting that neurotoxic effects of 3-HK are due to hydrogen peroxide production 
(108). In addition, the immediate 3-HK degradation product, 3-hydroxyanthranilic acid, has also 
been shown to be neurotoxic (117), as it readily undergoes auto-oxidation with the production of 
superoxide and hydrogen peroxide thus promoting oxidative protein damage (118). 
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KYNA as an astrocyte-derived neuromodulator 
KYNA has unique neuroinhibitory properties, which have been intensively investigated in the last 
years. A large body of studies has demonstrated that this compound is significantly involved in 
basal neurophysiological processes in the brain, particularly in the modulation of behaviour and 
cognition (119). Early in vivo studies on KYNA neurophysiological effects concerned the 
hypothesis of this KP metabolite as an endogenous neuroprotective agent endowed with 
antiexcitotoxic and anticonvulsant properties. As over-activation of glutamate receptors promotes 
neuronal cells damage, a mechanism capable of preventing glutamate receptors from being over-
stimulated seems essential for maintaining the normal physiological condition in the CNS. The 
antagonist activity of KYNA on NMDA receptors, whose excessive activation results in excitotoxic 
nerve cell loss, prompted the hypothesis that KYNA may exert neuroprotective properties, likely 
acting as an endogenous anti-excitotoxic agent limiting neurotoxicity arising from NMDA receptors 
over-stimulation (13). This hypothesis was first investigated in rats brain, showing that  KYNA 
prevented the neurotoxic effects induced by the local application of the related brain metabolite 
QUIN (85). Furthermore, pharmacologically administration of KYNA, or its pro-drugs analogues 
able to cross the blood brain barrier readily than the parent compound, have anticonvulsive effects 
and provide neuronal protection against brain damage resulting from ischemia, hypoxia or 
traumatic brain injury (85, 120-122). Nevertheless, it is possible to dissociate KYNA’s 
antiexcitotoxic and anticonvulsant properties, which can be realized at nanomolar concentrations 
(15, 122, 123), from its potentially harmful effects on cognition at much higher levels (87).  
The neurophysiological aspect of endogenous KYNA that has recently gained most attention is its 
modulatory function on glutamatergic and cholinergic neurotransmission. The antagonist activity of 
KYNA on NMDA and 7-nAChR receptors, which are intimately involved in synaptic plasticity and 
cognitive functions, prompted the hypothesis that KYNA may function as a unique glial modulator 
of cholinergic and glutamatergic activity, capable of influencing cognitive functions mediated by 
these neurotransmitters systems (13, 79, 81). A large number of in vivo experiments in rodents 
have demonstrated that nanomolar (i.e. endogenous) concentrations of KYNA in the prefrontal 
cortex cause a decrease in the extracellular levels of three neurotransmitters known to be 
associated with cognitive functions, i.e., glutamate, acetylcholine and dopamine. Interestingly, 
these modulatory effects are bidirectional, i.e., a selective reduction in KYNA formation 
substantially enhances the extracellular presence of these neurotransmitters (54, 124, 125). These 
results validated the role of KYNA as an endogenous modulator of cognitive processes closely 
linked to glutamatergic, dopaminergic and cholinergic neurotransmission. Moreover, KYNA’ s 
bidirectional control over these neurotransmitters is of special interest in view of the fact that 
KYNA’ s levels are abnormally high in the brain and cerebrospinal fluid of individuals with 
schizophrenia (47-49) and in those with Alzheimer’s disease (43), suggesting that increased levels 
of KYNA may contribute to glutamatergic and cholinergic–mediated cognitive dysfunction involved 
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in these two neuropathological conditions. The complexity of the neurophysiological actions of 
KYNA in the CNS implies its pathophysiological significance in situation of clinically relevant 
receptor impairments (126).  
 
KYNA’s imbalance in neurodegenerative disorders 
In recent years mounting attention has been paid to the possible physiopathological role of 
dysregulations in normal brain KYNA concentration. As fluctuations in the endogenous brain levels 
of KYNA influence glutamatergic, dopaminergic and cholinergic neurotransmission (53, 54), 
dysfunction of cerebral KYNA synthesis has been hypothesized as an important factor contributing 
to the pathogenesis and progression of neurological or psychiatric diseases that are associated 
with impaired cholinergic and/or glutamatergic neurotransmission. The hypothesis of a causative 
role of KYNA in neurophatological processes gained momentum because of reports of changes in 
its brain content in several neurological and psychiatric diseases (Table 1). Cerebral KYNA levels 
are increased in patients with Alzheimer’s disease (43), Down’s syndrome (127) and schizophrenia 
(47-50), and levels are decreased in patients with end-stage Parkinson’s disease (44) and 
Huntington’s disease (45, 46).  
 
INCREASED KYNA DECREASED KYNA 
Disease state Reference Disease state Reference 
Schizophrenia (47, 49, 50) Parkinson’s disease (44) 
Alzheimer’s disease (43) Huntington’s disease (45, 46) 
Down’s syndrome (127) Infantile spasms (128) 
Amyotrophic lateral 
sclerosis 
(52) Multiple sclerosis (51) 
Cerebral malaria (129)   
HIV infection (130, 131)   
 
Table 1.  Altered brain and cerebrospinal fluid KYNA levels in selected diseases states. 
 
Neurochemistry studies demonstrated that KYNA acts as a negative regulator of glutamatergic 
neurotransmission, that in turns modulates extracellular dopamine levels (54), whose unbalancing 
is co-responsible for the neurological symptoms of these diseases. In lower concentration KYNA is 
probably unable to inhibit NMDA receptors effectively and to prevent excitotoxicity arising from 
enhanced release of glutamate. On the other hand, increase in endogenous levels of  KYNA is 
associated with reduced glutamate release (glutamatergic hypofunction) and consequently 
decreased extracellular dopamine levels (54), and therefore may significantly influence cognitive 
process leading to impaired cognitive capacity (43). In human post-mortem studies, the brain 
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concentration of KYNA was found to be elevated in the prefrontal cortex (PFC) of individuals with 
schizophrenia (47, 50, 132). Hypofunction of both NMDA-receptor and the -7nACh-receptor are 
implicated in the pathophysiology of this disease, and especially in cognitive deficits and 
impairments in executive function (25). The discovery of increased cortical KYNA levels in the 
brain tissue of individuals with schizophrenia prompted  the hypothesis that elevated KYNA 
concentration may be causally correlated to the cognitive dysfunction that has been attributed to 
altered glutamatergic and cholinergic transmission (25). Indeed, increases in brain KYNA levels, by 
virtue of  the compound’s ability to antagonize NMDARs and 7nAChRs, both of which are 
critically involved in physiological process underlying learning, memory and other manifestations of 
synaptic plasticity (79, 80),  may cause or exacerbate cognitive impairments (86, 133). Behavioural 
studies in rats have demonstrated a causal link between increased cortical KYNA levels and 
neurocognitive deficits (86, 87, 95, 133). Animals with experimentally elevated KYNA levels exhibit 
performance deficits in behaviour task requiring cognitive process similar to those that are impaired 
in schizophrenia (86, 87, 95, 133, 134). These in vivo studies on rats provided more substantive 
evidence favoring a pathophysiological role of increased levels of endogenous KYNA, as a 
consequence of altered KP metabolism, to the hypoglutamatergic and cholinergic tone in 
schizophrenia (135). Notably, in post mortem studies of schizophrenic patients brains, the 
upregulation of KYNA levels was accompanied by increases in the tissue levels of KYN, KYNA’ s 
immediate bio precurosor (132). The increased cortical KYN content might be a direct 
consequence of enhanced synthesis catalyzed by either TDO or IDO (102, 136), or of a reduced 
KMO activity in the periphery and/or in the brain (25, 137).  
In addition to being associated with schizophrenia, abnormally high KYNA levels have been 
observed in the brain and cerebrospinal fluids of Alzheimer’s disease (AD) patients (43) and in the 
frontal and temporal cortices of Down’s syndrome (DS) subjects (127). It can be hypothesized that 
inhibition of 7nAChRs by increased levels of KYNA contributes to the cognitive deficits in patients 
with AD and DS (138). Cortical KYNA is therefore considered an attractive new target for 
significant cognitive enhancement. 
 
Modulation of KYNA synthesis as a future therapeutic strategy for cognitive enhancement 
In view of the involvement of neuroactive KP metabolites in several neurodegenerative and 
psychiatric disorders, enzymes of the KP have long been considered interesting targets for rational 
therapeutic interventions to cure mental illness (13). In particular, the inhibition of kynurenine 
aminotransferse activity would result in lowering KYNA levels, with a concomitant relieve of 
glutamatergic inhibition. Decreased KYNA production in the brain is supposed to causes 
diminished inhibition of NMDA and 7 nicotinic acetylcholine receptors function, therefore 
enhancing glutamate and dopamine release and consequently cognitive processes (139). In line 
with accumulating evidence suggesting a role of altered KYNA function in mental illness and 
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cognitive impairment (43, 49, 50, 133, 135), recent years witnessed a growing interest in the study 
of mechanisms controlling KYNA synthesis in the CNS. The brain content of KYNA is governed by 
a delicate balance of interconnected factors: (i) the competition of the KP with alternative pathways 
using tryptophan to generate other bioactive metabolites (i.e. serotonine and melatonine) (11), (ii) 
the availability of the pivotal KP metabolite KYN for degradation through the KP, and (iii) the 
differential cellular uptake of KYN into various brain cells types (13). The optimal approach to limit 
the effects of elevated brain KYNA levels is by direct pharmacological manipulation of kynurenine 
pathway metabolism. In principle, such “kynurenergic” agents do not need to penetrate into the 
brain, but could be efficacious by reducing the pheripheral levels of circulating KYN. This would 
lower brain uptake of the precursor and decrease cerebral KYNA formation. Examples in these 
category includes inhibitors of TDO and/or IDO. Such compounds are available and, in the case of 
IDO inhibitors, are being developed for the treatment of a variety of diseases ranging from cancer 
to asthma and infectious diseases (140, 141), but they are yet to be adequately tested for possible 
applications in psychiatry. 
Interventions resulting in the activation of KMO, too, might diminish peripheral and central KYN 
levels and consequently attenuate KYNA formation indirectly. However, the potential clinical merit 
of this approach will have to be weighed against possible detrimental consequences of inducing 
increased kynurenine pathway flux towards the neurotoxic compounds 3-hydroxykynurenine and 
quinolinic acid. 
Therefore, the most prudent strategy to reduce brain KYNA is to target KATs, the enzymes 
responsible of KYNA synthesis. Although the mammalian brain contains at least four distinct KATs 
(142), it appears that KAT II accounts for the majority of KYNA formation in the human brain. 
Indeed, in contrast to the other three KATs, KAT II is distinguished by its substrate specificity to 
KYN and abundant common amino acids do not interfere with the enzyme’s ability to convert KYN 
to KYNA. From the point of view of drug development, the existence in the human brain of at least 
four KYNA-synthesizing enzymes, combined with the necessity to fine-tune KYNA levels to avoid 
the potentially harmful effects caused by a drastic deficiency of this metabolite in the CNS, requires 
the design of isozymes-specific inhibitors. KAT II selective inhibitors could represent an effective 
way to sensibly lowering KYNA levels, whereas the potential harmful complete depletion of this 
neuroprotective compound would be prevented by the action of the other KAT isozymes. Selective 
inhibition of KAT II is therefore a rational pharmacological approach to attenuate KYNA formation 
in the brain with direct implications for the enhancement of cognitive process in disorders related to 
learning and memory deficits, such as schizophrenia and Alzheimer’s diseases, where lowering the 
levels of brain KYNA is sought to counterbalance glutamatergic and cholinergic hypofunction.  
The hypothesis that blockade of KAT II, causing a decrease in brain KYNA, may have cognition-
enhancing effects, recently received strong support from in vivo studies in which mutant mice with 
a target deletion of KAT II displayed reduced brain KYNA levels concomitant with an increased 
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performance in cognitive tests (25, 143, 144). These functional changes were accompanied by 
increased extracellular glutamate. Moreover, recent studies were designed to probe the functional 
consequence of an acute disruption of cerebral KYNA synthesis using specific KAT II inhibitors. 
Early attempt to develop selective KAT II inhibitors were based on the structure of KYN and lead to 
the synthesis of the substrate analogue (S)-4-(ethylsulfonyl) benzoylalanine (S-ESBA); its 
intracerebral application in the rat brain caused a rapid decrease in KYNA formation, accompanied 
by an increase in extracellular dopamine levels (15, 145). Together with the demonstration of 
increased glutamatergic tone and enhanced cognitive abilities in KAT II deficient mice, these two 
complementary experimental tools provide further support for the concept that  selective inhibition 
of KAT II is a rational approach to attenuate KYNA formation in the brain with direct implications for 
the enhancement of cognitive process.  
A recent in vivo study on rats, (21) assessed the hypothesis whether KAT II inhibition may lead to 
elevated 3-HK and/or QUIN levels and possibly increased risk of neurotoxicity. As the two KP 
branches are functionally segregated, acute blockade of KYNA synthesis using a specific KAT II 
inhibitor, BFF122, did not lead to a compensatory up-regulation of the neurotoxic QUIN branch of 
the KP. This further result stimulates the development of KYNA synthesis inhibitors as cognition 
enhancers in patients with neurodegenerative disorders.  
Despite its potential indication as a drug target in the treatment of schizophrenia and other 
neurological disorders, a through biochemical characterization of KAT II from human brain is still 
missing (34) and only a few compounds have been so far developed as KAT II selective inhibitors 
(21, 146). 
 
KYNURENINE AMINOTRANSFERASES (KATs) FAMILY 
Based on the demonstrated relationship between abnormal brain KYNA concentrations and 
neurodegenerative diseases and psychotic disorders, enzymes involved in brain KYNA synthesis 
have been considered as a potential drug target for regulating brain KYNA concentration (13, 17, 
42, 119, 120, 147-151). A number of studies concerning the identification and functional 
characterization of KATs in rat, mouse and human  have been undertaken. The relative importance 
of KATs in vivo appears to vary with species, tissue and developmental stage. In mammals, KAT 
activity is present in various tissues, such as liver, kidney, small intestine and brain (152-154). So 
far, in rat, mouse and human brain, four KATs have been reported to be implicated in KYNA 
biosynthesis in the central nervous system: 
1) KAT I,  glutamine transaminase K/cysteine conjugate beta-lyase 1 (KAT I/GTK/CCBL1), EC 
2.6.1.64. 
2) KAT II,  -aminoadipate aminotransferase (KAT II/AADAT), EC 2.6.1.7. 
3) KAT III, cysteine conjugate beta-lyase 2 (KAT III/CCBL2), EC 4.4.1.13. 
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4) KAT IV, glutamic-oxaloacetic transaminase II/mitochondrial aspartate aminotransferase (KAT 
IV/GOTII/mitASAT), EC 2.6.1.1. 
The genes of KAT I and KAT III are phylogenetically distant from those of KATII and KAT IV. 
Among the four human KATs, human KAT I and KAT III share the highest sequence identity 
(51.7%), whereas there is a significant sequence divergence between human KAT I and KAT II, as 
they share only 18% sequence identity (142). It is well established that KAT IV/mitonchondrial 
ASAT targets mitochondria (155-157). KAT II is also considered to be a mitochondrial protein (158-
160), but further confirmation about the mechanism of export to mitochondria is needed (142).  
 
Biochemical properties  
All four mammalian KATs posses transamination activity towards KYN leading to the formation of 
KYNA. Like all known aminotransferases, KAT enzyme catalysis takes place with a ping-pong bi-bi 
mechanism from amino acid 1 and keto acid 2 to amino acid 2 and keto acid 1 (further details on 
reaction mechanism are described in the Section on Structural Properties). As revealed by 
substrate specificity studies, all KATs are multifunctional transaminase and share many amino acid 
and -ketoacid substrates. In particular, all four KATs show activity with the aromatic amino acids 
phenylalanine, tyrosine and tryptophan and with the sulphur-containing amino acid methionine 
(142). On the other hand, they differ in substrate specificity and pH optimal range. Human KAT I 
and III display very similar amino acid substrate profiles, while hKAT II is the only one among KAT 
isoforms showing - aminoadipate transaminase (AADAT) activity.  
 
KAT II/AADAT 
The enzyme was initially named aminoadipate aminotransferase (AADAT) when it was first 
partially purified  from rat liver in 1969 (161) and its function in liver lysine degradation  is well 
described (162). Later it was reported that the same aminotransferase from liver and kidney had 
both KAT activity and AADAT activity (160, 163, 164) and Tobes and Mason definitely confirmed 
that AADAT was identical to rat KAT II (164). Biochemical analysis of human KAT II (hKAT II) 
revealed that this enzyme has very broad substrate specificity (34). Indeed, recombinant hKAT II is 
able to catalyze the transamination reaction of a number of amino acids. In particular, kinetic 
analysis of hKAT II (Table 2) revealed that the enzyme is efficient in catalyzing the transamination 
of aminoadipate, KYN, methionine and glutamate, and is less efficient in catalyzing tyrosine, 
phenylalanine, tryptophane, leucine, 3-HK, glutamine, alanine and aminobutyrate. hKAT II can use 
many -ketoacids as its amino group acceptors, but prefers -ketoglutarate. The enzyme shows 
maximum activity around 50°C and has broad optimum pH range from 7-9 (34). Although hKAT II 
has a relatively high Km for kynurenine (about 4.7 mM), its catalytic efficiency in KYN to KYNA 
pathway is enhanced by its relatively high turnover number (kcat for L-KYN 585 min
-1) and also by 
the irreversible nature of the transamination reaction. The enzymatic product of kynurenine 
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transamination is an instable -ketoacid intermediate that undergoes rapidly intramolecular 
cyclization to KYNA. Consequently, no direct enzymatic product will accumulate during KAT-
catalyzed KYN transamination and the equilibrium always proceeds towards KYNA production. On 
the basis of its biochemical properties, KAT II has been considered the principal enzyme 
responsible for the synthesis of KYNA in the rodent and human brain (13, 37), as supported by in 
vivo studies. Indeed, mice in which KAT II was knocked out by genomic manipulation showed a 
substantial decrease in brain KYNA levels and presented phenotypic changes that were in line with 
this biochemical deficit (139, 165). The irreversible transamination of KYN to KYNA is one of the 
major functions of hKAT II (34). Furthemore, this enzyme is also involved in lysine catabolism by 
catalyzing the transamination of aminoadipate to -ketoadipate (Scheme 2) (34, 166-169). 
Aminoadipate is a metabolic intermediate of the major route for the catabolism of lysine, an 
essential amino acid in humans, which is degraded when present in an excess beyond that 
required for protein synthesis. Aminoadipate occurs naturally in the brain (170, 171), where it is 
known to be a selective excitotoxin for astrocytes and related glial cells, as demonstrated by a 
number of in vivo and in vitro studies (172-174). High concentration of aminoadipate functions as a 
NMDA receptor agonist, inhibits glutamate transport, blocks glutamine synthetase and prevents the 
uptake of glutamate into synaptic vesicles. These effects can contribute to an increased excitatory 
tone because synaptic glutamate concentrations are elevated. High levels of aminoadipate in 
serum and/or urine have been observed in many cases with neurological and other disorders (160, 
175-184). As demonstrated by a substrate specificity study on recombinant hKAT II, this enzyme 
has higher catalytic efficiency for aminoadipate than to kynurenine (kcat/Km aminoadipate 196.2 
min-1mM-1, kcat/Km kynurenine 125.9 min
-1mM-1)(34). Moreover, the fact that the affinity of hKAT II to 
aminoadipate (Km = 0.9 mM) is much greater than its affinity for ketoadipate (Km = 20.9 mM), 
suggests that the AADAT enzyme reaction does not tend to be reversible and prefers the direction 
from aminoadipate to -ketoadipate, one of the reactions in lysine degradation. Accordingly, in 
addition to be responsible for the majority of KYNA formation in the adult mammalian brain, KAT II 
is considered primarily involved also in the neutralization of aminoadipate to  -ketoadipate across 
the lysine catabolism. 
The character of multiple substrates transaminase of hKAT II suggested that this enzyme may play 
a role in metabolism of other ketoacids and amino acids. It also raised a fundamental question 
regarding the structural basis of its broad substrate specificity. Structural analysis of hKAT II in 
complex with -ketoglutaric acid (34) revealed a conformational change of an N-terminal region, 
that is very flexible and able to adapt different conformations to bind different ligands. Basically, 
this N-terminal portion moves close to the active center when the protein binds small ligand and 
moves away from the center when the enzyme binds large ligand. This flexible N-terminal region 
therefore provides a structural basis for broad substrate specificity of hKAT II. 
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Scheme 2. Lysine catabolism pathway in mammals. 
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                                                            Km (mM)                  kcat (min
-1)                 kcat/Km (min
-1/mM-1) 
 
Amino acid substrates 
Aminoadipate                                         0.9  0.1                   179.4  5.7                    196.2                     
Kynurenine                                             4.7  0.8                   585.3  39.9                  125.9 
Methionine                                             1.7  0.5                   206.4  17                      123.8 
Glutamate                                              1.6  0.4                   185.0  14.8                   118.7 
Tyrosine                                                 1.8  0.2                   131.5  5.2                     74.4 
Phenylalanine                                        5.2  1.7                    327.1  46.2                   63.4 
Tryptophan                                            4.3  0.4                    254.0  8.6                     58.7 
Leucine                                                 5.1  3.0                     285.0  70.4                   56.1 
3-HK                                                      3.8  1.0                    102.1  12.2                   26.8 
Glutamine                                              8.1  2.9                    95.5  16.6                     11.8 
Alanine                                                  19.4  9.2                   173.6  43.2                   9.0 
Aminobutyrate                                       17.8  4.3                   157.2  19.4                   8.8 
 
Keto acid substrates 
-ketoglutarate                                      1.2  0.4                     460.1  49.8                   374.5 
-ketocaproic acid                                 1.5  0.1                     289.7  8.1                    188.0 
Phenylpyruvate                                     1.8  0.2                     284.0  13                      156.9 
KMB                                                    2.4  0.7                     256.2  31.9                   105.2 
Mercaptopyruvate                                 2.8  0.5                     215.5  12.6                    77.7 
Indo-3-pyruvate                                    1.4  1.2                      89.1  32.5                      64.6 
-Ketovalerate                                      3.4  0.3                     159.3  4.9                       47.0 
-Ketoleucine                                       3.3  0.8                      150.5  13.6                    45.4 
-Ketobutyrate                                     12.7  2.1                    208.9  12.5                    16.4 
Hydroxyphenylpyruvate                       1.5  1.1                      23.6  9.5                        16.2 
-Ketoadipate                                      20.9  5                       290.3  30                       13.9 
Glyoxylate                                            18.0  3.7                    218.4  18.4                    12.1 
Oxaloacetate                                       16.8  12.4                   93.9  51.6                      5.6 
-Ketovaline                                        12.9  2.9                     55.1  4.6                        4.3 
-Ketoisoleucine                                 14.2  3.8                     55.2  6.9                        3.9 
Pyruvate                                              9.7  5.6                       21.8  6.4                        2.3 
 
Table 2: Kinetics parameters of recombinant hKAT II towards amino acid and -keto acids (34). 
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KAT I/GTK/CCBL1 
Analysis of substrate specificity revealed that hKAT I is a multifunctional PLP-dependent enzyme 
which possesses transaminase activity towards many amino acids and also cysteine conjugates -
lyase activity. As an aminotransferase, hKAT I has a broad amino acid specificity (33, 36) and can 
use many -keto acids as its amino group acceptors. Unlike hKAT II, hKAT I is generally most 
active with large neutral, aromatic, sulphur-containing amino acids and prefers glyoxylate as amino 
group acceptor. hKAT I shows lower catalytic efficiency for KYN compared to hKAT II (hKAT II: 
Kcat/Km 125.9 min
-1mM-1, hKAT I: Kcat/Km 42.8 min
-1mM-1) (33). Moreover, hKAT I-mediated 
transamination of KYN is inhibited by physiologically abundant, competing amino acids (30, 33). 
The optimal pH range of human brain KAT I is 9.5-10 (29, 37, 127, 185). These biochemical 
properties led to the conclusion that hKAT I has a very limited contribution to brain KYNA 
production under physiological conditions (13, 28, 37). A further impediment to KYNA synthesis 
catalyzed by hKAT I could be the intrinsic enzyme’s PLP-associated -lyase activity (35, 36). This 
additional function not only underlines the intrinsic catalytic promiscuity of hKAT I, but also 
supports its role in mediating the toxicity of the sulphur-containing fragments released from 
halogenated alkene-derived cysteine S-conjugates (186, 187), that likely contributes to liver and 
kidney carcinogenesis (188). On the basis of these considerations, and in view of the biochemical 
properties of hKAT II (i.e., neutral pH optimum and insensitivity, at physiological KYN 
concentrations, to abundant amino acids), at a physiological concentration of KYN (i.e., in the low 
micromolar range), hKAT II is primarily responsible for the majority of KYNA formation in the adult 
mammalian brain (30, 37).  
 
KAT III/CCBL2 
Recently proposed as a novel member of the mammalian KAT family, KAT III has been identified in 
mouse, rat and human (31). The biochemical properties of KAT III have been further determined in 
mice (32). This enzyme showed activity towards a number of amino acids, including some aromatic 
amino acids (phenylalanine, KYN, tryptophan, 3-HK, tyrosine and hystidine) and sulphur-containing 
amino acids (methionine and cysteine). Human KAT I and mouse KAT III are highly similar in terms 
of both primary sequence and 3-dimensional structure, furthermore they also share a similar 
substrate profiles, but human KAT I favours certain hydrophobic substrates, while mouse KAT III 
prefers relatively hydrophilic substrates. Also the keto acid substrate profile of mouse KAT III is 
very similar to that of human KAT I (32). Moreover, mouse KAT III display optimal activity around 
pH 9.0-10.0 (32), which is close to the pH optimum reported for human brain KAT I (29, 37, 127, 
185).  
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KAT IV/GOT2/mitASAT 
The KAT activity of mit ASAT was first reported in E. coli (189) and later it was found that mit 
ASATs in mouse, rat and human posses KAT activity, therefore mammalian mit ASAT was named 
KAT IV (30). In addition to its KAT activity, mit ASAT, also called GOT2, catalyzes the reversible 
transamination of oxalacetate to aspartate in conjunction with conversion of glutamate to -
ketoglutarate (142). The enzymes is involved in a number of physiological process in astrocytes 
and neurons (190-194). Firstly, it as a role in the entry of glutamate into the tricarboxylic acid cycle, 
and in the re-synthesis of intra-mitochondrial glutamate from tricarboxylic acid cycle intermediates 
(193, 195-199); secondly, it has a key role in the synthesis of neurotransmitter glutamate in brains 
(200, 201); and at least it is an essential component of the malate-aspartate shuttle, which is 
considered the most important mechanism for transferring reducing equivalents from the cytosol 
into mitochondria in brain (196, 202). KAT IV was also reported to have cysteine conjugate beta-
lyase activity (203). Mouse KAT IV has greatest activity at pH 8 (142).  
 
Structural properties of hKAT II 
Overall structure 
Cristallographic studies of KATs from different organism, including human, have revealed that all of 
the functionally validated KATs whose structures have been experimentally determinated, namely 
human KAT I (204) and KAT II (205, 206), the KAT I orthologs of the mosquito Aedes aegypti  
(207), yeast S.cerevisiae (208), and the archeobacterium Pyrococcus horikoshii (209), as well as 
3-hydrokynurenine aminotransferase of Anopheles gambiae (210), belong to the -family of 
pyridoxal-5’-phosphate (PLP)-dependent enzymes (211), and they are assigned to the fold type I 
group (212-216). As observed for the majority of others members of this group, KATs invariably 
function as homodimers, hosting two active sites at the inter-subunit interface (126, 142). Crystal 
structure analysis revealed that all KATs share an overall protein structure in which an N-terminal 
region, a small and a large domain can be distinguished (126). Comparisons of KATs crystal 
structures revealed a high degree of structural conservation in the PLP-bearing large domain, 
featured by an open / / -fold that is conserved in all aminotransferases (211). On the other hand, 
peculiar structural traits characterize hKAT II (Figures 3 and 4). In particular, the functional hKAT II 
homodimer is featured by a strikingly swapped conformation of the catalytically essential N-
terminal region encompassing residues 13-43, whose movements have been suggested to control 
substrate access into the enzyme active site during the catalysis (34, 126, 142, 205). In 
aminotransferases, the N-terminal region is a key structural component, which is involved in the 
enzyme’s proper assembly and subcellular fate (217) and also plays a role in the catalysis by 
participating in substrate binding and structuring of the active site (126). The N-terminal region of 
hKAT II bears a substrate-recognition helix and an associated loop, which buds from the large 
domain of each subunit and protrudes toward the facing subunit, where it provides multiple inter-
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subunits contacts and essential residues for shaping the PLP-binding site. While in the hKAT II 
dimer the N-terminal region of each subunit contributes to built up the active site of the symmetry 
mate, the N-terminal regions of KAT I, KAT III and KAT IV participate in building up the small 
domain and structuring the active site of the same subunit, that is, they do not show the swapping 
N-terminal observed in hKAT II. The topology observed for the hKAT II N-terminal motif has never 
been reported in the structure of any aminotransferase, and thus represents a distinct structural 
trait of hKAT II. Moreover, a unique strand/loop/strand motif (S2/S3) marks the boundary between 
the N-terminal element and the large domain (206). The latter is organized around a canonical 
PLP-binding inner core whose topology, consisting of a mainly parallel seven-stranded -sheet 
sandwiched between -helices, is strictly conserved through PLP-dependent aminotranferases 
(211). Furthemore in hKAT II structure, in contrast to what observed in the majority of 
aminotransferases, only residues of the C-terminal portion of the enzyme build up the small 
domain, with no contribution from the N-terminal region (206). Another striking structural element of 
hKAT II, critically contributing to the overall stability of the functional dimer, is represented by a 
four-stranded antiparallel flat -sheet, formed by the unique S2/S3 motifs, that appears to sealing 
the two large domains together. Such an inter-subunit -sheet has never been observed in the 
structure of any aminotransferase reported so far, therefore representing an element of novelty 
(206). 
Interestingly, an ion binding site, located at the inter-subunit interface, was observed in the 
structure of hKAT II  functional dimer, suggesting a possible contribution toward hKAT II dimer 
stability (206). 
Fold type I aminotransferases are further classified into seven subgroups, I , I , I , I , I , I  and 
I . KAT I and KAT IV have been assigned to I  and I  respectively (213). KAT III is highly similar to 
KAT I in terms of primary sequence and crystal structure, therefore it can be assigned to I , too 
(32). Because of its striking feature of the N-terminal tertiary structure, KAT II does not belong to 
any existing fold type I subgroups. Therefore it was proposed as a new subgroup in fold type I 
aminotransferase (205). A further sequence phylogenetic analysis revealed that KAT II and KAT II 
homologs form a separate lineage (218). This indicate that KAT II and its homologs form a new 
subgroup in fold type I aminotransferase, which has been designed as subgroup I  (142). 
The conformation adopted by the N-terminal region in KAT II is not unprecedented amongst PLP-
depended enzymes and resembles what observed in the N-terminal sub-domain of members of 
PLP-dependent lyases, such as the cystathionine -lyase from E.coli (219). Indeed, this -lyase 
was identified as a far structural ortholog of hKAT II (206). Interestingly, hKAT II appears to contain 
structural elements that are typical of PLP-dependent enzymes belonging to functionally distinct 
subfamilies in the fold type I group. It can therefore not be excluded that hKAT II could catalyze, 
beside transamination of kynurenine and aminoadipate, additional PLP-dependent reactions (126, 
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206). An extensive functional characterization of hKAT II should be undertaken to assess this 
hypothesis.  
 
 
 
Figure 3. Stereo and ribbon representation of the hKAT II subunit. The N-terminal motif and the 
large domain are colored in magenta; the small domain and the C-termini are colored in blue. The 
enzyme active site can be observed at the domain interface where the PLP molecule, in its internal 
aldimine form, is shown in ball-and-stick. The S2/S3 motif and the secondary structural elements of 
the N-terminal motif as well as residues delimiting the disordered region are indicated (206).  
 
  
 
 
Figure 4. Ribbon representation of the functional dimer of hKAT II. The two sububits are 
differentially colored and the PLP molecules are shown as ball-and-sticks. The inter-subunit four-
stranded antiparallel flat -sheet, formed by the unique S2/S3 motifs of the two subunits and that 
seals the two large domains together is indicated (206). 
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Ligand-binding sites and substrate specificity 
Each of the two active sites present in hKAT II functional dimers is located in a wide and deep cleft 
built up by residues of both domains of one subunit and by regions of the N-terminal motif and the 
large domain of the opposite one. Each active site hosts a PLP molecule, whose C4’ atom, in the 
ligand-free form of the enzyme, is Schiff-base linked to the N  atom of Lys263. Several residues 
are in direct contact with the PLP molecule and contribute to keep it in the proper orientation 
(Figure 5). In particular, the nitrogen atom in the PLP pyridine ring is in contact with the extremely 
conserved residue Asp230; the cofactor O3’ atom is hydrogen bonded to the OH group of Tyr233, 
that points towards the PLP molecule from the bottom of the active site, and it is also in contact 
with Asn202 N 2. The resulting bonding network strongly affects the PLP plane orientation, 
resulting in the absence of a perfect -stacking of its pyridine ring to the side chain of Tyr142, 
which is placed just above the cofactor molecule. The presence of a tyrosine residue in this 
position is uncommon in aminotransferases, where tryptophan or phenylalanine are the most 
frequently observed residues. Interestingly, a structural equivalent tyrosine residue characterizes a 
number of PLP-dependent enzymes involved in trans-sulphuration (e.g cystathionine -lyases and 
cystathionine -lyases). Therefore, as already underlined when describing the N-terminal motif, 
hKAT II reveals intriguing structural determinants in common with PLP-dependent lyases. This 
observation suggests the possibility of a not yet investigated -lyase activity of hKAT II. 
Interestingly, such activity has previously been reported for human KAT I (36, 188), even if this 
enzyme harbours a phenylalanine at the position equivalent to hKAT II Tyr142 (204, 220). 
 
 
 
Figure 5. Stereo view of hKAT II active site with the PLP cofactor in its internal aldimine form. The 
protein portions building up the active site and contributed to by the two subunits of the functional 
homodimer are shown in a schematic representation and are colored in deep teal (subunit A) and 
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violet (subunit B). The PLP cofactor and the protein residues within a 5-Ǻ distance of PLP are 
shown. The C4’ atom of PLP is covalently attached to the N  atom of Lys263, through the 
formation of an internal Shiff base, and the internal aldimine gives rise to the residue LLP263, 
represented as a stick. (205). 
 
The structural homology among human KATs isoenzymes is restricted to high conserved subset of 
residues required for optimal PLP binding and to the C-terminal region of the small domain, while 
severe differences are observed for the rest of the molecule, including the unique hKAT II N-
terminal region and S2/S3 motif. Consequently, the identification of the structural determinants that 
regulate substrate specificity in human KAT I and KAT II, can be obtained only by carefully 
inspecting the structures of the isoenzymes in their ligand-bound states. Indeed, the crystal 
structure of the Michaelis complex of human KAT I with L- phenyalanine or indole-3-acetate (204, 
220), human KAT II with KYN (205), mouse KAT III with KYN (32), and chicken mitoshondrial 
ASAT (86% sequence identical to human KAT IV) structure (221), allowed the identification of 
residues that regulate substrate specificity and thus ligand binding in four KAT enzymes. In 
particular, the -carboxylic group of KYN invariabily forms a salt bridge with the guanidinium group 
of Arg399, which drives the correct positioning of the substrate -amino group just above the PLP 
C4’ catalytic center. The presence of this Arg residue is a strictly conserved hallmark of all 
members of the aminotransferase superfamily and accounts for the anchoring of the amino acid 
group of KYN to the catalytic site of KAT (213). On the contrary, the recognition of the substrate 
side chain is achieved by different structural determinants in hKAT I and hKAT II (Figure 6). 
Specifically, the major molecular determinants responsible for substrate recognition in hKAT I 
consists of a hydrophobic pocket or a crown of aromatic residues in which the substrate side-chain 
is perfectly nested. Mouse KAT III has a similar aromatic crown. In contrast, the aromatic 
hydrophobic pocket observed in hKAT I and mKAT III is largely absent in the structure of hKAT II 
and chicken mitochondrial ASAT (human KAT II homolog), where the equivalent positions are 
occupied by polar or neutral amino acids. In addition, the substrate binding pocket in hKAT II 
appears sensibly wider, mainly owing to the absence of a residue equivalent to hKAT I Trp18 and 
to the substitution of KAT I Phe278 with Leu293 (206).  
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Figure 6. Representation of hKAT I and hKAT II active sites, after optimal superimposition of the 
two structures. The residues involved in L-Phe binding in hKAT I and their structurally equivalent 
residues in hKAT II are colored in white and green, respectively. The L-Phe sits above the PLP 
cofactor as observed in the structure of hKAT I: L-Phe complex (pdb code 1W7M) (206). 
 
Conformational changes 
It is well known that binding of substrates causes to aminotransferses a conformational change 
from the open to the closed form (222-224). However, similar conformational changes have not 
been observed in subgroup I  KATs (human KAT I and mouse KAT III) and in the new subgroup I  
aminotransferase (human KAT II). Another peculiar structural feature of human KAT II is a 
pronounced conformational change of the N-terminal region (residues 13-46) that affects the 
enzyme upon substrate binding, resulting in the correct structuring of the catalytic site (Figure 7). 
In particular, the loop encompassing residues 16-31 in hKAT II is subjected to a severe 
repositioning upon ligand binding. Indeed, it moves from one side of the active center to the other, 
becoming more exposed to the solvent and leaving space for the substrate aminophenyl side to 
bind. It also encapsulates the carboxylic side of the substrate within the center, thereby shielding 
the substrate binding pocket from bulk solvent (205). It has been proposed that the driving force of 
this conformational movement from a close conformation in the ligand-free form to an open 
conformation in the hKAT II/L-KYN complex, may be the interaction of Arg20 with the aromatic ring 
of L-KYN (225). Therefore, it was proposed that substrate specificity in human KAT II is achieved 
through an induced-fit mechanism, which, by properly structuring the active site of the enzyme, 
ultimately controls the recognition of substrates (34, 126, 218). In contrast, only limited 
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conformational changes take place during catalysis in human KAT I and mouse KAT III, which are 
characterized by a largely pre-formed active site that restricts the admission to the rigid enzyme’s 
catalytic cavity to relatively small and hydrophobic molecules (142).  
 
 
 
 
Figure 7. Conformational changes of KATs during catalysis. The structures of free (magenta) and 
ligand-bound (cyan) forms of each KAT structure are superposed upon each other. A human KAT 
I, B mouse KAT III, C human KAT II. The N-terminal -helices are shown as ribbons and the other 
residues that show significant side chain repositioning are depicted as sticks. Residues with an 
asterisk are from the secondary subunit in each functional dimer. The arrows show the direction of 
the movement of the N-terminal -helices and some crucial residues upon ligand binding (142). 
 
KAT catalyzed transamination reaction 
KATs irreversibly convert KYN to KYNA through a typical two-step transamination reaction, in 
which PLP acts as a coenzyme, alternating between the keto and amine forms in the two half-
reactions that constitute a catalytic cycle (225). The transamination mechanism of KYN catalyzed 
by hKAT II has been theoretically determined in details performing combined quantum mechanical 
and molecular mechanical (QM/MM) simulations (225). A reliable model of the ternary complex 
hKAT II/KYN/H20 system was built on the basis of the crystal structures of hKAT II recently 
released by Rizzi et al. (pdb code: 2vgz) (206), showing a ligand free enzyme co-crystallized with 
the cofactor in its PLP form,  and by Han et al. (pdb code: 2r2n) (205), showing KYN bound to the 
enzyme with the cofactor in its PMP form.  
The reaction mechanism (Scheme 3) begins with the PLP cofactor covalently bound in a Schiff-
base linkage to the -amino group of a specific and highly conserved lysine residue (Lys263 
according to hKAT II), forming an internal aldimmine. Consequently to substrate binding, the 
external aldimine intermediate is formed upon the nucleofilic attack of KYN to the internal aldimine 
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and the following displacement of Lys263. This reversible process then proceeds first through a 
hydrogen abstraction from the substrate C , leading to the ketimine intermediate. Following the 
electrophilic attack of the water molecule to the imine double bond, the covalent complex between 
the substrate and the cofactor is broken to give the cofactor in its PMP form and the ketoacid, 
namely 4-(2-aminophenyl)-2,4-dioxobutanoic acid, which quickly and spontaneously undergoes 
intramolecular cyclization leading the formation of KYNA. The intramolecular condensation leading 
KYNA is still poorly understood, but it is possible to envisage the formation of the pseudo-cyclic 
intermediate, as depicted in scheme 3. Moreover, it is not clear whether the intramolecualr 
cyclization of the keto acid 4-(2-aminophenyl)-2,4-dioxobutanoic acid may take place into the 
catalytic site of hKAT II or outside, in the external buffer. Computational evidence suggests that the 
formation of the cyclic product may take place directly into the catalytic site of hKAT II, and then it 
is released as final product from the catalytic centre (225).  
 
 
 
Scheme 3. Schematic representation of the first half-reaction catalyzed by KATs according to the 
standard catalytic mechanism adopted by PLP-dependent aminotransferases (211). 
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Scheme 4. Irreversible intramolecular condensation of the ketoacid intermediate to form KYNA 
(225). 
 
Moreover, the QM/MM theoretical study of the transamination mechanism of KYN catalyzed by 
hKAT II pointed out a set of five basic and aromatic residues that differently contribute to the 
interactions with the substrate and the intermediates along the catalytic cycle of hKAT II. A peculiar 
feature of hKAT II is the pronounced conformational change of the N-terminal region, that is highly 
flexible and folds over the catalytic site upon the binding of the substrate, resulting in the correct 
structuring of the catalytic site. The residue Arg20 is located on this N-terminal loop and is critically 
involved in stabilizing the complexes between KYN, the ketimine, the keto acid and the enzyme 
through -cation interaction with the anthranilic moiety of the substrates and intermediates. 
Another basic residue, Arg399, is involved in binding the substrate through salt bridge interactions 
between its guanidinium group and the -carboxylic group of KYN. This basic residue is highly 
conserved across all aminotransferases and has a pivotal role in the recognition of the substrate in 
the active site. The salt bridge anchors the amino acid group of the substrate into the active site, 
allowing its correct binding pose along the catalysis. Lys263 is the catalytic base that performs the 
heterolytic cleavage of the C -H bond in order to promote the transition from the external aldimine 
to the ketimine intermediate. This residue also provides a general base assistance in the hydrolysis 
of the immine double bond by stabilizing the water molecule. Two aromatic residues are involved in 
mediating interactions between the substrate, the intermediates and the enzyme along the catalytic 
path. While Tyr74 is indirectly involved in the stabilization of the external aldimine by stabilizing the 
catalytic Lys263 with hydrogen bonds, Tyr142 has a direct role in favouring the substrate 
approaching to the cofactor.  
Besides the roles of specific basic and aromatic residues, another interesting finding unveiled by 
this QM/MM theoretical study is the active role of the carbonyl group of KYN in driving a catalytic 
water molecule to adopt the correct pose over the imine bond for the hydrolysis. Indeed, the water 
molecule forms hydrogen bonds mainly with the carbonyl function of the substrate, with Lys263 
being the only residue responsible for positioning the water molecule over the catalytic centre in 
the final step of the reaction. This finding may have important implications for the rational design of 
new hKAT II competitive inhibitors that may incorporate a water molecule in the structrure (225). 
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KATs structure – based drug design     
From the point of view of drug development, the existence in the human brain of at least four 
KYNA-synthesizing enzymes, combined with the necessity of fine–tune KYNA levels to avoid the 
potentially harmful effects caused by a drastic deficiency of this neuroprotective metabolite in the 
CNS, requires the design of isozymes–specific inhibitors. This ambitious goal can be pursued only 
by defining the exquisite molecular traits governing substrates specificity in the different KATs 
isoforms. The different features of the ligand-biding pocket in KATs isoenzymes could be exploited 
for the rational design of highly specific hKAT II inhibitors. The structural informations about the 
steric requirement for KYN homing displayed by the active of hKAT I and hKAT II were exploited 
for the design of hKAT II specific inhibitors. Indeed, while in the human KAT I/KYN complex model 
the substrate anthranilic moiety perfectly fits the narrow and highly aromatic ligand binding site, 
some empty space is left in the structure of the human KAT II/KYN complex (206). Therefore the 
anthranilic moiety was proposed as hot spot for the chemical modification of substrate–like highly 
selective hKAT II inhibitors. In particular, increasing the steric hindrance of the anthranilic moiety 
would hamper binding to hKAT I, but would be tolerated by the wider hKAT II active site, as 
demonstrated by the synthesis of the first potent rat KAT II–specific inhibitor, (S)-4-
ethylsulfonylbenzoylalanine (S-ESBA), that bears a bulky substituent on the anthranilc ring of L-
KYN (146). 
 
                                              L-KYN                                    S-ESBA 
 
S-ESBA is an efficient and isoenzyme-selective inhibitor, as demonstrated by KYN transamination 
assay using either liver tissue homogenate or partially purified rat KAT II (IC50= 6.1 M)(146). 
Moreover, infusion of 5 mM ESBA in the rats hippocampus caused a decrease in extracellualr 
KYNA levels, which returned to normal values soon after the removal of the drug (145). However, 
the rat KAT II specific inhibitor S-ESBA is poorly active towards the human ortholog, as signalled 
by a 20-fold higher IC50 value (146). On the basis of the results of a molecular docking approach, 
two residues in KAT II amino acid sequence have been pointed out as the potential structural 
determinants responsible for the observed species-specificity of S-ESBA action (226). In particular, 
in the rat ortholog of KAT II, both the hydrophobic residues Leu 40 and pro 76 of human KAT II are 
substituted by polar serine residues. Since docking studies have proposed that these two residues 
may contribute to the different inhibitory activity exerted by ESBA, this hypothesis was further 
investigated by adopting a site-directed mutagenesis and a structural approach. A hKAT II double-
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mutant harbouring at position 40 and 76 the serine residues characterizing the rat isoenzyme was 
generated and further assayed in the presence of S-ESBA to evaluate its inhibitor potency. 
Unexpectedly, S-ESBA potency was actually reduced rather than increased by the two amino acid 
substitutions that were engineered in the human KAT II active site. Therefore, factors other than 
the two non-conserved mutated amino acids need to be identified to explain the striking difference 
in S-ESBA inhibitory efficiencies toward rat and human KAT II.  
 
Introduction 
 32 
REFERENCES 
 
1. Smith, S. A., Carr, F. P., and Pogson, C. I. (1980) The metabolism of L-tryptophan by 
isolated rat liver cells. Quantification of the relative importance of, and the effect of 
nutritional status on, the individual pathways of tryptophan metabolism, The Biochemical 
journal 192, 673-686. 
2. Beadle, G. W., Mitchell, H. K., and Nyc, J. F. (1947) Kynurenine as an Intermediate in the 
Formation of Nicotinic Acid from Tryptophane by Neurospora, Proceedings of the National 
Academy of Sciences of the United States of America 33, 155-158. 
3. Reinhard, J. F., Jr. (2004) Pharmacological manipulation of brain kynurenine metabolism, 
Annals of the New York Academy of Sciences 1035, 335-349. 
4. Hayaishi, O. (1976) Properties and function of indoleamine 2,3-dioxygenase, J Biochem 79, 
13P-21P. 
5. Hayaishi, O., Rothberg, S., Mehler, A. H., and Saito, Y. (1957) Studies on oxygenases; 
enzymatic formation of kynurenine from tryptophan, The Journal of biological chemistry 
229, 889-896. 
6. Dale, W. E., Dang, Y., and Brown, O. R. (2000) Tryptophan metabolism through the 
kynurenine pathway in rat brain and liver slices, Free radical biology & medicine 29, 191-
198. 
7. Comings, D. E., Muhleman, D., Dietz, G., Sherman, M., and Forest, G. L. (1995) Sequence 
of human tryptophan 2,3-dioxygenase (TDO2): presence of a glucocorticoid response-like 
element composed of a GTT repeat and an intronic CCCCT repeat, Genomics 29, 390-396. 
8. Guillemin, G. J., Brew, B. J., Noonan, C. E., Takikawa, O., and Cullen, K. M. (2005) 
Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease 
hippocampus, Neuropathology and applied neurobiology 31, 395-404. 
9. Byrne, G. I., Lehmann, L. K., Kirschbaum, J. G., Borden, E. C., Lee, C. M., and Brown, R. 
R. (1986) Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-
stimulated activity, Journal of interferon research 6, 389-396. 
10. Mehler, A. H., and Knox, W. E. (1950) The conversion of tryptophan to kynurenine in liver. 
II. The enzymatic hydrolysis of formylkynurenine, The Journal of biological chemistry 187, 
431-438. 
11. Moroni, F. (1999) Tryptophan metabolism and brain function: focus on kynurenine and 
other indole metabolites, European journal of pharmacology 375, 87-100. 
12. Guidetti, P., Eastman, C. L., and Schwarcz, R. (1995) Metabolism of [5-3H]kynurenine in 
the rat brain in vivo: evidence for the existence of a functional kynurenine pathway, Journal 
of neurochemistry 65, 2621-2632. 
Introduction 
 33 
13. Schwarcz, R., and Pellicciari, R. (2002) Manipulation of brain kynurenines: glial targets, 
neuronal effects, and clinical opportunities, The Journal of pharmacology and experimental 
therapeutics 303, 1-10. 
14. Stone, T. W. (1993) Neuropharmacology of quinolinic and kynurenic acids, 
Pharmacological reviews 45, 309-379. 
15. Pellicciari, R., Natalini, B., Costantino, G., Mahmoud, M. R., Mattoli, L., Sadeghpour, B. M., 
Moroni, F., Chiarugi, A., and Carpenedo, R. (1994) Modulation of the kynurenine pathway 
in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-
nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase, Journal of medicinal 
chemistry 37, 647-655. 
16. Fukui, S., Schwarcz, R., Rapoport, S. I., Takada, Y., and Smith, Q. R. (1991) Blood-brain 
barrier transport of kynurenines: implications for brain synthesis and metabolism, Journal of 
neurochemistry 56, 2007-2017. 
17. Nemeth, H., Toldi, J., and Vecsei, L. (2005) Role of kynurenines in the central and 
peripheral nervous systems, Curr Neurovasc Res 2, 249-260. 
18. Heyes, M. P., Achim, C. L., Wiley, C. A., Major, E. O., Saito, K., and Markey, S. P. (1996) 
Human microglia convert l-tryptophan into the neurotoxin quinolinic acid, The Biochemical 
journal 320 ( Pt 2), 595-597. 
19. Schwarcz, R., Ceresoli, G., and Guidetti, P. (1996) Kynurenine metabolism in the rat brain 
in vivo. Effect of acute excitotoxic insults, Advances in experimental medicine and biology 
398, 211-219. 
20. Guillemin, G. J., Kerr, S. J., Smythe, G. A., Smith, D. G., Kapoor, V., Armati, P. J., Croitoru, 
J., and Brew, B. J. (2001) Kynurenine pathway metabolism in human astrocytes: a paradox 
for neuronal protection, Journal of neurochemistry 78, 842-853. 
21. Amori, L., Guidetti, P., Pellicciari, R., Kajii, Y., and Schwarcz, R. (2009) On the Relationship 
between the Two Branches of the Kynurenine Pathway in the Rat Brain in Vivo, Journal of 
neurochemistry. 
22. Stone, T. W. (2001) Kynurenines in the CNS: from endogenous obscurity to therapeutic 
importance, Prog Neurobiol 64, 185-218. 
23. Heyes, M. P., Saito, K., Milstien, S., and Schiff, S. J. (1995) Quinolinic acid in tumors, 
hemorrhage and bacterial infections of the central nervous system in children, Journal of 
the neurological sciences 133, 112-118. 
24. Heyes, M. P., Saito, K., Lackner, A., Wiley, C. A., Achim, C. L., and Markey, S. P. (1998) 
Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and 
retrovirus-infected macaques, Faseb J 12, 881-896. 
25. Wonodi, I., and Schwarcz, R. Cortical kynurenine pathway metabolism: a novel target for 
cognitive enhancement in schizophrenia, Schizophrenia bulletin 36, 211-218. 
Introduction 
 34 
26. Bender, D. A., and McCreanor, G. M. (1985) Kynurenine hydroxylase: a potential rate-
limiting enzyme in tryptophan metabolism, Biochemical Society transactions 13, 441-443. 
27. Okuno, E., and Kido, R. (1991) Kynureninase and kynurenine 3-hydroxylase in mammalian 
tissues, Advances in experimental medicine and biology 294, 167-176. 
28. Okuno, E., Nakamura, M., and Schwarcz, R. (1991) Two kynurenine aminotransferases in 
human brain, Brain research 542, 307-312. 
29. Schmidt, W., Guidetti, P., Okuno, E., and Schwarcz, R. (1993) Characterization of human 
brain kynurenine aminotransferases using [3H]kynurenine as a substrate, Neuroscience 55, 
177-184. 
30. Guidetti, P., Amori, L., Sapko, M. T., Okuno, E., and Schwarcz, R. (2007) Mitochondrial 
aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain, 
Journal of neurochemistry 102, 103-111. 
31. Yu, P., Li, Z., Zhang, L., Tagle, D. A., and Cai, T. (2006) Characterization of kynurenine 
aminotransferase III, a novel member of a phylogenetically conserved KAT family, Gene 
365, 111-118. 
32. Han, Q., Robinson, H., Cai, T., Tagle, D. A., and Li, J. (2009) Biochemical and structural 
properties of mouse kynurenine aminotransferase III, Mol Cell Biol 29, 784-793. 
33. Han, Q., Li, J., and Li, J. (2004) pH dependence, substrate specificity and inhibition of 
human kynurenine aminotransferase I, Eur J Biochem 271, 4804-4814. 
34. Han, Q., Cai, T., Tagle, D. A., Robinson, H., and Li, J. (2008) Substrate specificity and 
structure of human aminoadipate aminotransferase/kynurenine aminotransferase II, Biosci 
Rep 28, 205-215. 
35. Cooper, A. J., and Pinto, J. T. (2006) Cysteine S-conjugate beta-lyases, Amino Acids 30, 1-
15. 
36. Cooper, A. J., Pinto, J. T., Krasnikov, B. F., Niatsetskaya, Z. V., Han, Q., Li, J., Vauzour, D., 
and Spencer, J. P. (2008) Substrate specificity of human glutamine transaminase K as an 
aminotransferase and as a cysteine S-conjugate beta-lyase, Archives of biochemistry and 
biophysics 474, 72-81. 
37. Guidetti, P., Okuno, E., and Schwarcz, R. (1997) Characterization of rat brain kynurenine 
aminotransferases I and II, Journal of neuroscience research 50, 457-465. 
38. Lapin, I. P. (1978) Stimulant and convulsive effects of kynurenines injected into brain 
ventricles in mice, J Neural Transm 42, 37-43. 
39. Stone, T. W., and Perkins, M. N. (1981) Quinolinic acid: a potent endogenous excitant at 
amino acid receptors in CNS, European journal of pharmacology 72, 411-412. 
40. Schwarcz, R., and Kohler, C. (1983) Differential vulnerability of central neurons of the rat to 
quinolinic acid, Neuroscience letters 38, 85-90. 
Introduction 
 35 
41. Schwarcz, R., Whetsell, W. O., Jr., and Mangano, R. M. (1983) Quinolinic acid: an 
endogenous metabolite that produces axon-sparing lesions in rat brain, Science (New York, 
N.Y 219, 316-318. 
42. Stone, T. W., and Darlington, L. G. (2002) Endogenous kynurenines as targets for drug 
discovery and development, Nat Rev Drug Discov 1, 609-620. 
43. Baran, H., Jellinger, K., and Deecke, L. (1999) Kynurenine metabolism in Alzheimer's 
disease, J Neural Transm 106, 165-181. 
44. Ogawa, T., Matson, W. R., Beal, M. F., Myers, R. H., Bird, E. D., Milbury, P., and Saso, S. 
(1992) Kynurenine pathway abnormalities in Parkinson's disease, Neurology 42, 1702-
1706. 
45. Beal, M. F., Matson, W. R., Swartz, K. J., Gamache, P. H., and Bird, E. D. (1990) 
Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced 
formation of kynurenic acid, Journal of neurochemistry 55, 1327-1339. 
46. Jauch, D., Urbanska, E. M., Guidetti, P., Bird, E. D., Vonsattel, J. P., Whetsell, W. O., Jr., 
and Schwarcz, R. (1995) Dysfunction of brain kynurenic acid metabolism in Huntington's 
disease: focus on kynurenine aminotransferases, Journal of the neurological sciences 130, 
39-47. 
47. Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindstrom, L. H., and Engberg, G. (2001) 
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia, 
Neuroscience letters 313, 96-98. 
48. Erhardt, S., Schwieler, L., and Engberg, G. (2003) Kynurenic acid and schizophrenia, 
Advances in experimental medicine and biology 527, 155-165. 
49. Erhardt, S., Schwieler, L., Nilsson, L., Linderholm, K., and Engberg, G. (2007) The 
kynurenic acid hypothesis of schizophrenia, Physiol Behav 92, 203-209. 
50. Nilsson, L. K., Linderholm, K. R., Engberg, G., Paulson, L., Blennow, K., Lindstrom, L. H., 
Nordin, C., Karanti, A., Persson, P., and Erhardt, S. (2005) Elevated levels of kynurenic 
acid in the cerebrospinal fluid of male patients with schizophrenia, Schizophr Res 80, 315-
322. 
51. Rejdak, K., Bartosik-Psujek, H., Dobosz, B., Kocki, T., Grieb, P., Giovannoni, G., Turski, W. 
A., and Stelmasiak, Z. (2002) Decreased level of kynurenic acid in cerebrospinal fluid of 
relapsing-onset multiple sclerosis patients, Neuroscience letters 331, 63-65. 
52. Ilzecka, J., Kocki, T., Stelmasiak, Z., and Turski, W. A. (2003) Endogenous protectant 
kynurenic acid in amyotrophic lateral sclerosis, Acta neurologica Scandinavica 107, 412-
418. 
53. Carpenedo, R., Pittaluga, A., Cozzi, A., Attucci, S., Galli, A., Raiteri, M., and Moroni, F. 
(2001) Presynaptic kynurenate-sensitive receptors inhibit glutamate release, Eur J Neurosci 
13, 2141-2147. 
Introduction 
 36 
54. Wu, H. Q., Rassoulpour, A., and Schwarcz, R. (2007) Kynurenic acid leads, dopamine 
follows: a new case of volume transmission in the brain?, J Neural Transm 114, 33-41. 
55. Dani, J. A., and Mayer, M. L. (1995) Structure and function of glutamate and nicotinic 
acetylcholine receptors, Current opinion in neurobiology 5, 310-317. 
56. Daoudal, G., and Debanne, D. (2003) Long-term plasticity of intrinsic excitability: learning 
rules and mechanisms, Learn Mem 10, 456-465. 
57. Whitlock, J. R., Heynen, A. J., Shuler, M. G., and Bear, M. F. (2006) Learning induces long-
term potentiation in the hippocampus, Science (New York, N.Y 313, 1093-1097. 
58. Ogura, A., Miyamoto, M., and Kudo, Y. (1988) Neuronal death in vitro: parallelism between 
survivability of hippocampal neurones and sustained elevation of cytosolic Ca2+ after 
exposure to glutamate receptor agonist, Experimental brain research. Experimentelle 
Hirnforschung 73, 447-458. 
59. Vergun, O., Keelan, J., Khodorov, B. I., and Duchen, M. R. (1999) Glutamate-induced 
mitochondrial depolarisation and perturbation of calcium homeostasis in cultured rat 
hippocampal neurones, J Physiol 519 Pt 2, 451-466. 
60. Mark, L. P., Prost, R. W., Ulmer, J. L., Smith, M. M., Daniels, D. L., Strottmann, J. M., 
Brown, W. D., and Hacein-Bey, L. (2001) Pictorial review of glutamate excitotoxicity: 
fundamental concepts for neuroimaging, AJNR Am J Neuroradiol 22, 1813-1824. 
61. Danysz, W., and Parsons, C. G. (1998) Glycine and N-methyl-D-aspartate receptors: 
physiological significance and possible therapeutic applications, Pharmacological reviews 
50, 597-664. 
62. Yamazaki, M., Mori, H., Araki, K., Mori, K. J., and Mishina, M. (1992) Cloning, expression 
and modulation of a mouse NMDA receptor subunit, FEBS letters 300, 39-45. 
63. Pereira, E. F., Hilmas, C., Santos, M. D., Alkondon, M., Maelicke, A., and Albuquerque, E. 
X. (2002) Unconventional ligands and modulators of nicotinic receptors, J Neurobiol 53, 
479-500. 
64. Clementi, F., Fornasari, D., and Gotti, C. (2000) Neuronal nicotinic receptors, important 
new players in brain function, European journal of pharmacology 393, 3-10. 
65. Castro, N. G., and Albuquerque, E. X. (1995) alpha-Bungarotoxin-sensitive hippocampal 
nicotinic receptor channel has a high calcium permeability, Biophysical journal 68, 516-524. 
66. Decker, E. R., and Dani, J. A. (1990) Calcium permeability of the nicotinic acetylcholine 
receptor: the single-channel calcium influx is significant, J Neurosci 10, 3413-3420. 
67. Dani, J. A. (2001) Overview of nicotinic receptors and their roles in the central nervous 
system, Biological psychiatry 49, 166-174. 
68. Albuquerque, E. X., Alkondon, M., Pereira, E. F., Castro, N. G., Schrattenholz, A., Barbosa, 
C. T., Bonfante-Cabarcas, R., Aracava, Y., Eisenberg, H. M., and Maelicke, A. (1997) 
Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization 
Introduction 
 37 
and modulation of synaptic function, The Journal of pharmacology and experimental 
therapeutics 280, 1117-1136. 
69. Levin, E. D., Bradley, A., Addy, N., and Sigurani, N. (2002) Hippocampal alpha 7 and alpha 
4 beta 2 nicotinic receptors and working memory, Neuroscience 109, 757-765. 
70. Broide, R. S., and Leslie, F. M. (1999) The alpha7 nicotinic acetylcholine receptor in 
neuronal plasticity, Molecular neurobiology 20, 1-16. 
71. Nordberg, A. (1994) Human nicotinic receptors--their role in aging and dementia, 
Neurochemistry international 25, 93-97. 
72. Perry, E. K., Morris, C. M., Court, J. A., Cheng, A., Fairbairn, A. F., McKeith, I. G., Irving, 
D., Brown, A., and Perry, R. H. (1995) Alteration in nicotine binding sites in Parkinson's 
disease, Lewy body dementia and Alzheimer's disease: possible index of early 
neuropathology, Neuroscience 64, 385-395. 
73. Turski, W. A., Gramsbergen, J. B., Traitler, H., and Schwarcz, R. (1989) Rat brain slices 
produce and liberate kynurenic acid upon exposure to L-kynurenine, Journal of 
neurochemistry 52, 1629-1636. 
74. Swartz, K. J., During, M. J., Freese, A., and Beal, M. F. (1990) Cerebral synthesis and 
release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors, J 
Neurosci 10, 2965-2973. 
75. Moroni, F., Russi, P., Lombardi, G., Beni, M., and Carla, V. (1988) Presence of kynurenic 
acid in the mammalian brain, Journal of neurochemistry 51, 177-180. 
76. Turski, W. A., and Schwarcz, R. (1988) On the disposition of intrahippocampally injected 
kynurenic acid in the rat, Experimental brain research. Experimentelle Hirnforschung 71, 
563-567. 
77. Turski, W. A., Nakamura, M., Todd, W. P., Carpenter, B. K., Whetsell, W. O., Jr., and 
Schwarcz, R. (1988) Identification and quantification of kynurenic acid in human brain 
tissue, Brain research 454, 164-169. 
78. Moroni, F., Russi, P., Carla, V., and Lombardi, G. (1988) Kynurenic acid is present in the 
rat brain and its content increases during development and aging processes, Neuroscience 
letters 94, 145-150. 
79. Kessler, M., Terramani, T., Lynch, G., and Baudry, M. (1989) A glycine site associated with 
N-methyl-D-aspartic acid receptors: characterization and identification of a new class of 
antagonists, Journal of neurochemistry 52, 1319-1328. 
80. Hilmas, C., Pereira, E. F., Alkondon, M., Rassoulpour, A., Schwarcz, R., and Albuquerque, 
E. X. (2001) The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity 
and increases non-alpha7 nicotinic receptor expression: physiopathological implications, J 
Neurosci 21, 7463-7473. 
Introduction 
 38 
81. Perkins, M. N., and Stone, T. W. (1982) An iontophoretic investigation of the actions of 
convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid, 
Brain research 247, 184-187. 
82. Kloog, Y., Lamdani-Itkin, H., and Sokolovsky, M. (1990) The glycine site of the N-methyl-D-
aspartate receptor channel: differences between the binding of HA-966 and of 7-
chlorokynurenic acid, Journal of neurochemistry 54, 1576-1583. 
83. Mayer, M. L., Westbrook, G. L., and Vyklicky, L., Jr. (1988) Sites of antagonist action on N-
methyl-D-aspartic acid receptors studied using fluctuation analysis and a rapid perfusion 
technique, Journal of neurophysiology 60, 645-663. 
84. Birch, P. J., Grossman, C. J., and Hayes, A. G. (1988) Kynurenate and FG9041 have both 
competitive and non-competitive antagonist actions at excitatory amino acid receptors, 
European journal of pharmacology 151, 313-315. 
85. Foster, A. C., Vezzani, A., French, E. D., and Schwarcz, R. (1984) Kynurenic acid blocks 
neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid, 
Neuroscience letters 48, 273-278. 
86. Chess, A. C., and Bucci, D. J. (2006) Increased concentration of cerebral kynurenic acid 
alters stimulus processing and conditioned responding, Behavioural brain research 170, 
326-332. 
87. Shepard, P. D., Joy, B., Clerkin, L., and Schwarcz, R. (2003) Micromolar brain levels of 
kynurenic acid are associated with a disruption of auditory sensory gating in the rat, 
Neuropsychopharmacology 28, 1454-1462. 
88. Stone, T. W. (2007) Kynurenic acid blocks nicotinic synaptic transmission to hippocampal 
interneurons in young rats, Eur J Neurosci 25, 2656-2665. 
89. Mansvelder, H. D., and McGehee, D. S. (2000) Long-term potentiation of excitatory inputs 
to brain reward areas by nicotine, Neuron 27, 349-357. 
90. Zoli, M., Picciotto, M. R., Ferrari, R., Cocchi, D., and Changeux, J. P. (1999) Increased 
neurodegeneration during ageing in mice lacking high-affinity nicotine receptors, The 
EMBO journal 18, 1235-1244. 
91. Kihara, T., Shimohama, S., Sawada, H., Honda, K., Nakamizo, T., Shibasaki, H., Kume, T., 
and Akaike, A. (2001) alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 
3-kinase to block A beta-amyloid-induced neurotoxicity, The Journal of biological chemistry 
276, 13541-13546. 
92. D'Angelo, E., Rossi, P., and Garthwaite, J. (1990) Dual-component NMDA receptor 
currents at a single central synapse, Nature 346, 467-470. 
93. Singh, L., Oles, R. J., and Tricklebank, M. D. (1990) Modulation of seizure susceptibility in 
the mouse by the strychnine-insensitive glycine recognition site of the NMDA receptor/ion 
channel complex, British journal of pharmacology 99, 285-288. 
Introduction 
 39 
94. Bergeron, R., Meyer, T. M., Coyle, J. T., and Greene, R. W. (1998) Modulation of N-methyl-
D-aspartate receptor function by glycine transport, Proceedings of the National Academy of 
Sciences of the United States of America 95, 15730-15734. 
95. Erhardt, S., Schwieler, L., Emanuelsson, C., and Geyer, M. (2004) Endogenous kynurenic 
acid disrupts prepulse inhibition, Biological psychiatry 56, 255-260. 
96. Kiss, C., Ceresoli-Borroni, G., Guidetti, P., Zielke, C. L., Zielke, H. R., and Schwarcz, R. 
(2003) Kynurenate production by cultured human astrocytes, J Neural Transm 110, 1-14. 
97. Roberts, R. C., McCarthy, K. E., Du, F., Ottersen, O. P., Okuno, E., and Schwarcz, R. 
(1995) 3-Hydroxyanthranilic acid oxygenase-containing astrocytic processes surround 
glutamate-containing axon terminals in the rat striatum, J Neurosci 15, 1150-1161. 
98. Wang, J., Simonavicius, N., Wu, X., Swaminath, G., Reagan, J., Tian, H., and Ling, L. 
(2006) Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35, The 
Journal of biological chemistry 281, 22021-22028. 
99. Kotani, M., Detheux, M., Vandenbogaerde, A., Communi, D., Vanderwinden, J. M., Le Poul, 
E., Brezillon, S., Tyldesley, R., Suarez-Huerta, N., Vandeput, F., Blanpain, C., Schiffmann, 
S. N., Vassart, G., and Parmentier, M. (2001) The metastasis suppressor gene KiSS-1 
encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54, 
The Journal of biological chemistry 276, 34631-34636. 
100. Lin, S. H., and Civelli, O. (2004) Orphan G protein-coupled receptors: targets for new 
therapeutic interventions, Annals of medicine 36, 204-214. 
101. Mellor, A. L., and Munn, D. H. (2004) IDO expression by dendritic cells: tolerance and 
tryptophan catabolism, Nature reviews 4, 762-774. 
102. Taylor, M. W., and Feng, G. S. (1991) Relationship between interferon-gamma, 
indoleamine 2,3-dioxygenase, and tryptophan catabolism, Faseb J 5, 2516-2522. 
103. Ito, S., Komatsu, K., Tsukamoto, K., and Sved, A. F. (2000) Excitatory amino acids in the 
rostral ventrolateral medulla support blood pressure in spontaneously hypertensive rats, 
Hypertension 35, 413-417. 
104. Kapoor, V., Kapoor, R., and Chalmers, J. (1994) Kynurenic acid, an endogenous glutamate 
antagonist, in SHR and WKY rats: possible role in central blood pressure regulation, 
Clinical and experimental pharmacology & physiology 21, 891-896. 
105. Kiely, J. M., and Gordon, F. J. (1994) Role of rostral ventrolateral medulla in centrally 
mediated pressor responses, The American journal of physiology 267, H1549-1556. 
106. Kapoor, V., Thuruthyil, S. J., and Human, B. (1998) Reduced kynurenine aminotransferase-
I activity in SHR rats may be due to lack of KAT-Ib activity, Neuroreport 9, 1431-1434. 
107. Mizutani, K., Sugimoto, K., Okuda, T., Katsuya, T., Miyata, T., Tanabe, T., Higaki, J., 
Ogihara, T., Yamori, Y., Tsujita, Y., Tago, N., and Iwai, N. (2002) Kynureninase is a novel 
Introduction 
 40 
candidate gene for hypertension in spontaneously hypertensive rats, Hypertens Res 25, 
135-140. 
108. Smith, A. J., Stone, T. W., and Smith, R. A. (2007) Neurotoxicity of tryptophan metabolites, 
Biochemical Society transactions 35, 1287-1289. 
109. Tavares, R. G., Schmidt, A. P., Abud, J., Tasca, C. I., and Souza, D. O. (2005) In vivo 
quinolinic acid increases synaptosomal glutamate release in rats: reversal by guanosine, 
Neurochemical research 30, 439-444. 
110. Braidy, N., Grant, R., Adams, S., Brew, B. J., and Guillemin, G. J. (2009) Mechanism for 
quinolinic acid cytotoxicity in human astrocytes and neurons, Neurotoxicity research 16, 77-
86. 
111. Heyes, M. P., Swartz, K. J., Markey, S. P., and Beal, M. F. (1991) Regional brain and 
cerebrospinal fluid quinolinic acid concentrations in Huntington's disease, Neuroscience 
letters 122, 265-269. 
112. Moroni, F., Russi, P., Gallo-Mezo, M. A., Moneti, G., and Pellicciari, R. (1991) Modulation of 
quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and 
nicotinylalanine, Journal of neurochemistry 57, 1630-1635. 
113. Saito, K., Markey, S. P., and Heyes, M. P. (1992) Effects of immune activation on quinolinic 
acid and neuroactive kynurenines in the mouse, Neuroscience 51, 25-39. 
114. Rios, C., and Santamaria, A. (1991) Quinolinic acid is a potent lipid peroxidant in rat brain 
homogenates, Neurochemical research 16, 1139-1143. 
115. Behan, W. M., McDonald, M., Darlington, L. G., and Stone, T. W. (1999) Oxidative stress 
as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin 
and deprenyl, British journal of pharmacology 128, 1754-1760. 
116. Eastman, C. L., and Guilarte, T. R. (1989) Cytotoxicity of 3-hydroxykynurenine in a 
neuronal hybrid cell line, Brain research 495, 225-231. 
117. Jhamandas, K., Boegman, R. J., Beninger, R. J., and Bialik, M. (1990) Quinolinate-induced 
cortical cholinergic damage: modulation by tryptophan metabolites, Brain research 529, 
185-191. 
118. Goldstein, L. E., Leopold, M. C., Huang, X., Atwood, C. S., Saunders, A. J., Hartshorn, M., 
Lim, J. T., Faget, K. Y., Muffat, J. A., Scarpa, R. C., Chylack, L. T., Jr., Bowden, E. F., 
Tanzi, R. E., and Bush, A. I. (2000) 3-Hydroxykynurenine and 3-hydroxyanthranilic acid 
generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion 
reduction, Biochemistry 39, 7266-7275. 
119. Vamos, E., Pardutz, A., Klivenyi, P., Toldi, J., and Vecsei, L. (2009) The role of kynurenines 
in disorders of the central nervous system: possibilities for neuroprotection, Journal of the 
neurological sciences 283, 21-27. 
Introduction 
 41 
120. Coyle, J. T. (2006) Glial metabolites of tryptophan and excitotoxicity: coming unglued, Exp 
Neurol 197, 4-7. 
121. Gigler, G., Szenasi, G., Simo, A., Levay, G., Harsing, L. G., Jr., Sas, K., Vecsei, L., and 
Toldi, J. (2007) Neuroprotective effect of L-kynurenine sulfate administered before focal 
cerebral ischemia in mice and global cerebral ischemia in gerbils, European journal of 
pharmacology 564, 116-122. 
122. Scharfman, H. E., Hodgkins, P. S., Lee, S. C., and Schwarcz, R. (1999) Quantitative 
differences in the effects of de novo produced and exogenous kynurenic acid in rat brain 
slices, Neuroscience letters 274, 111-114. 
123. Cozzi, A., Carpenedo, R., and Moroni, F. (1999) Kynurenine hydroxylase inhibitors reduce 
ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-
N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global 
brain ischemia, J Cereb Blood Flow Metab 19, 771-777. 
124. Zmarowski, A., Wu, H. Q., Brooks, J. M., Potter, M. C., Pellicciari, R., Schwarcz, R., and 
Bruno, J. P. (2009) Astrocyte-derived kynurenic acid modulates basal and evoked cortical 
acetylcholine release, Eur J Neurosci 29, 529-538. 
125. Wu, H. Q., Pereira, E. F., Bruno, J. P., Pellicciari, R., Albuquerque, E. X., and Schwarcz, R. 
The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls 
extracellular glutamate levels in the prefrontal cortex, J Mol Neurosci 40, 204-210. 
126. Rossi, F., Schwarcz, R., and Rizzi, M. (2008) Curiosity to kill the KAT (kynurenine 
aminotransferase): structural insights into brain kynurenic acid synthesis, Curr Opin Struct 
Biol 18, 748-755. 
127. Baran, H., Cairns, N., Lubec, B., and Lubec, G. (1996) Increased kynurenic acid levels and 
decreased brain kynurenine aminotransferase I in patients with Down syndrome, Life Sci 
58, 1891-1899. 
128. Yamamoto, H., Shindo, I., Egawa, B., and Horiguchi, K. (1994) Kynurenic acid is decreased 
in cerebrospinal fluid of patients with infantile spasms, Pediatr Neurol 10, 9-12. 
129. Medana, I. M., Day, N. P., Salahifar-Sabet, H., Stocker, R., Smythe, G., Bwanaisa, L., 
Njobvu, A., Kayira, K., Turner, G. D., Taylor, T. E., and Hunt, N. H. (2003) Metabolites of 
the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian 
children with malaria, J Infect Dis 188, 844-849. 
130. Heyes, M. P., Brew, B. J., Saito, K., Quearry, B. J., Price, R. W., Lee, K., Bhalla, R. B., Der, 
M., and Markey, S. P. (1992) Inter-relationships between quinolinic acid, neuroactive 
kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-
infected patients, J Neuroimmunol 40, 71-80. 
131. Heyes, M. P., Saito, K., Crowley, J. S., Davis, L. E., Demitrack, M. A., Der, M., Dilling, L. A., 
Elia, J., Kruesi, M. J., Lackner, A., and et al. (1992) Quinolinic acid and kynurenine pathway 
Introduction 
 42 
metabolism in inflammatory and non-inflammatory neurological disease, Brain 115 ( Pt 5), 
1249-1273. 
132. Linderholm, K. R., Skogh, E., Olsson, S. K., Dahl, M. L., Holtze, M., Engberg, G., 
Samuelsson, M., and Erhardt, S. Increased Levels of Kynurenine and Kynurenic Acid in the 
CSF of Patients With Schizophrenia, Schizophrenia bulletin. 
133. Chess, A. C., Simoni, M. K., Alling, T. E., and Bucci, D. J. (2007) Elevations of endogenous 
kynurenic acid produce spatial working memory deficits, Schizophrenia bulletin 33, 797-
804. 
134. Chess, A. C., Landers, A. M., and Bucci, D. J. (2009) L-kynurenine treatment alters 
contextual fear conditioning and context discrimination but not cue-specific fear 
conditioning, Behavioural brain research 201, 325-331. 
135. Schwarcz, R., Rassoulpour, A., Wu, H. Q., Medoff, D., Tamminga, C. A., and Roberts, R. 
C. (2001) Increased cortical kynurenate content in schizophrenia, Biological psychiatry 50, 
521-530. 
136. Zelante, T., Fallarino, F., Bistoni, F., Puccetti, P., and Romani, L. (2009) Indoleamine 2,3-
dioxygenase in infection: the paradox of an evasive strategy that benefits the host, 
Microbes and infection / Institut Pasteur 11, 133-141. 
137. Aoyama, N., Takahashi, N., Saito, S., Maeno, N., Ishihara, R., Ji, X., Miura, H., Ikeda, M., 
Suzuki, T., Kitajima, T., Yamanouchi, Y., Kinoshita, Y., Yoshida, K., Iwata, N., Inada, T., 
and Ozaki, N. (2006) Association study between kynurenine 3-monooxygenase gene and 
schizophrenia in the Japanese population, Genes, brain, and behavior 5, 364-368. 
138. Court, J., Spurden, D., Lloyd, S., McKeith, I., Ballard, C., Cairns, N., Kerwin, R., Perry, R., 
and Perry, E. (1999) Neuronal nicotinic receptors in dementia with Lewy bodies and 
schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus, Journal of 
neurochemistry 73, 1590-1597. 
139. Alkondon, M., Pereira, E. F., Yu, P., Arruda, E. Z., Almeida, L. E., Guidetti, P., Fawcett, W. 
P., Sapko, M. T., Randall, W. R., Schwarcz, R., Tagle, D. A., and Albuquerque, E. X. (2004) 
Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of 
endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic 
receptors in the hippocampus, J Neurosci 24, 4635-4648. 
140. Salter, M., Hazelwood, R., Pogson, C. I., Iyer, R., and Madge, D. J. (1995) The effects of a 
novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin 
metabolism in the rat, Biochemical pharmacology 49, 1435-1442. 
141. Tan, P. H., and Bharath, A. K. (2009) Manipulation of indoleamine 2,3 dioxygenase; a novel 
therapeutic target for treatment of diseases, Expert opinion on therapeutic targets 13, 987-
1012. 
Introduction 
 43 
142. Han, Q., Cai, T., Tagle, D. A., and Li, J. Structure, expression, and function of kynurenine 
aminotransferases in human and rodent brains, Cell Mol Life Sci 67, 353-368. 
143. Yu, P., Di Prospero, N. A., Sapko, M. T., Cai, T., Chen, A., Melendez-Ferro, M., Du, F., 
Whetsell, W. O., Jr., Guidetti, P., Schwarcz, R., and Tagle, D. A. (2004) Biochemical and 
phenotypic abnormalities in kynurenine aminotransferase II-deficient mice, Mol Cell Biol 24, 
6919-6930. 
144. Potter, M. C., Elmer, G. I., Bergeron, R., Albuquerque, E. X., Guidetti, P., Wu, H. Q., and 
Schwarcz, R. Reduction of endogenous kynurenic acid formation enhances extracellular 
glutamate, hippocampal plasticity, and cognitive behavior, Neuropsychopharmacology 35, 
1734-1742. 
145. Amori, L., Wu, H. Q., Marinozzi, M., Pellicciari, R., Guidetti, P., and Schwarcz, R. (2009) 
Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the 
rodent striatum, Neuroscience 159, 196-203. 
146. Pellicciari, R., Rizzo, R. C., Costantino, G., Marinozzi, M., Amori, L., Guidetti, P., Wu, H. Q., 
and Schwarcz, R. (2006) Modulators of the kynurenine pathway of tryptophan metabolism: 
synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a 
potent and selective kynurenine aminotransferase II (KAT II) inhibitor, ChemMedChem 1, 
528-531. 
147. Schwarcz, R. (2004) The kynurenine pathway of tryptophan degradation as a drug target, 
Curr Opin Pharmacol 4, 12-17. 
148. Stone, T. W., Mackay, G. M., Forrest, C. M., Clark, C. J., and Darlington, L. G. (2003) 
Tryptophan metabolites and brain disorders, Clin Chem Lab Med 41, 852-859. 
149. Costantino, G. (2009) New promises for manipulation of kynurenine pathway in cancer and 
neurological diseases, Expert opinion on therapeutic targets 13, 247-258. 
150. Erhardt, S., Olsson, S. K., and Engberg, G. (2009) Pharmacological manipulation of 
kynurenic Acid: potential in the treatment of psychiatric disorders, CNS Drugs 23, 91-101. 
151. Nemeth, H., Toldi, J., and Vecsei, L. (2006) Kynurenines, Parkinson's disease and other 
neurodegenerative disorders: preclinical and clinical studies, J Neural Transm Suppl, 285-
304. 
152. Noguchi, T., Minatogawa, Y., Okuno, E., Nakatani, M., and Morimoto, M. (1975) Purification 
and characterization of kynurenine--2-oxoglutarate aminotransferase from the liver, brain 
and small intestine of rats, The Biochemical journal 151, 399-406. 
153. Okuno, E., Minatogawa, Y., Nakamura, M., Kamoda, N., Nakanishi, J., Makino, M., and 
Kido, R. (1980) Crystallization and characterization of human liver kynurenine--glyoxylate 
aminotransferase. Identity with alanine--glyoxylate aminotransferase and serine--pyruvate 
aminotransferase, The Biochemical journal 189, 581-590. 
Introduction 
 44 
154. Okuno, E., Schmidt, W., Parks, D. A., Nakamura, M., and Schwarcz, R. (1991) 
Measurement of rat brain kynurenine aminotransferase at physiological kynurenine 
concentrations, Journal of neurochemistry 57, 533-540. 
155. Papadimitriou, J. M., and van Duijn, P. (1970) The ultrastructural localization of the 
isozymes of aspartate aminotransferase in murine tissues, The Journal of cell biology 47, 
84-98. 
156. Cechetto, J. D., Sadacharan, S. K., Berk, P. D., and Gupta, R. S. (2002) Immunogold 
localization of mitochondrial aspartate aminotransferase in mitochondria and on the cell 
surface in normal rat tissues, Histology and histopathology 17, 353-364. 
157. Tanaka, M., Takeda, N., Tohyama, M., and Matsunaga, T. (1990) Immunocytochemical 
localization of mitochondrial and cytosolic aspartate aminotransferase isozymes in the 
vestibular end-organs of rats, Eur Arch Otorhinolaryngol 247, 119-121. 
158. Goh, D. L., Patel, A., Thomas, G. H., Salomons, G. S., Schor, D. S., Jakobs, C., and 
Geraghty, M. T. (2002) Characterization of the human gene encoding alpha-aminoadipate 
aminotransferase (AADAT), Molecular genetics and metabolism 76, 172-180. 
159. Mawal, M. R., Mukhopadhyay, A., and Deshmukh, D. R. (1991) Purification and properties 
of kynurenine aminotransferase from rat kidney, The Biochemical journal 279 ( Pt 2), 595-
599. 
160. Takeuchi, F., Otsuka, H., and Shibata, Y. (1983) Purification, characterization and 
identification of rat liver mitochondrial kynurenine aminotransferase with alpha-
aminoadipate aminotransferase, Biochimica et biophysica acta 743, 323-330. 
161. Nakatani, Y., Fujioka, M., and Higashino, K. (1970) Alpha-aminoadipate aminotransferase 
of rat liver mitochondria, Biochimica et biophysica acta 198, 219-228. 
162. Higashino, K., Fujioka, M., and Yamamura, Y. (1971) The conversion of L-lysine to 
saccharopine and alpha-aminoadipate in mouse, Archives of biochemistry and biophysics 
142, 606-614. 
163. Tobes, M. C., and Mason, M. (1975) L-kynurenine aminotransferase and L-alpha-
aminoadipate aminotransferase. I. Evidence for identity, Biochemical and biophysical 
research communications 62, 390-397. 
164. Tobes, M. C., and Mason, M. (1977) Alpha-Aminoadipate aminotransferase and kynurenine 
aminotransferase. Purification, characterization, and further evidence for identity, The 
Journal of biological chemistry 252, 4591-4599. 
165. Sapko, M. T., Guidetti, P., Yu, P., Tagle, D. A., Pellicciari, R., and Schwarcz, R. (2006) 
Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: 
Implications for Huntington's disease, Exp Neurol 197, 31-40. 
Introduction 
 45 
166. Miyazaki, T., Miyazaki, J., Yamane, H., and Nishiyama, M. (2004) alpha-Aminoadipate 
aminotransferase from an extremely thermophilic bacterium, Thermus thermophilus, 
Microbiology (Reading, England) 150, 2327-2334. 
167. Xu, H., Andi, B., Qian, J., West, A. H., and Cook, P. F. (2006) The alpha-aminoadipate 
pathway for lysine biosynthesis in fungi, Cell biochemistry and biophysics 46, 43-64. 
168. Zabriskie, T. M., and Jackson, M. D. (2000) Lysine biosynthesis and metabolism in fungi, 
Natural product reports 17, 85-97. 
169. Matsuda, M., and Ogur, M. (1969) Separation and specificity of the yeast glutamate-alpha-
ketoadipate transaminase, The Journal of biological chemistry 244, 3352-3358. 
170. Chang, Y. E. (1978) Lysine metabolism in the rat brain: the pipecolic acid-forming pathway, 
Journal of neurochemistry 30, 347-354. 
171. Chang, Y. F. (1982) Lysine metabolism in the human and the monkey: demonstration of 
pipecolic acid formation in the brain and other organs, Neurochemical research 7, 577-588. 
172. Brown, D. R., and Kretzschmar, H. A. (1998) The glio-toxic mechanism of alpha-
aminoadipic acid on cultured astrocytes, Journal of neurocytology 27, 109-118. 
173. Nishimura, R. N., Santos, D., Fu, S. T., and Dwyer, B. E. (2000) Induction of cell death by 
L-alpha-aminoadipic acid exposure in cultured rat astrocytes: relationship to protein 
synthesis, Neurotoxicology 21, 313-320. 
174. Takada, M., and Hattori, T. (1986) Fine structural changes in the rat brain after local 
injections of gliotoxin, alpha-aminoadipic acid, Histology and histopathology 1, 271-275. 
175. Candito, M., Richelme, C., Parvy, P., Dageville, C., Appert, A., Bekri, S., Rabier, D., 
Chambon, P., Mariani, R., and Kamoun, P. (1995) Abnormal alpha-aminoadipic acid 
excretion in a newborn with a defect in platelet aggregation and antenatal cerebral 
haemorrhage, Journal of inherited metabolic disease 18, 56-60. 
176. Casey, R. E., Zaleski, W. A., Philp, M., Mendelson, I. S., and MacKenzie, S. L. (1978) 
Biochemical and clinical studies of a new case of alpha-aminoadipic aciduria, Journal of 
inherited metabolic disease 1, 129-135. 
177. Duran, M., Beemer, F. A., Wadman, S. K., Wendel, U., and Janssen, B. (1984) A patient 
with alpha-ketoadipic and alpha-aminoadipic aciduria, Journal of inherited metabolic 
disease 7, 61. 
178. Fischer, M. H., and Brown, R. R. (1980) Tryptophan and lysine metabolism in alpha-
aminoadipic aciduria, American journal of medical genetics 5, 35-41. 
179. Gray, R. G., O'Neill, E. M., and Pollitt, R. J. (1980) Alpha-aminoadipic aciduria: chemical 
and enzymatic studies, Journal of inherited metabolic disease 2, 89-92. 
180. Jakobs, C., and de Grauw, A. J. (1992) A fatal case of 2-keto-, 2-hydroxy- and 2-
aminoadipic aciduria: relation of organic aciduria to phenotype?, Journal of inherited 
metabolic disease 15, 279-280. 
Introduction 
 46 
181. Lee, J. S., Yoon, H. R., and Coe, C. J. (2001) A Korean girl with alpha-aminoadipic and 
alpha-ketoadipic aciduria accompanied with elevation of 2-hydroxyglutarate and glutarate, 
Journal of inherited metabolic disease 24, 509-510. 
182. Manders, A. J., von Oostrom, C. G., Trijbels, J. M., Rutten, F. J., and Kleijer, W. J. (1981) 
alpha-Aminoadipic aciduria and persistence of fetal haemoglobin in an oligophrenic child, 
European journal of pediatrics 136, 51-55. 
183. Sela, B. A., Massos, T., Fogel, D., and Zlotnik, J. (1999) [Alpha-amino adipic aciduria: a 
rare psychomotor syndrome], Harefuah 137, 451-453, 511. 
184. Vianey-Liaud, C., Divry, P., Cotte, J., and Teyssier, G. (1985) alpha-Aminoadipic and 
alpha-ketoadipic aciduria: detection of a new case by a screening program using two-
dimensional thin layer chromatography of amino acids, Journal of inherited metabolic 
disease 8 Suppl 2, 133-134. 
185. Baran, H., Okuno, E., Kido, R., and Schwarcz, R. (1994) Purification and characterization of 
kynurenine aminotransferase I from human brain, Journal of neurochemistry 62, 730-738. 
186. Dekant, W., Vamvakas, S., and Anders, M. W. (1994) Formation and fate of nephrotoxic 
and cytotoxic glutathione S-conjugates: cysteine conjugate beta-lyase pathway, Advances 
in pharmacology (San Diego, Calif 27, 115-162. 
187. McGoldrick, T. A., Lock, E. A., Rodilla, V., and Hawksworth, G. M. (2003) Renal cysteine 
conjugate C-S lyase mediated toxicity of halogenated alkenes in primary cultures of human 
and rat proximal tubular cells, Archives of toxicology 77, 365-370. 
188. Cooper, A. J. (2004) The role of glutamine transaminase K (GTK) in sulfur and alpha-keto 
acid metabolism in the brain, and in the possible bioactivation of neurotoxicants, 
Neurochemistry international 44, 557-577. 
189. Han, Q., Fang, J., and Li, J. (2001) Kynurenine aminotransferase and glutamine 
transaminase K of Escherichia coli: identity with aspartate aminotransferase, The 
Biochemical journal 360, 617-623. 
190. Faff-Michalak, L., and Albrecht, J. (1991) Aspartate aminotransferase, malate 
dehydrogenase, and pyruvate carboxylase activities in rat cerebral synaptic and 
nonsynaptic mitochondria: effects of in vitro treatment with ammonia, hyperammonemia 
and hepatic encephalopathy, Metabolic brain disease 6, 187-197. 
191. Moran, J., Alavez, S., Rivera-Gaxiola, M., Valencia, A., and Hurtado, S. (1999) Effect of 
NMDA antagonists on the activity of glutaminase and aspartate aminotransferase in the 
developing rat cerebellum, Int J Dev Neurosci 17, 57-65. 
192. Moran, J., and Rivera-Gaxiola, M. (1992) Effect of potassium and N-methyl-D-aspartate on 
the aspartate aminotransferase activity in cultured cerebellar granule cells, Journal of 
neuroscience research 33, 239-247. 
Introduction 
 47 
193. Westergaard, N., Drejer, J., Schousboe, A., and Sonnewald, U. (1996) Evaluation of the 
importance of transamination versus deamination in astrocytic metabolism of [U-
13C]glutamate, Glia 17, 160-168. 
194. Yudkoff, M., Daikhin, Y., Nissim, I., Horyn, O., Lazarow, A., Luhovyy, B., Wehrli, S., and 
Nissim, I. (2005) Response of brain amino acid metabolism to ketosis, Neurochemistry 
international 47, 119-128. 
195. Hertz, L., Drejer, J., and Schousboe, A. (1988) Energy metabolism in glutamatergic 
neurons, GABAergic neurons and astrocytes in primary cultures, Neurochemical research 
13, 605-610. 
196. McKenna, M. C., Tildon, J. T., Stevenson, J. H., Boatright, R., and Huang, S. (1993) 
Regulation of energy metabolism in synaptic terminals and cultured rat brain astrocytes: 
differences revealed using aminooxyacetate, Developmental neuroscience 15, 320-329. 
197. McKenna, M. C., Tildon, J. T., Stevenson, J. H., and Huang, X. (1996) New insights into the 
compartmentation of glutamate and glutamine in cultured rat brain astrocytes, 
Developmental neuroscience 18, 380-390. 
198. Schousboe, A., Westergaard, N., Sonnewald, U., Petersen, S. B., Huang, R., Peng, L., and 
Hertz, L. (1993) Glutamate and glutamine metabolism and compartmentation in astrocytes, 
Developmental neuroscience 15, 359-366. 
199. Sonnewald, U., Westergaard, N., and Schousboe, A. (1997) Glutamate transport and 
metabolism in astrocytes, Glia 21, 56-63. 
200. Palaiologos, G., Hertz, L., and Schousboe, A. (1988) Evidence that aspartate 
aminotransferase activity and ketodicarboxylate carrier function are essential for 
biosynthesis of transmitter glutamate, Journal of neurochemistry 51, 317-320. 
201. Palaiologos, G., Hertz, L., and Schousboe, A. (1989) Role of aspartate aminotransferase 
and mitochondrial dicarboxylate transport for release of endogenously and exogenously 
supplied neurotransmitter in glutamatergic neurons, Neurochemical research 14, 359-366. 
202. McKenna, M. C., Stevenson, J. H., Huang, X., and Hopkins, I. B. (2000) Differential 
distribution of the enzymes glutamate dehydrogenase and aspartate aminotransferase in 
cortical synaptic mitochondria contributes to metabolic compartmentation in cortical 
synaptic terminals, Neurochemistry international 37, 229-241. 
203. Cooper, A. J., Bruschi, S. A., Iriarte, A., and Martinez-Carrion, M. (2002) Mitochondrial 
aspartate aminotransferase catalyses cysteine S-conjugate beta-lyase reactions, The 
Biochemical journal 368, 253-261. 
204. Rossi, F., Han, Q., Li, J., Li, J., and Rizzi, M. (2004) Crystal Structure of Human Kynurenine 
Aminotransferase I, J. Biol. Chem. 279, 50214-50220. 
205. Han, Q., Robinson, H., and Li, J. (2008) Crystal structure of human kynurenine 
aminotransferase II, The Journal of biological chemistry 283, 3567-3573. 
Introduction 
 48 
206. Rossi, F., Garavaglia, S., Montalbano, V., Walsh, M. A., and Rizzi, M. (2008) Crystal 
structure of human kynurenine aminotransferase II, a drug target for the treatment of 
schizophrenia, The Journal of biological chemistry 283, 3559-3566. 
207. Han, Q., Gao, Y. G., Robinson, H., Ding, H., Wilson, S., and Li, J. (2005) Crystal structures 
of Aedes aegypti kynurenine aminotransferase, The FEBS journal 272, 2198-2206. 
208. Wogulis, M., Chew, E. R., Donohoue, P. D., and Wilson, D. K. (2008) Identification of formyl 
kynurenine formamidase and kynurenine aminotransferase from Saccharomyces cerevisiae 
using crystallographic, bioinformatic and biochemical evidence, Biochemistry 47, 1608-
1621. 
209. Chon, H., Matsumura, H., Koga, Y., Takano, K., and Kanaya, S. (2005) Crystal structure of 
a human kynurenine aminotransferase II homologue from Pyrococcus horikoshii OT3 at 
2.20 A resolution, Proteins 61, 685-688. 
210. Rossi, F., Garavaglia, S., Giovenzana, G. B., Arca, B., Li, J., and Rizzi, M. (2006) Crystal 
structure of the Anopheles gambiae 3-hydroxykynurenine transaminase, Proceedings of the 
National Academy of Sciences of the United States of America 103, 5711-5716. 
211. Jansonius, J. N. (1998) Structure, evolution and action of vitamin B6-dependent enzymes, 
Curr Opin Struct Biol 8, 759-769. 
212. Alexander, F. W., Sandmeier, E., Mehta, P. K., and Christen, P. (1994) Evolutionary 
relationships among pyridoxal-5'-phosphate-dependent enzymes. Regio-specific alpha, 
beta and gamma families, Eur J Biochem 219, 953-960. 
213. Jensen, R. A., and Gu, W. (1996) Evolutionary recruitment of biochemically specialized 
subdivisions of Family I within the protein superfamily of aminotransferases, J Bacteriol 
178, 2161-2171. 
214. Schneider, G., Kack, H., and Lindqvist, Y. (2000) The manifold of vitamin B6 dependent 
enzymes, Structure 8, R1-6. 
215. Christen, P., and Mehta, P. K. (2001) From cofactor to enzymes. The molecular evolution of 
pyridoxal-5'-phosphate-dependent enzymes, Chemical record (New York, N.Y 1, 436-447. 
216. Percudani, R., and Peracchi, A. (2003) A genomic overview of pyridoxal-phosphate-
dependent enzymes, EMBO Rep 4, 850-854. 
217. Zhang, X., Roe, S. M., Hou, Y., Bartlam, M., Rao, Z., Pearl, L. H., and Danpure, C. J. 
(2003) Crystal structure of alanine:glyoxylate aminotransferase and the relationship 
between genotype and enzymatic phenotype in primary hyperoxaluria type 1, Journal of 
molecular biology 331, 643-652. 
218. Tomita, T., Miyagawa, T., Miyazaki, T., Fushinobu, S., Kuzuyama, T., and Nishiyama, M. 
(2008) Mechanism for multiple-substrates recognition of alpha-aminoadipate 
aminotransferase from Thermus thermophilus, Proteins. 
Introduction 
 49 
219. Clausen, T., Huber, R., Laber, B., Pohlenz, H. D., and Messerschmidt, A. (1996) Crystal 
structure of the pyridoxal-5'-phosphate dependent cystathionine beta-lyase from 
Escherichia coli at 1.83 A, Journal of molecular biology 262, 202-224. 
220. Han, Q., Robinson, H., Cai, T., Tagle, D. A., and Li, J. (2009) Structural insight into the 
inhibition of human kynurenine aminotransferase I/glutamine transaminase K, Journal of 
medicinal chemistry 52, 2786-2793. 
221. McPhalen, C. A., Vincent, M. G., and Jansonius, J. N. (1992) X-ray structure refinement 
and comparison of three forms of mitochondrial aspartate aminotransferase, Journal of 
molecular biology 225, 495-517. 
222. Goto, M., Omi, R., Miyahara, I., Hosono, A., Mizuguchi, H., Hayashi, H., Kagamiyama, H., 
and Hirotsu, K. (2004) Crystal structures of glutamine:phenylpyruvate aminotransferase 
from Thermus thermophilus HB8: induced fit and substrate recognition, The Journal of 
biological chemistry 279, 16518-16525. 
223. Hirotsu, K., Goto, M., Okamoto, A., and Miyahara, I. (2005) Dual substrate recognition of 
aminotransferases, Chemical record (New York, N.Y 5, 160-172. 
224. Okamoto, A., Nakai, Y., Hayashi, H., Hirotsu, K., and Kagamiyama, H. (1998) Crystal 
structures of Paracoccus denitrificans aromatic amino acid aminotransferase: a substrate 
recognition site constructed by rearrangement of hydrogen bond network, Journal of 
molecular biology 280, 443-461. 
225. Bellocchi, D., Macchiarulo, A., Carotti, A., and Pellicciari, R. (2009) Quantum 
mechanics/molecular mechanics (QM/MM) modeling of the irreversible transamination of L-
kynurenine to kynurenic acid: the round dance of kynurenine aminotransferase II, 
Biochimica et biophysica acta 1794, 1802-1812. 
226. Pellicciari, R., Venturoni, F., Bellocchi, D., Carotti, A., Marinozzi, M., Macchiarulo, A., 
Amori, L., and Schwarcz, R. (2008) Sequence variants in kynurenine aminotransferase II 
(KAT II) orthologs determine different potencies of the inhibitor S-ESBA, ChemMedChem 3, 
1199-1202. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 50 
 
 
 
Spectroscopic characterization of hKAT II 
 51 
CHAPTER 2 
 
  SPECTROSCOPIC CHARACTERIZATION OF HKAT II 
 
Introduction and aim of the work 
Aminotransferases contain pyridoxal-5’-phosphate (PLP) as coenzyme, which provides 
characteristic absorption spectra in the wavelength range of 300-500 nm. Free PLP and 
pyridoxamine phosphate (PMP) show absorption bands in the near ultraviolet, at 388 nm and 330 
nm respectively. When covalently bound to the enzyme active site, the Schiff’s base of cofactor 
with the catalytic Lys residue can exist in several different tautomeric forms, depending on their 
protonation equilibria. In aminotransferases the deprotonated species is in equilibrium with a 
protonated form that can be present as either the enolimine tautomer, that absorbs at about 330 or 
the ketoenamine tautomer, characterized by an unprotonated phenolic oxygen and a protonated 
imino group absorbing at 420 nm (Scheme 1, species 1a and 1b). Accordingly, aminotransferases 
absorb at a specific wavelength depending on the the predominant form of these species. 
Furthermore, the complete process of enzymatic transamination involves at least five kinetically 
distinguishable steps (see Scheme 3 in chapter 1). The different covalent intermediates formed 
during PLP-dependent catalysis exhibit characteristic UV-visible spectra, as shown in Scheme 1. 
The quinonoid intermediate formed upon -proton removal can follow two pathways: protonation 
on the imine nitrogen to form the ketimine (transamination pathway) or elimination of the -
substituent to form the -aminoacrylate Schiff’s base ( -elimination pathway) that spontaneously 
hydrolyzes to pyruvate and ammonia. It is well assessed that transaminases, due to the chemistry 
of the catalyzed reaction, are prone, in the presence of substrates with good leaving groups, to 
carry out  -elimination as a side reaction (1-5). Since the tautomeric species of the enzyme-bound 
cofactor as well as certain PLP-derived reaction intermediates have distinctive UV-visible 
absorption maxima, their spectrophotometric detection provides a convenient means for  
monitoring the binding of substrates, substrate analogs and inhibitors, as well as the formation of 
catalytic intermediates (6-9). There is a multitude of examples in literature that capitalize the 
spectroscopic properties of the cofactor to study the catalytic mechanism and the substrate 
specificity of PLP-dependent enzymes.  
Although hKAT II is considered a potential drug target for cognition enhancement, a detailed 
spectroscopic analysis regarding its native form and reaction intermediates has never been 
addresses so far. The analysis of spectral changes that accompany substrate interaction is 
essential not only for the understanding of the catalytic mechanism of this enzyme, but also for the 
investigation of the interaction mechanisms with inhibitors. Therefore, a detailed spectral analysis 
of the enzyme was carried out. The reactivity of hKAT II with its natural substrates -aminoadipate 
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(AAD) and glutamine was investigated either in solution or in the crystalline state by 
spectrophotometry and spectrofluorimetry, and polarized absorption microspectrophotometry, 
respectively. We also report the spectroscopic characterization of the mutant hKAT II Tyr142Phe, 
expected, on the basis of structural considerations (10), to exhibit a decrease propensity for -
elimination, a side reaction common to transaminases (5).  
 
 
Scheme 1. General reaction mechanism of aminotransferases, including tautomeric and 
protonation equilibria. The absorption maxima for the catalytic intermediates are reported. The -
elimination side reaction is boxed. Adapted from (3, 11, 12).  
 
Materials and methods  
Chemicals. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and were used 
as received. Experiments, unless otherwise specified, were carried out in 50 mM Hepes buffer, pH 
7.5 at 25 °C.  
 
Protein expression and purification. Human KAT II and the mutant Tyr142Phe were expressed 
and purified as previously described (10). The expression and purification procedures were kindly 
carried out by Proff. Menico Rizzi and Franca Rossi, Università Piemonte Orientale. The purified 
enzyme was fully saturated with PLP by addition of a ten fold molar excess cofactor, followed by 
overnight dialysis against a solution containing 20 mM Hepes, 50 mM NaCl, pH 8.0. The purified 
recombinant hKAT II was concentrated to 10 mg/ml using a Vivaspin 10,000 concentrator 
(Sartorius), and stored at -80°C in aliquots of 30 L.  
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Determination of hKAT II extinction coefficient. The extinction coefficient of hKAT II was 
calculated by the amount of PLP released upon alkali denaturation by the method of Peterson (13). 
An absorption spectra of 25 M hKAT II in water was collected and corrected for water 
contribution. Then, 10 N NaOH was added to a final concentration of 1 N and the solution was 
incubated at 25°C for 20 minutes. A final absorption spectra was collected, to verify the presence 
in the visible region of a single band centered at 388 nm, indicating that all PLP molecules were 
released from enzyme active sites. hKAT II extinction coefficient was calculated using the following 
formula: 
 
f .d*PLP  388nm
protein  358nm
PLP  388nm358nm
A
A
*ε*nε  
where:  
n is the stechiometric ratio between PLP and protein, equal to 1 for hKAT II 
f.d. is the dilution factor after the addition of NaOH 
A358 nm is the absorption at 358 nm of olo-hKAT II  
A388 nm is the absorption at 388 nm of free PLP, ε 388 nm PLP = 6,600 M
-1∙cm-1at basic pH. 
 
Spectroscopic measurements in solution. Absorption spectra were collected in 50 mM Hepes, 
pH 7.5, using a Cary 400 Scan spectrophotometer (Varian Inc.). Cuvette holders were 
thermostated at 25°C. Spectra were corrected for buffer contribution.  
Fluorescence emission spectra were collected in 50 mM Hepes, pH 7.5, 25°C, using a Spex 
Fluoromax-2 fluorimeter (Jobin-Yvon) by exciting at 298 nm the emission of tryptophan residues or 
by exciting at 330, 360 and 420 nm the emission of the cofactor. Excitation and emission slits were 
set at 1,5 nm ( exc = 298 nm), 3,5 nm ( exc = 330 nm and 360 nm) and 4 nm ( exc = 420 nm). 
Spectra were corrected for buffer contribution.   
 
Single-crystal polarized absorption microspectrophotometric measurements. Crystals of 
recombinant hKAT II were kindly provided by Proff. Menico Rizzi and Franca Rossi. They were 
obtained as previously described (10) by mixing 1 L of a protein solution at 16 mg/ml with an 
equal volume of a reservoir solution containing 22% (w/v) polyethylene glycol (PEG) 3350, 0.3 M 
potassium iodide, 0.1 M Tris HCl pH 8.0, and equilibrating the resulting drop against 500 L of the 
reservoir solution, at 20°C. Needle-shaped yellow crystals grew in about three weeks. Crystals 
obtained under the same conditions were used to X-ray crystallographic structure determination 
(pdb code 2VGZ) (10). For polarized microspectrophotometric measurements single crystals were 
resuspended at least six times in a solution containing 26% (w/v) PEG 3350, 0.3 M potassium 
iodide, 0.1 M Tris HCl pH 8.0. Individual crystals were placed within a quartz observation cell, 
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located on the microscope stage. The cell upper window can be easily removed for mounting or 
handling the crystal. The replacement of the suspending medium for the different experiments was 
carried out by flowing solution through the cell. Channels through the cell allow the suspending 
medium to be quickly replace without causing appreciable crystal movements. The cell was 
mounted on the stage of a Zeiss MPM03 microspectrophotometer, equipped with a thermostatic 
apparatus. Polarized absorption spectra were recorded in the range between 250 and 600 nm, with 
the electric vector of linearly polarized light parallel to crystal edges that coincide with crystal 
extinction directions. Single crystal polarized absorption spectra were usually recorded on one flat 
face of the crystal. All the experiments were carried out at 25°C. 
Results  
hKAT II extinction coefficient 
The accurate measurement of protein concentration by spectroscopic methods requires the 
knowledge of its extinction coefficient. As hKAT II extinction coefficient has never been reported so 
far in the literature, it was calculated following cofactor release by alkali denaturation. For a PLP-
dependent enzyme the calculation of protein concentration using the extinction coefficient of the 
cofactor calculated by this method is the most accurate and allow reproducible results also with 
different enzymes preparation. hKAT II extinction coefficients at 280 and 360 nm were found to be 
47,575 and 9,510 M-1∙cm-1, respectively. For the mutant Tyr142Phe KAT II the calculated values 
are 47,000 and 9400 M-1∙cm-1 at 280 and 360 nm, respectively. 
Absorption spectroscopy 
The absorption spectrum of native hKAT II (Figure 1A) exhibits two main bands at 280 nm and 360 
nm, attributed to the aromatic residues and to the deprotonated internal aldimine of the cofactor 
with the catalytic Lys263, respectively. The observed ratio A280/A360 for the enzyme fully saturated 
with PLP is 5. The absorption spectrum of hKAT II also shows a shoulder at about 420 nm, likely 
the ketoenamine tautomer of the protonated internal aldimine. KATII instability below pH 6 
precludes the determination of the pKa of the cofactor (Fig. 1B).  
In the presence of the natural and non-cromophoric substrate -amino adipate (AAD) (14) the 
band at 360 nm rapidly disappears with the concomitant formation of a new species absorbing 
maximally at 325 nm, likely the pyridoxamine form of the cofactor (Figure 1C; Scheme 1, species 
5). The shoulder at 420 nm corresponds to a species that does not react with  AAD. Addition of 2 
mM KG (  320 nm = 32 M
-1∙cm-1 ) to the reaction mixture does not lead to appreciable changes in the 
spectrum of the cofactor, an indication that, at equilibrium, the most stable species is the PMP form 
of the enzyme, i.e. the rate of the first half reaction is significantly faster than the rate of the second 
half reaction.  
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Tyr142Phe KAT II exhibits an absorption spectrum almost superimposable with that of the wild 
type enzyme with an invariant A280/A360 (Figure 1A). This finding can be attributed to a decrease in 
both the extinction coefficient at 280 nm due to the Y→F substitution and the extinction coefficient 
of the cofactor at 360 nm, which is 9,400 M-1∙cm-1
spectroscopic changes as those observed for the wt enzyme (data not shown).  
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Figure 1. Absorption spectra of hKAT II and Tyr142Phe KAT II in the absence and in the 
presence of the natural substrate -aminoadipate. 
A Absorption spectra of 10 M hKAT II (solid line) and Tyr142Phe KAT II (dashed line) in 50 mM 
Hepes, pH 7.5, at 25°C. 
B Absorption spectra of 6 M hKAT II in 200 mM potassium phosphate, pH 8.0 (solid grey line), pH 
7.5 (dashed line) and pH 6.0 (solid black line),  at 25°C. 
C The reaction mixture contained 10 M of hKAT II in the absence (solid line) and in the presence 
of 10 mM -aminoadipate (dotted line) in 50 mM Hepes, pH 7.5, at 25°C. 2 mM KG was added to 
the reaction mixture (dashed line).  
 
Fluorescence spectroscopy 
hKAT II contains three tryptophan residues that can be selectively excited at 298 nm. The emission 
spectrum upon excitation at 298 nm shows a band centred at 345 nm, indicative of tryptophan 
residues exposed to the solvent. No energy transfer occurs between tryptophan and PLP, as 
indicated by the absence of peaks centred at either  420 or 500 nm (Figure 2A), in contrast with 
observations on fold type II enzymes, such as tryptophan synthase (15) and O-acetylserine 
sulfhydrylase (16). Direct excitation of PLP at the absorbance maximum, i.e. 360 nm, gives a 
structured emission with a maximum at 417 nm and a shoulder at 520 nm (Figure 2B). The 
emission at 520 is typical of the ketoenamine tautomer of the internal aldimine of the cofactor, 
whereas the emission at 415 nm is typical of the enolimine tautomer. In fact, direct excitation of the 
enolimine tautomer at 330 nm gives an emission with a main peak centred at about 415 nm, 
whereas direct excitation of the ketoenamine tautomer at 420 nm gives an emission centred at 
about 520 nm. The fluorescence emission spectra of Tyr142Phe KAT II is indistinguishable from 
that of wt KAT II and the addition of -KG to both enzyme variants does not lead to any 
appreciable change in the emission properties (data not shown). 
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Figure 2. Spectrofluorimetric properties of KATII.   
A  Emission spectrum of a solution containing 26 M KAT II in 50 mM Hepes, pH 7.5, at 25 °C, 
excited at 298 nm. 
B  Emission spectra of a solution containing 26 M KAT II in 50 mM Hepes, pH 7.5, at 25 °C, 
excited at 330 nm (continuous line), 360 nm (dotted line) and 420 nm (dash-dotted line).  
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 Microspectrophotometric study on single crystals of hKAT II  
Polarized absorption spectra of hKAT II single crystal in 26% (w/v) PEG 3350, 0.3 M potassium 
iodide, 0.1 M Tris HCl pH 8.0 exhibits a mean peak centered at about 332 nm, a shoulder at 360 
nm and a broad band at 400-500 nm (Figure 3, grey line). The positions of cofactor absorption 
maxima differ from those of the enzyme in solution (Figure 1A). In the latter case, absorption 
maxima is situated at 360 nm, corresponding to the deprotonated form of the internal pyridoxal 5’-
phosphate-lysine aldimine. In the spectrum of hKAT II crystal, the 360 nm band is blue-shifted to 
about 332 nm. This shift might be caused by the formation of a covalent adduct between enzyme-
bound cofactor and Tris buffer during the long crystallization period. Indeed, although Tris has 
been used as a standard buffer in biochemical research for over 40 years, its use with systems 
containing pyridoxal 5’-phosphate can result in complications from the non-enzymatic reaction of 
the primary amine function of Tris buffer that is capable of forming a Schiff’s base with the 
aldehyde moiety of the coenzyme (17, 18). Indeed, when hKAT II crystals were resuspended in 
potassium phosphate a decrease of the band at 332 nm was observed, likely due to the partial 
removal of the Tris-pyridoxal 5’-phosphate Schiff’s base from the enzyme active site (Figure 3, 
dotted line). Soaking of the crystals in a phosphate solution containing PLP led to a spectrum 
peaked at 360 nm, indicating the recovery of the deprotonated internal aldimine with the cofactor 
(Figure 3, dashed line). This species is the reactive one, as demonstrated by its fast 
disappearance after soaking of the crystal in a solution containing 20 mM glutamine, the natural 
substrate (Figure 3, black line). However, the spectral changes brought about by the addition of the 
glutamine do not correspond to those observed in solution (Figure 3, inset). The absence of the 
appearance of the pyridoxamine species absorbing at about 330 nm might be due to the diffusion 
of the PMP species  out of the crystal. Further studies are required to fully understand these events 
and the nature of the band at about 400 nm. Nevertheless, polarized absorption spectra of hKAT II 
single crystal indicate that hKAT II is catalytically competent in the crystalline state.  
 
 
 
 
 
 
 
 
 
 
 
 
Spectroscopic characterization of hKAT II 
 60 
 
 
 
 
 
 
 
 
Figure 3. Polarized absorption spectra of hKAT  II 
Polarized absorption spectra of hKAT II crystals were recorded in solutions containing 26% (w/v) 
PEG 3350, 0.3 M potassium iodide, 0.1 M Tris HCl pH 8.0 (grey line), 26% (w/v) PEG 3350, 0.1 M 
potassium phosphate at pH 8.0 (dotted line), 26% (w/v) PEG 3350, 50 M PLP, 0.1 M potassium 
phosphate pH 8.0 (dashed line), and 26% (w/v) PEG 3350, 20 mM glutamine, 0.1 M potassium 
phosphate pH 8.0 (black line).  
Inset: Absorption spectra of a solution containing 10 M hKAT II in the absence (black line) and in 
the presence of 20 mM glutamine (grey line) about 5 minutes after addition of the amino acid. 
Temperature was maintained constant at 25°C.  
 
Discussion  
The absorption spectrum of KAT II shows a band at 360 nm that, based on previous reports on 
aminotransferases (19-21), can be attributed to a Schiff base of the active site lysine (in KATII, 
K263) with a deprotonated imine nitrogen (Figure 1A; Scheme 1, species 1a). Interestingly, a 
previous work on bovine and rat KAT II reported absorption spectra with two main peaks at 320-
330 and 400 nm (22). Furthermore, hKAT I shows a completely different absorption spectrum with 
two bands attributable to the cofactor: a band centered at 335 nm and a band centered at 422 nm, 
probably indicative of a mixture of the PLP and PMP forms of the enzyme (23), with PLP 
protonated at the imine nitrogen. PLP is a probe of the active site environment and thus the 
distribution of its tautomers is an indication of the active site polarity and amino acidic composition. 
The deprotonated form of the internal aldimine of PLP is quite typical of aminotransferases, as in 
aspartate aminotransferase (AAT) (24). It is well assessed that the deprotonated form of PLP in 
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transaminases is stabilized by a hydrogen bond with the hydroxyl group of a tyrosine that lowers 
the pKa of the imine nitrogen by two orders of magnitude (24-26). Based on crystallographic 
studies, a conserved tyrosine residue in hKAT II, Y233, is suggested to play this stabilizing role 
(10). Curiously, a structurally corresponding residue, i.e. Y216, is also present in hKAT I, although 
the predominant form of the cofactor at pH 7.5 is the protonated ketimine. In aminotransferases the 
deprotonated species is in equilibrium with a protonated form that can be present as either the 
enolimine tautomer, absorbing at about 330 or the ketoenamine tautomer that absorbs at 420 nm 
(Scheme 1, species 1a and 1b).  The pKa for the equilibrium is 6.3 for glutamate aminotransferase 
GAT (20). The pKa for the equilibrium of protonation of the internal aldimine of hKAT II could not be 
determined due to the instability of the enzyme below pH 6 and is estimated to be lower than 6. 
As already observed for other aminotransferases (20, 27), the species that absorbs at 360 nm is 
the reactive one, whereas the species absorbing at 420 nm is unreactive (20). In agreement, the 
shoulder at 420 nm. This finding also suggests that the 420 nm band is not a tautomeric form but a 
covalent modification of PLP. KAT II was previously indicated as ADD aminotransferase. Indeed, 
the catalytic efficiency of the enzyme towards AAD is slightly higher than that towards KYN (14). 
Reaction of hKAT II with AAD in the absence of ketoacids leads to the transamination of PLP to 
form PMP (Figure 1C), that stably accumulates also in the presence of KG. Thus, at equilibrium, 
the PMP form of KATII is the most stable enzyme form, i.e. the rate of its formation is higher than 
the rate of its consumption. The high absorbance of KYN in the spectral range where also PLP and 
PMP intermediates absorb hampers to carry out the same analysis on the reaction between KYN, 
KG and hKAT II. 
PLP is an intrinsic fluorescent probe often exploited in vitamin B6-dependent enzymes 
spectroscopy due to its sensitivity to the environment surrounding the cofactor and thus to changes 
in the conformation and ligation state of the active site (28-30). However, very few studies have 
investigated the fluorescence in aminotransferases (31-40). Often, fluorescence was exploited to 
monitor the release of PMP from the enzyme active site, binding of the cofactor and protein folding 
(32-36, 38). Differently from other PLP-dependent enzymes (29), the  emission spectrum of hKAT 
II does not show any energy transfer between tryptophan residues and the cofactor (Figure 2A). 
The analysis of hKAT II three-dimensional structure (10) reveals that three tryptophan residues are 
within a 30 Å distance from the cofactor, thus the absence of energy transfer is an indication of an 
unfavourable orientation between tryptophan and PLP. The deprotonated internal aldimine, 
absorbing at 360 nm, is fluorescent with a structured emission showing a maximum at 420 nm and 
a shoulder at about 500 nm (Figure 2B). This is in agreement with findings on PLP Schiff bases 
and AspAT (40). Only the emission at 420 nm is directly attributed to the excitation of the 
deprotonated internal aldimine, whereas the band at 500 nm is due to the spurious excitation of the 
420 nm band. This is confirmed by the emission spectra  upon excitation at 420 nm. Excitation at 
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330 nm gives a structured emission with a shoulder at about 380 nm that could originate from the 
excitation of some residual PMP (40) and a band centred at about 420 nm that is likely originated 
from the excitation of the deprotonated internal aldimine band. Despite the reported conformational 
change induced by -KG on the N-terminal stretch of KATII (14, 41), no spectral changes are 
observed in the emission spectrum of the protein upon binding of the substrate.  
The mutation Tyr142Phe does not change the absorption (Figure 1A) and emission properties of 
KAT II (data not shown), its reactivity towards AAD 
(data not shown). These findings indicate that the mutation does not have significant effects on the 
overall structure and function of the enzyme.  
The spectral properties of the crystalline enzyme differ in some respect with those observed in 
solution. The absorption band of the enzyme-bind cofactor is blue-shifted as compared to the 
spectra in solution, where the main band is the peak of the deprotonated internal aldimine at 360 
nm. This spectral differences could be attributed to the effect of Tris buffer. Its primary amine 
function breaks the imine bond between pyridoxal 5’-phosphate and the Lys263 residue to form a 
Tris-pyridoxal 5’-phosphate Schiff base in the enzyme active site. The effect of Tris on the 
polarized-light spectrum of hKAT II crystals is of interest as it confirms what already observed for 
other PLP-dependent enzymes. For example, in human mitochondrial branched-chain 
aminotransferase, Tris was found to bind the cofactor PLP and form a Schiff base in the protein 
structure (42). Spectral shift of PLP cofactor in the presence of Tris was also observed in hKAT I, 
suggesting that Tris can interact with the enzyme-associated PLP (43). Inspection of the crystal 
structure of the hKATI-Tris complex revealed that Tris is located in the enzyme active center and 
that its amine does not form an external aldimine with PLP. In this case Tris interacts with protein 
residues through a hydrogen-bonding network in the active center (44). Interactions with Tris 
molecules in the enzyme active site could interfere with the substrate binding and internal aldimine 
formation, therefore affecting the enzyme activity. The results of the experiments carried out on 
crystal of hKAT II suggest that the use of primary or secondary amine buffers should be avoided 
when inhibitors are being tested with hKAT II or aminotransferases in general. Moreover, single-
crystal spectrophotometric study of hKAT II shown that, after replacement of Tris buffer with 
phosphate, the enzyme in the crystalline state is catalitically competent. Indeed, the natural 
substrate glutamine rapidly diffused through crystals of hKAT II and reacted at the active site 
causing spectral changes.  
The detailed information obtained from the spectroscopic analysis of hKAT II both in solution and in 
the crystalline state, allowed to compare the spectroscopic properties of hKAT II to the well-defined 
spectroscopic properties of other aminotransferases. Furthermore,  it was essential to establish the 
conditions for the enzyme functional characterization and investigation of the interaction 
mechanisms with inhibitors, which are discussed in the following chapters. 
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CHAPTER 3 
 
  FUNCTIONAL CHARACTERIZATION OF hKAT II 
  
Development of new spectrophotometric assays for hKAT II activity 
 
Introduction and aim of the work  
Despite the number of works present in the literature dealing with KATs, no reliable continuous 
method has been so far developed (based on data present on Brenda and from a survey of the 
literature). The activity assays for this enzyme rely on a cumbersome discontinuous assay coupled 
to a HPLC determination or liquid scintillation spectrometry of KYNA (1-5). Briefly, a typical 
reaction mixture of 50 L, containing 10 mM KYN, 5 mM -KG, 40 M PLP and 2 g of protein 
sample, is prepared in 100 mM phosphate buffer pH 7.5. The mixture is incubated for 15 minutes 
at 37°C, the reaction is then stopped by adding an equal volume of 0.8 M formic acid. The 
supernatant of the reaction mixture, obtained by centrifugation at 15,000 g for 10 minutes at 4°C, is 
analyzed by HPLC for KYNA detection (3,4). Exiting HPLC-based methods for the quantification of 
KYNA as a product of KAT enzymatic activity are based on the chromatographic separation of 
KYNA on a HPLC column, followed by its detection based on either its electrochemical properties 
or the fluorescent properties as a complex with Zn2+ ( ex = 344, em = 398 nm) nm (6,7). An 
assay in which the reaction is stopped by addition of an acid and then protein is removed by 
centrifugation is complicated, time consuming and presents a high degree of variability. Moreover, 
this discontinuous assay require specific equipment and instrumental set up, and is difficult to 
apply to large-scale screenings for inhibitors. Obviously, the search for specific hKAT II inhibitors 
must rely on a continuous assay that allow for the determination of KI values and, more 
importantly, of the mechanisms of inhibition. Furthermore, the high-throughput screening of 
inhibitors needs the careful optimization of a 96-wells plate suited assay, i.e. a spectrophotometric 
assay adapted to an end-point determination.  
The development of a continuous spectrophotometric assay for hKAT II using KYN as a substrate 
has been hampered by its non-optimal spectrophotometric properties. In facts, KYN strongly 
absorbs at 361 nm (  = 4,350 M-1 cm-1) (8) and does not thus allow for assays at concentrations 
higher than 2 mM, being the estimated KM of the enzyme about 5 mM (3). In a recent study on KAT 
from yeast Saccharomyces cerevisiae (9), a continuous spectrophotometric assay was used to 
monitor KYNA production by measuring the increase in absorbance at 285 nm over time. 
Unfortunately, this method was unreliable as data were not convincingly fitted with a standard 
Michaelis-Menten curve. Moreover, both KYNA and KYN have significant absorbance at this 
wavelength (8), thus the loss of KYN has a substantial effect on the absorbance at 285 nm.  
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Continuous coupled assays based on dehydrogenases are very convenient to study the kinetics of 
a specific transamination reaction and can be easily employed in large-scale screenings. 
Moreover, these assays are specific, since detection of different keto acid products requires the 
use of different coupling enzymes, i.e. malate dehydrogenase to monitor the formation of 
oxaloacetate from aspartate (ASP) aminotransferase activity. hKAT II can use many -keto acids 
as amino group acceptors, but prefers -ketoglutarate (KG) (3). This substrate preference can be 
exploited to set up an enzymatic coupled assay based on the consumption, by a specific enzyme, 
of the glutamate produced during the transamination of KYN, or other substrates, in the presence 
of KG. In general, the main enzymatic systems employed for the determination of L-glutamate are 
the glutamate dehydrogenase (GDH) and glutamate decarboxylase (GDC) assays (10,11). 
However, these enzymatic methods have some drawbacks due to the poor substrate specificity 
and the requirement for NAD+ coenzyme. L-glutamate oxidase (GOX) holds excellent potentials for 
the use in the determination of L-glutamate due to the relatively high substrate specificity 
comparing to GDH and GDC and no requirement of additional coenzyme. GOX specifically 
catalyzes the oxidative deamination of L-glutamate in the presence of water and oxygen with the 
formation of -ketoglutarate, ammonia and hydrogen peroxide (12). The hydrogen peroxide formed 
in this reaction can be easily detected by a chromogenic peroxidase reaction (13). Peroxidase 
readily combines with hydrogen peroxide and the resultant peroxidase-H2O2 complex can oxidize a 
wide variety of hydrogen donors, generating a chromogenic, chemilumnescent or fluorogenic 
signal depending on the substrate used. Although the productivities of the GOX enzyme from 
microbiological sources are still low and the commercially available GOX is very expensive, this 
enzyme attracted attention because of its biotechnological applications. Indeed, it is used as a 
diagnostic tool for the determination of L-glutamic acid in physiological fluids, and as an analytical 
reagent for the evaluation of food quality (14). Furthermore, an important application of GOX is in 
the diagnosis of liver function, as it is used in the determination of serum glutamate oxaloacetate 
transaminase (GOT) and glutamate pyruvate transaminase (GPT) levels in the clinical laboratories 
(12). Moreover, the immobilization of this enzyme to solid supports and membranes for the assay 
of glutamate has been reported (14).  
Great advantages in the discovery of hKAT II inhibitors would arise from the development of new 
KAT activity assays which allow first the rapid screening of potential inhibitors and then further 
characterization of the inhibition mechanisms of selected compounds. We reasoned that two 
options for the activity assay of KATII are available: the exploitation of any significant difference in 
the absorption spectrum of KYN with respect to KYNA or the coupling of the reaction to a reporter 
assay with a product absorbing in the red side of the visible spectrum. The first option has been 
exploited for the development of a continuous assay based on the large difference in the extinction 
coefficient of KYN and KYNA at 310 nm, which allows rapid measurement of hKAT II activity and 
analysis of  inhibition mechanisms. The second option has been exploited for the development of 
Functional characterization of hKAT II 
 69 
an end-point assay to measure the concentration of glutamate formed by transamination activity in 
the presence of the amino group acceptor -KG. This assay was further optimized to a 96-wells 
plate format for high-throughput screening of hKAT II transamination substrates and inhibitors, as 
discussed in  chapter 5.  
 
Materials and methods 
Materials. L-Kynurenine (K8625), L-aspartate (A6558), glutamate oxidase from Streptomyces 
sp. (G5921), peroxidase from horseradish (P8375), o-dianisidine (D9143), glutamate 
dehydrogenase from bovine liver (G2626) and malate dehydrogenase from porcine heart (M7383) 
were purchased from Sigma-Aldrich (St.Louis, MO).  
 
KAT activity measured by a continuous spectrophotometric assay. A continuous assay for the 
measurement of transamination of KYN by hKAT II using KG as the acceptor was developed (see 
Results). KYN and KYNA concentrations were calculated from the absorbance in the UV-visible 
range using published extinction coefficients at pH 7.3 (8) (for KYN 257 = 6,750 M
-1 ∙ cm-1, 361 = 
4,350 M-1 ∙ cm-1; for KYNA 332 = 9,800 M
-1 ∙ cm-1, 344 = 7,920 M
-1 ∙ cm-1).  
 
Data fitting. Data fitting was carried out using Sigma Plot software, release 9.0. Plots of initial 
velocity as a function of KYN concentration at a constant KG concentration (10 mM) were fitted to 
a hyperbolic equation: 
  
                                                                            
KYNK'
KYNV'
V
max
0
          [1] 
where: 
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        [2] 
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        [3] 
 
max
V'  and K'  are apparent KM and Vmax, 
KYN
M
K and 
KG
M
K are Michaelis constants for KYN and KG, 
respectively (15).    
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KAT transamination activity measured by a coupled glutamate oxidase-peroxidase assay 
(GOX-peroxidase coupled assay). The amounts of glutamate produced by transamination activity 
in the presence of KG were determined by an end-point assay based on the use of GOX and 
peroxidase. A reaction mixture containing 10 mM KG, 40 M PLP and 10 mM KYN was 
equilibrated at the desired reaction temperature (25°C) in 50 mM Hepes, pH 7.5, before starting 
the reaction with addition of 2 M KATII. Aliquots (20 L each) were removed after 30 minutes, and 
stopped by mixing with 2 L of 1.14 M phosphoric acid (final concentration 14 mM). Each aliquot 
was subsequently mixed with a solution containing 0.02 units of glutamate oxidase (GOX-Sigma 
G5921), 3 units of peroxidase (perox-Sigma P8375), 1 mM o-dianisidine and 50 mM Hepes pH 7.5, 
in a final volume of 200 L. The mixture was incubated at 37 °C for 30 minutes. Finally, the mixture 
was supplemented with 50 L sulphuric acid (final concentration 3.36 mM) to dissolve the 
occasional precipitates of oxidized o-dianisidine and to increase the assay sensitivity (13), before 
measuring the absorbance at 530 nm to quantify the extent of o-dianisidine oxidation. A calibration 
curve was prepared, using known concentrations of glutamate, ranging from 10 to 800 M in the 
presence of 10 mM KG, 40 M PLP, 14 mM phosphoric acid, 1 mM o-dianisidine, 0.02 units of 
glutamate oxidase (GOX-Sigma G5921), 3 units of peroxidase (Perox-Sigma P8375) and 50 mM 
Hepes pH 7.5, in a final volume of 200 L. The reaction mixtures were incubated and treated as 
above, and the absorbance at 530 nm was plotted against the initial amount of glutamate to 
generate a calibration curve. Blanks (control reactions) were set  up using the same reagents as 
for the assay except for hKAT II that was replaced by the same volume of buffer.  
 
KAT activity measured by a coupled malate dehydrogenase assay (MDH assay).  A continuous 
spectrophotometric assay for the measurement of transamination rate between aspartate (ASP) 
and KG by hKAT II was developed (see Results).  Reactions (200 L final volume) containing 50 
mM Hepes pH 7.5, 5 mM KG, 10 M PLP, 1.35 mM NADH, 6 U MDH and variable concentrations 
of ASP (1-40 mM) were incubated at 37°C. The reaction was started by the addition of 1.6 M 
hKAT II and carried out at 37 °C in a 0.1 cm optical path cuvette. The disappearance of NADH was 
monitored at 340 nm (  = 6,220 M-1∙ cm-1). 
 
KAT activity measured by a coupled glutamate dehydrogenase assay (GDH assay). The rate of 
transamination reaction between -aminoadipate (AAD) and KG by hKAT II was determined 
spectrophotometrically by an assay coupled with glutamate dehydrogense (GDH). A reaction 
mixture (200 L final volume) containing 10 mm AAD, 10 mM KG, 10 M PLP, 1.5 mM NADP+  and 
1 U GDH, in 50 mM Hepes pH 7.5 was incubated at 25°C. The reaction was started by the 
addiction of 62 nM hKAT II and carried out at 25 °C in a 0.1 cm optical path cuvette. The 
accumulation of NADPH was monitored at 340 nm (  = 6,220 M-1∙ cm-1). 
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Results 
A new continuous spectrophotometric assay for hKAT II activity 
To overcome the limitations of the discontinuous KAT assay (2-5,16,17), an assay for the 
continuous monitoring of KYN transamination was developed. The absorption spectrum of a 
solution containing 900 M KYN, 10 mM KG and 40 M PLP, in 50 mM Hepes pH 7.5,  at 37°C, 
exhibits a maximum at 361 nm, typical of KYN at neutral pH. The spectrum obtained when hKAT II 
is added to the reaction mixture and reaction reaches equilibrium is blue shifted with a peak at 332 
and a shoulder at approximately 344 nm (Figure 1A), typical of KYNA (8). The difference spectra 
(Figure 1A, inset) shows a positive peak at about 340 nm  and a negative peak at 360 nm. At 
wavelengths lower than 352 nm it is possible to follow the accumulation of KYNA and thus to 
develop an assay with a good sensitivity for product formation. Nonetheless, the extinction 
coefficient of KYN at 340 nm is too high (3,290 M-1 cm-1 ) to allow for initial velocities 
determinations at KYN concentrations higher than 8 mM, being the published KM for KYN about 5 
mM (3). We thus chose to carry out the assays at 310 nm, a wavelength that represents a good 
compromise between high sensitivity and an extinction coefficient of KYN low enough to monitor 
kinetics up to about 3 times the expected KM. Extinction coefficients at 310 nm of 1049 M
-1 ∙ cm-1 
and 4674 M-1 ∙ cm-1 were calculated for KYN and KYNA, respectively. Thus, a Δ  at 310 nm of 
3625 M-1 ∙ cm-1 was used to calculate the initial velocities from kinetic traces at 310 nm. A series of 
reactions were carried out as a function KYN concentration from 2 mM to 23 mM KYN, at constant 
KG concentration (10 mM), that, based on a previously determined KM for KG of 1.2 mM, should be 
saturating (3). We found that V0 values are independent of KG concentration down to 200 M. 
From a typical Michaelis Menten plot (Figure 1B) K' of 10 ± 1 mM,  
max
V'  of  0.022 ± 0.001 mM/min 
and kcat of 25 min
-1 were calculated.  
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Figure 1. Reactivity of KATII towards KYN 
A Absorption spectra of KYN and its reaction products in the presence of hKAT II and KG  
The reaction mixture contained 10 mM KG, 40 M PLP and 900 M KYN in 50 mM Hepes pH 7.5, 
at 37 °C (solid line). The reaction, carried out in 0.1 cm optical path cuvettes,  was started by the 
addition of 9.4 M hKAT II. A spectrum was collected at equilibrium about 150’ upon enzyme 
addition (dashed line). Inset: difference spectrum. 
B Dependence of the rate of reaction of hKAT II on KYN in the presence of KG 
The reaction mixture contained 870 nM hKAT II in 50 mM Hepes pH 7.5 in the presence of 10 mM 
KG, 40 M PLP and variable concentrations of KYN. The reaction was carried out at 25 °C in a 0.1 
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cm optical path cuvette. The solid line through data points represents the fitting to the Michaelis-
Menten equation with Vmax  = 0.022 ± 0.001 mM/min and KM = 10 ± 1 mM.  
 
Development and validation of an end-point assay using GOX and peroxidase as coupling 
enzymes. 
A GOX-peroxidase coupling end-point assay was developed to assess the concentration of 
glutamate produced by hKAT II transamination activity in the presence of KG. The principle of the 
assay is illustrated in Scheme 1. Glutamate is deaminated to ketoglutaric acid and hydrogen 
peroxide by glutamate oxidase. Hydrogen peroxide reacts with O-dianisidine in the presence of 
peroxidase to form a coloured product. Oxidized O-dianisidine reacts with sulfuric acid to form a 
stable coloured product. The intensity of the absorbance measured at 530 nm is proportional to the 
glutamate concentration. This method is simple and advantageous for routine usage. Moreover, its 
accuracy and precision are excellent, compared to more commonly used non enzymatic methods 
(13). As references (13,18) mention the use of strong acid for optimal colour development, we 
employed a final sulphuric acid concentration of 3.36 mM, which gives an intense and stable pink 
colour with maximum absorbance at 415 and 530 nm (Figure 2A). 
 
 
Scheme 1. The principle of the GOX-peroxidase assay for glutamate quantification 
First, GOX oxidizes glutamate, yielding hydrogen peroxide, which is then used by peroxidase to 
convert o-dianisidine into a coloured product. This oxidized O-dianisidine turns deep pink in the 
presence of concentrated sulfuric acid. 
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Figure 2. GOX-peroxidase coupled assay 
A Absorption spectra of the chromogen used in the enzymatic procedure. 
Absorption spectra of a solution containing 400 M O-dianisidine in 50 mM Hepes at 25°C in the 
reduced (solid line), oxidized form in the absence of sulphuric acid (dotted line) and oxidized form 
in the presence of 3.36 mM sulphuric acid (dashed line).  
B Calibration curve for GOX-peroxidase end-point assay.  
Reactions were prepared as described in Materials and Methods, using known concentrations of 
glutamate, ranging from 10 to 800 M. Each reaction was repeated in triplicate. The solid line 
through data points represents the fitting to linear equation with slope 0.001  2.92 ∙ 10-5. 
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The optimization procedure for GOX-peroxidase endpoint assay was performed with the following 
conditions held constant: i) the buffer was 50 mM Hepes pH 7.5 containing 40 M PLP; ii) the final 
volume of the solution containing O-dianisidine, GOX and peroxidase as mentioned in the 
literature, was 200 L (18); iii) the reaction mixture was incubated for 30 minutes at 37°C and then 
stopped with a final sulphuric acid concentration of 3.36 mM. 
Incubation time and concentrations of hKAT II and substrates (KYN and KG) were optimized to 
ensure steady-state conditions of the endpoint readings, preventing equilibrium achievement and 
therefore consumption of glutamate by hKAT II. Moreover, as this coupled endpoint assay was 
designed also to assess the inhibition of transamination activity brought about by screened 
compounds, it should be possible to evaluate even low decreases in absorbance intensity in the 
presence of inhibitors.  Therefore, the conditions of hAKTII reaction were optimized to obtain the 
highest possible absorbance intensity (about 800 M glutamate). Optimized concentrations were 
found to be 2 M for hKAT II and 10 mM for both KYN and KG. These concentrations ensure a 
linear substrate consumption over a period of 30 minutes, with minimal enzyme amount. After this 
time period, only approximately 8% of the total substrate amount was consumed, therefore 
ensuring steady state conditions and a constant substrate turnover rate. Furthermore, the resulting 
signal provided the desired assay sensitivity. Termination of hKAT II  reaction was tested  with 
either phosphoric acid or TCA. The absorbance intensity generated in the latter was lower, 
indicating a possible inhibition of one or both the coupled enzymes. Therefore, phosphoric acid in a 
final concentration of 14 mM was used. 
An assay validation for the endpoint system was performed. For comparison, the amounts of 
KYNA and glutamate produced by hKAT II in the presence of 10 mM KYN and 10 mM KG, were 
determined through the continuous assay based on the absorbance increase at 310 nm and the 
GOX-peroxidase end-point assay, respectively, using the same substrate concentrations and 
reaction conditions. The reaction mixture contained 10 mM KYN, 10 mM KG, and 40 M PLP in 50 
mM Hepes pH 7.5. The reaction, carried out at 25°C in 0.1 cm optical path cuvettes, was started 
by the addition of 2 M hKAT II. The transamination of 10 mM KYN leads to the accumulation of 
814 M KYNA (specific activity 0.27 mol/ g∙min), as determined spectroscopically using the Δ  at 
310 nm  (3625 M-1 ∙ cm-1) for KYNA. The amount of glutamate produced by the same reaction was 
701  67 M (specific activity 0.24 mol/ g∙min), as detected by the GOX-peroxidase end-point 
assay. The concentrations of transamination products (KYNA and glutamate) obtained through the 
two methods are enough similar to validate the application of the GOX-based assay for measuring 
the amounts of enzymatic glutamate production. 
 
Discussion 
KAT activity has been usually assayed by a cumbersome discontinuous method coupled to a 
HPLC determination or liquid scintillation spectrometry of KYNA (2-5,16). The spectral properties of 
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KYN have hindered the development of a continuous assay for KATII activity using KYN as 
substrate. As KYN strongly absorbs at 361 nm (  = 4,350 M-1∙ cm-1) (8), activity assays could not 
be performed at concentrations higher than 2 mM, a value below the estimated KM of the enzyme 
(about 5 mM). Our strategy towards the development of a continuous assay was the observation 
that only at 310 nm the absorbance of KYN is low enough to allow assays at up to 23 mM KYN in 
cuvettes with 0.1 cm optical path. At the same time, at 310 nm there is a significant  absorbance 
difference between KYN and KYNA to make easily detectable transamination time courses. Kinetic 
traces collected at 310 nm were linear over the time needed to calculate initial velocities (about 10 
minutes) and showed no lag or burst phases. The extinction coefficient used to calculate V0 was 
3625 M-1 ∙ cm-1, i.e. for each molecule of KYN consumed in the reaction (1049 M-1 ∙ cm-1) one 
molecule of KYNA (4674 M-1 ∙ cm-1) is produced. The amount of KYN consumed during the linear 
portion of the kinetics is less than 5 %, thus fulfilling the requirements for steady state. 
Furthermore, this assay allows for the determination of V0 in a range of substrate concentrations 
from 0.3 to more than 2.5 KM, that is acceptable for an accurate determination of Vmax and KM (15).  
The assay was intended for use in conjunction with the 96-well plate assay for the characterization 
of the mechanism of action of selected inhibitors. We thus checked that the concentration of KG 
was saturating under our experimental conditions. We estimated 
KG
M
K to be lower than 20 M. At 
saturating KG concentrations 
max
V' is equal to 
max
V that exhibits a value of 0.022 mM/min, and K' is 
equal to 
KYN
M
K that has a  = k4/k2. 
 
 
 
In many cases (19) the rate-limiting step for transaminases is the -proton abstraction (see 
scheme 1 in chapter 2), thus k4 > k2 and K’ represents an upper limit to 
KYN
M
K . Consequently, 
KYN
M
K is in the mM range, in agreement with a previous work on KATII (3), where a value of about 
5 mM was reported. On the contrary, the kcat value, that we found to be about 25 min
-1, does not 
agree with the value previously reported, about 580 min-1. The discrepancy can be due to the use 
of a discontinuous assay and the intrinsic heterogeneity in different enzyme preparations. 
Furthermore, an inaccurate determination of enzyme concentration leads to significant errors in the 
determination of kcat. In this work, the enzyme concentration was evaluated following cofactor 
release by alkali denaturation, a method that is accepted to be the most accurate for PLP-
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dependent enzymes. Notably, the continuous assay allows the rapid measurement of enzyme 
activity, and more importantly, the fast determination of KI values and inhibition mechanisms, as 
discussed in chapter 4. As a further advantage, the amount of enzyme needed for each assay is 
low, about 9 g, compatible with the low yields of KAT II expression.  
A colorimetric end-point assay was developed to quantify the amount of glutamate produced by 
hKAT II transamination activity in the presence of KG. The GOX-peroxidase coupling system is 
very efficient and sensitive in converting the enzymatic production of glutamate into an intense 
chromogenic signal. GOX catalyses the conversion of glutamate into KG and H2O2. The latter is 
then used by peroxidase to oxidize o-dianisidine, yielding an intensely coloured product (13). The 
method was optimized to fulfill the requirements of steady state conditions for hAKT II catalyzed 
reaction and to enhance the assay sensitivity. This assay was validated using the natural substrate 
KYN and allows to test the transamination activity on a variety of other substrates. Moreover, it can 
be adapted  for use with different members of the KAT superfamily, thus allowing the comparison 
of substrate preferences among the different isoforms. In principle, the use of GOX and peroxidase 
as indicator enzymes could allow monitoring of glutamate formation in real time by means of 
continuous assay. However, in continuous coupled assay, the reaction catalyzed by the indicator 
enzyme must not be rate-limiting to the overall kinetics. This requisite is difficult to meet with GOX, 
which is a slow enzyme (kcat  86 min
-1) (20). Moreover, commercially available GOX is very 
expensive. Hence, we developed a discontinuos method, which, despite being more cumbersome, 
is not limited by the rate of the coupled reaction, affords an improved reliability of the assay and 
provides a much greater flexibility in terms of the kinetics conditions that can be explored. More 
importantly, this assay was designed and optimized to be further implemented on a 96-wells plate 
format to rapidly monitor the transamination of potential substrates and the inhibitory activity 
brought about by screened compounds, as discussed in chapter 5. 
In summary, two new useful assays for KAT II activity were developed. Both are advantageous in 
terms of specificity and reliability. More interestingly, they were intended for use in conjunction: the 
GOX-peroxidase end-point assay was adapted to a 96-wells plate assay for the fast evaluation of 
libraries of compounds as potential hKAT II inhibitors via an initial visual inspection, subsequently 
the continuous spectrophotometric assay at 310 nm allows the rapid determination of KI values 
and the characterization of mechanisms of action of selected inhibitors.  
 
As a part of the activities carried out during the thesis, we report here the unsuccessful attempts to 
develop a continuous spectrophotometric assays for hKAT II activity, based on coupled enzyme 
reactions different from above. To develop a continuous spectrophotometric assay for hKAT II 
activity other two methods were first examined.  
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MDH coupled assay 
The ability of hKAT II to use L-aspartate (ASP) as an amino group donor was first assessed 
spectroscopically. In the presence of 10 mM ASP, the internal aldimine band disappears with the 
concomitant appearance of a peak centred at 325-330 nm, indicating the formation of PMP that 
accumulates in the absence of keto acids (Figure 3). The aspartate aminotransferase activity of 
hKAT was exploited to developed a continuous  spectrophotometric assay coupled with  NADH-
dependent malate dehydrogenase (MDH). The oxaloacetate produced by the transamination of 
aspartate serves as a substrate for malate dehydrogenase, that reduces oxaloacetate to malate in 
the presence of dihydronicotinamide-adenine dinucleotide (NADH), which is simultaneously 
oxidized (Scheme 2). NADH has an absorption peak at 340 nm (  = 6,220 M-1∙ cm-1) whereas NAD 
does not shown any absorption. The absorbance decrease at this wavelength provides a means 
for the measurement of the rate of transaminase activity (21-23). A series of reactions were carried 
out as a function ASP concentration from 1 mM to 40 mM, at constant KG concentration (5 mM), 
that, based on a previously determined KM for KG of 1.2 mM, should be saturating (3). From a 
typical Michaelis Menten plot (Figure 4), KM of 27 ± 6 mM, Vmax of  0.029 ± 0.003 mM/min, kcat of 18 
min-1 and kcat/ KM of 0.67  mM
-1 min-1 were calculated. 
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Figure 3. Absorption spectra of hKAT II in the presence of ASP  
Absorption spectra of  8 M hKATI, 50 mM Hepes pH 7.5 at 25 °C, in the absence (solid line) and 
in the presence of 10 mM ASP, about 10’ upon addition (dotted line).  
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Scheme 2. The principle of MDH coupled assay for aspartate aminotransferase activity. 
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Figure 4. Dependence of the rate of reaction of hKAT II on ASP in the presence of KG 
The reaction mixture (200 L final volume) contained 1.6 M hKAT II in 50 mM Hepes pH 7.5 in 
the presence of 5 mM KG, 10 M PLP, 1.35 mM NADH,  6 U MDH and variable concentrations of 
ASP (1-40 mM). The reaction was carried out at 37 °C in a 0.1 cm optical path cuvette. The 
disappearance of NADH was monitored at 340 nm. The solid line through data points represents 
the fitting to the Michaelis-Menten equation with Vmax = 0.029 ± 0.003 mM/min and KM = 27 ± 6 
mM.  
 
The MDH coupled assay has been optimized to fulfill the kinetic requirements for a continuous 
coupled enzymatic assay. The reaction catalyzed by the indicator enzyme, in this case MDH, was 
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not rate-limiting to the overall kinetic, whereas initial rate measurements were linearly dependent to 
hKAT II concentration. Kinetic traces collected at 340 nm were linear over the time needed to 
calculate initial velocities (about 10 minutes) and showed no lag or burst phases. The amount of 
ASP consumed during the linear portion of the kinetics was less than 10 %, thus fulfilling the 
requirements for steady state conditions. Unfortunately, the estimate of the catalytic efficiency of 
hKAT II to ASP indicates that ASP is a poor substrate for transamination reaction. Moreover, MDH 
coupled assay is not a specific method for the detection of hKAT II activity. Indeed, little amounts of 
contaminant aminotransferases present in the enzymatic preparation may exert aspartate 
aminotransferase activity, thereby interfering with KATII activity measurement. This represents a 
significant drawback in the determination of inhibition mechanisms and inhibition constants 
measurement. Therefore, we focused to developed a specific KAT activity assay based on the use 
of KYN as substrate. 
 
GDH coupled assay 
In principle, the kinetic of the transamination reaction between aminoadipate (AAD) and KG could 
be monitored spectrophotometrically by an assay coupled with glutamate dehydrogenase (GDH). 
This enzyme catalyzes the reversible oxidative deamination of glutamate to KG and ammonia (24). 
As the enzymatic oxidation of glutamate is coupled to the reduction of NAD+/NADP+ to 
NADH/NADPH, the absorbance increase at 340 nm provides a useful mean for the measurement 
of the transaminase activity. Mammalian forms of GDH, including the bovine form, can use either 
NADP(H) or NAD(H) as coezymes with comparable efficacy (25).  
 
 
 
Scheme 3. The principle of GDH coupled assay for AAD aminotransferase activity. 
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A reaction mixture (200 L final volume) containing 10 mm AAD, 10 mM KG, 10 M PLP, 1.5 mM 
NADP+  and 1 U GDH, in 50 mM Hepes pH 7.5 was incubated at 25°C. The reaction was started by 
the addiction of 62 nM hKAT II and the reduction of the coenzyme was monitored at 340 nm. The 
initial rate was 2.4 μM/min, corresponding to a kcat of 39 min-1, which is well below the rate 
measured on AAD with glyoxylate as an acceptor of amino groups, 179 min-1 (3). A possible 
reason for this discrepancy is the fact that the oxidative deamination of glutamate to KG and 
ammonia actually is not favored. The equilibrium is in favor of the reverse reaction to form 
glutamate. It is well assessed that KG exhibits feed-back inhibition on GDH (26,27). Studies of 
steady-state kinetics of the oxidative deamination of glutamate by GDH and NADP+ revealed that 
the product KG is a potent competitive inhibitor of L-glutamate oxidation (28). It behaves as a 
tightly bound substrate analogue competing with glutamate in the formation of complexes at the 
enzyme active site. In particular, stopped-flow studies showed that both binary enzyme-KG and 
ternary enzyme-NADP+-KG complexes are inhibitory in the burst phase of the enzyme-catalyzed 
reaction (29). Dissociation constants of 2.5  0.4 mM (30) and 1.7  0.3 mM (29) for the enzyme-
KG complex have been reported. We also found a considerable (about 60%) inhibition of bovine 
GDH activity by 10 mM KG. On the basis of these observations, coupled assay with GDH could not 
be considered a reliable method for continuous measuring of hKAT II transamination activity.   
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Investigation on beta-lyase activity of wild type hKAT II and the mutant Tyr142Phe  
 
Introduction and aim of the work  
Pyridoxal-5’-phosphate (PLP)-dependent enzymes are unrivalled in the diversity of reactions that 
they catalyze (31). The catalytic versatility of PLP-dependent enzymes arises from the ability of the 
cofactor pyridoxal-5’-phosphate to covalently bind the substrate and then to function as an electron 
sink, thereby stabilizing different types of carbanionic reaction intermediates (32,33). PLP-
catalyzed reactions can be divided according to the position at which the net reaction occurs. 
Reaction at the  position include transamination, decarboxylation, racemization, and elimination 
and replacement of an electrophilic R group. Those at the  or  position include elimination and 
replacement (31). As many of the reaction pathways share common intermediates, PLP-dependent 
enzymes often show “catalytic promiscuity”, that is, the ability of a single enzyme to catalyze 
different chemical reactions (34,35). In addition, PLP-dependent enzyme may exhibit a 
promiscuous reaction specificity (36). Indeed, it is known that many PLP-dependent enzymes, 
including tryptophan synthase (37), DOPA decarboxylase (38), aspartate aminotransferase (39) 
and serine racemase (40,41) can catalyze side reactions with substrates analogues or even with 
their natural substrates, some of which have been suggested to play a physiological role (40,41). In 
particular, it is well assessed that transaminases, due to the chemistry of the catalyzed reaction, 
are prone, in the presence of substrates with good leaving groups at the  position, to carry out  -
elimination as a side reaction (42-45), with the formation of -aminoacrylate that spontaneously 
hydrolyzes to pyruvate and ammonia (see Scheme 1 in chapter 2).   
KAT I was initially identified as glutamine transaminase K (GTK) and later was shown to be 
identical to cysteine S-conjugate -lyase 1 (CCBL1). KAT I/GTK/CCBL1 from both human and rat 
is one of the several PLP-depending enzymes that catalyze non-physiological -elimination 
reactions with cysteine S-conjugates that possess an electron-withdrawing group attached at the 
sulphur (43,46). Cysteine S-conjugates are intermediates in the “mercapturate pathway”, a 
mechanism by which potentially dangerous electrophilic xenobiotics, that enter in mammalian 
tissues as environmental pollutants from industrial and commercial use, are detoxified. However, 
this pathway may sometimes generate metabolites more toxic than the parent unmodified 
electrophile. Toxicity may results from the action of cysteine S-conjugates -lyases. If a cysteine S-
conjugate contains a good leaving groups in the  position, it may be diverted away from the 
mercapturate pathway by the action of cysteine S-conjugate -lyases. These enzymes convert the 
cysteine S-conjugate to aminoacrylate, which is non-enzymatically hydrolyzed to pyruvate and 
ammonia, and a sulphur-containing fragment. The thiol released can be highly toxic or 
pharmacologically active depending on its structure (47). If the sulphur-containing fragment 
eliminated by the cysteine S-conjugate -lyase reaction is chemically reactive, the parent cysteine 
S-conjugate may be toxic, particularly to kidney mitochondria, liver, brain and possibly other 
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organs. The toxicity of most halogenated cysteine S-conjugates is associated with the formation of 
reactive thioacylating agents, which thioacylate macromolecules, particularly at the -amino group 
of lysine residues in proteins (48-50). Halogenates xenobiotics that are present in the environment 
and are metabolized, at least in part, to toxic cysteine S-conjugates, include tetrafluoroethylene, 
which is used in industry as precursor of Teflon, trichloroethylene, used in industry as solvent and 
degreasing agent, and tetrachloroethylene. The corresponding toxic cysteine S-conjugates are S-
(1,1,2,2-tetrafluoroethyl)-L-cysteine (TFEC), (S-(1,2-dichlorovinyl)-L-cysteine (DVDC) and S-(1,2,2-
trichlorovinyl)-L-cysteine, respectively (44). DVDC is nephro- and hepatotoxic/carcinogenic in 
experimental animals (51). Toxicity of DVDC is associated in part with covalent modification of 
macromolecules and initiation of lipid peroxidation (52). Both human and rat KAT I/GTK/CCBL1 
efficiently catalyze -lyase reactions with TFEC and DCVC, therefore they can potentially 
contribute to the bioactivation of these toxic cysteine S-conjugates (43,46). Conversely, when the 
sulphur-containing fragment eliminated in a cysteine S-conjugate -lyase reaction is not reactive, 
the parent cysteine S-conjugate is not particularly toxic (53).  
On the other hand, cysteine S-conjugates -lyase side reactions can also have beneficial 
physiological consequences (53). Indeed, the ability of cysteine S-conjugate -lyase to cleave a C-
S bond has been exploited in the design of cysteine S-conjugate prodrugs of sulphur-containing 
anti-cancer agents. Studies (53-56) show the potential pharmacological application in cancer 
therapy for some designed cysteine S-conjugates prodrugs, that release active anti-proliferative 
and pro-apoptotic agents in target tumor tissues by the -lyase-dependent bioactivation.  
Considerable effort has been devoted in last years to identify mammalian cysteine S-conjugates -
lyases that might contribute to this bioactivation process. Mammalian tissues are known to contain 
at least eleven PLP-dependent enzymes capable of catalyzing cysteine S-conjugates -lyase 
reactions (53), they include the cytosolic enzymes kynureninase (57), GTK/KAT I/CCBL1 (43,46), 
cytosolic aspartate aminotransferase (cytAspAT) (58), alanine aminotransferase(AlaAT) (58-60) 
and cytosolic branched- chain aminotransferase (BCATc) (61) and the mitochondrial enzymes 
mitochondrial aspartate aminotransferase (mitAspAT) (44), mitochondrial branched-chain 
aminotransferase (BCATm) (61), alanine glyoxylate aminotransferase II (62) and GABA 
aminotransferase (53). Most of the cysteine S-conjugate -lyases discovered so far are 
aminotransferases. Thus an aminotransferase reaction may compete with the -elimination 
reaction. Interestingly, most of the cysteine S-conjugate -lyases identified to date, including 
kynureninase, cytAspAT, mitAspAT, AlaAT and cytosolic BCAT, but not cytosolic GTK/KAT I, are 
syncatatalitically inactivated by end-products (63). Aminoacrylate eliminated from the -lyase 
active site is known to inactivate pig heart cytAspAT by reacting with the PLP-coenzyme to 
generate a PLP-pyruvate aldol condensation product that remains attached to the active site (64). 
Moreover, the sulphur-containing fragment released from the halogenated cysteine S-conjugate 
may react with a lysine residue leading to self-inactivation (53). 
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Because the ability to catalyze non-physiological -lyase reactions appears to be a common 
feature among many aminotransferases (62), and in particularly human GTK/KAT I like its rat 
counterpart, has the potential to bioactivate halogenated cysteine S-conjugates (43), the 
exploration of the -lyase activity for hKAT II is particularly intriguing. Furthermore, it is worth 
noting that hKAT II contains structural elements which are typical of members of PLP-dependent 
lyases, such as the conformation of the N-terminal region and a tyrosine residue in position 142, 
which is normally occupied by a tryptophan or a phenylalanine in most AT (65). On the basis of 
these interesting observations, we decided to investigate the possible -lyase activity of hKAT II 
and a variant carrying the Tyr142Phe mutation, expected, on the basis of structural evaluation (65), 
to exhibit a decrease propensity for -elimination.  
 
Materials and methods 
-lytic activity. -elimination reactions carried out by aminotransferases involve formation of an 
-aminoacrylate intermediate that, being unstable, rapidly decomposes to pyruvate and ammonia. 
The rates of -elimination of -chloro-L-alanine (BCA) by KATII and Tyr142Phe KATII were 
measured by monitoring the the absorbance increase at 220 nm associated with the formation of 
pyruvate ( 220 nm  pyruvate = 1050 M
-1 cm-1) (62,66). Kinetics were collected at 25 °C using a 0.1 cm 
path length cuvette. The reaction was initiated by adding 64 nM KATII or Tyr142Phe KATII. The 
assay was carried out in 100 mM phosphate buffer pH 7.5 to minimize background signal at 220 
nm.  
When the substrate tested for -elimination reaction heavy interfered with the spectroscopic signal 
used to monitor pyruvate formation, as in the case of S-phenylcysteine, KYN and ESBA, the -lytic 
activity of KATII was evaluated by measuring the accumulation of ammonia by the Nessler’s 
method. 
Nessler’s assay. Reaction mixtures containing ammonia produced by -elimination were tested 
with the Nessler’s assay (67) using a ready-to-use solution (Fluka, code 72190). At pH 7.5 98% of 
ammonia is in the NH4
+ form and the solubility of NH3 in water at 25 °C is about 50 % (w/w), thus 
no significant loss of ammonia by evaporation is expected under our experimental conditions. A 
standard curve was built using ammonium sulfate concentrations in the range 1-20 mM. 40 l of a 
solution containing ammonia were diluted with 860 l of water. 100 l of Nessler’s reagent were 
added to the mixture and the absorbance of the solution immediately recorded at 436 nm.  
 
Results 
The propensity of hKAT II for -elimination was first evaluated on -chloro-L-alanine (BCA), a 
substrate that contains chloride as a good -leaving group (68). Transamination of BCA in the 
presence of 10 mM KG was found to be negligible, as measured by the GOX coupled assay that 
monitors the formation of glutamate. On the contrary, a series of spectra recorded as a function of 
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time for a reaction of 15 M hKAT II in the presence of 5 mM BCA exhibited the immediate 
decrease of the deprotonated internal aldimine band at 360 nm and the concomitant accumulation 
of a species absorbing maximally at 330 nm (Figure 5A), that progressively shifted to about 315-
320 nm, indicating the accumulation of pyruvate (69). Upon reaction completion, the concentration 
of pyruvate was estimated on the basis of its absorbance at 315 nm ( 315 nm  pyruvate = 23 M
-1 cm-1) 
and found to be 3.7 mM. An equivalent amount of ammonia (3.8 mM) was produced, as 
determined by the Nessler’s assay. This indicates that a significant amount of BCA has undergone 
a -elimination reaction with formation of -aminoacrylate that decomposes to pyruvate and 
ammonia. The same assay, carried out on Tyr142Phe KATII, indicated a reduced efficiency of the 
mutant in the -elimination of chloride from BCA. In fact, at equilibrium only about 1.8 mM 
ammonia was produced from 5 mM BCA under the same conditions.  
The initial rates of pyruvate formation catalyzed by KATII and Tyr142Phe KATII in the presence of 
5 mM BCA were measured by monitoring pyruvate accumulation at 220 nm. (Figure 5B). Specific 
activities of 5 nmol/ g∙min and 0.22 nmol/ g∙min, were determined, respectively. The formation of 
pyruvate was characterized by a fast linear phase (Figure 5B), followed by a slow establishment of 
the chemical equilibrium. Deviation from linearity in the reaction took place at a concentration of 
pyruvate that was less than 1% of the total substrate concentration. This deviation, hardly 
attributable to lack of adherence to steady state conditions, is strongly suggestive of an inactivation 
process that is taking place as a consequence of the -elimination reaction. Two possible 
mechanisms can be invoked to explain enzyme inhibition: covalent modification of the enzyme and 
product inhibition. In the latter case, removal of the products from the reaction mixture should lead 
to the recovery of enzymatic activity, whereas covalent modification causes a permanent 
inactivation of the enzyme. It is known that some aminotransferases during -lytic reactions 
become covalently inactivated by a syncatalytic mechanism involving the cofactor and a basic 
residue in the active site (42,70). To test if this is the case also for KATII, the residual activity of the 
enzyme was measured upon reaction with BCA. KATII (174 M), incubated with 50 mM BCA for 20 
minutes at 25 °C, was assayed upon 200-fold dilution using 10 mM KYN and 10 mM KG. The initial 
rate was compared to the value obtained for KATII incubated for 20 minutes at 25°C, in the 
absence of BCA. The activity of the enzyme reacted with BCA was found to be only 3 % compared 
to the activity of the unreacted enzyme, indicating that a significant amount of the enzyme has 
been covalently inactivated as a consequence of the occurrence of the -elimination reaction. 
Therefore, the observed decreased in the rate of -elimination reaction with time resulted from an 
irreversible inactivation of the enzyme rather than from accumulation of an inhibitor in the reaction 
mixture. BCA is capable of permanently inactivating KATII through a mechanism that, likely, 
involves formation of a covalent adduct between the active site lysine residue and the –
aminoacrylate intermediate, as already reported for AlaAT (42) and AspAT (44) (Scheme 4). 
Apparently, the covalently modified form of the enzyme is quite unstable, as it could not be 
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recovered neither after ultrafiltration nor after gel filtration on micro spin columns. This hampered 
the determination of the type of modification by mass spectrometry. The pseudo-first order rate 
constant, kobs, for the inactivation process was obtained fitting to a single exponential decay the 
dependence of the percent of initial activity of KATII on time of incubation in the presence of 5 mM 
BCA (Figure 5C). The calculated value is kobs = 0.7 min
-1. The time required for inactivating one-
half the enzyme initially present (t1/2) was obtained from the pseudo-first order rate constant kobs 
using the equation t1/2 = 0,693/ kobs (69). The value calculated (t1/2 ≈ 1’) is comparable to those 
measured for other aminotransferase. Indeed, in the case of AlaAT the pseudo-first order rate 
constant for inactivation was 0.36 min-1, with a t1/2 ≈ 2’ in the presence of 5 mM BCA (42). The 
partition ratio (moles of product per mole of inactivated enzyme) is about 500, a value comparable 
with those found for AlaAT, 1050 (42), and for kynureninase, 530 (71).  
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Figure 5. -lyase activity of KATII on BCA. 
A Reaction of KATII with BCA. The reaction mixture contained 15 M KATII, 50 mM Hepes, pH 
7.5, at 25°C, in the absence (solid gray line) and presence of 5 mM BCA, after 1, 5, 10, and 28 min 
after mixing (dashed lines). Inset: difference spectra obtained from raw spectra by subtracting the 
spectrum of the unreacted KATII.  
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B Time courses of pyruvate formation by KATII and Y142F KATII. The reaction mixture contained 
either 64 nM KATII or 64 nM Tyr142phe KATII (solid black line and solid gray line, respectively) 
and 5 mM BCA, 100 mM K2PO4, pH 7.5, at 25 °C. The black dashed lines represent the fitting to 
linear equations with slopes 17 M/min and 0.74 M/min for KATII and Tyr142phe KATII, 
respectively.  
C Monophasic progress curve for the inactivation process of hKAT II by BCA. The plot of percent 
of initial activity versus time for hKAT II in the presence of 5 mM BCA (calculated from data in 
figure 5B) was best fit to a single exponential decay. The solid line represents the fitting to an 
exponential decay equation with kobs = 0.7 min
-1 and t1/2 ≈ 1’. 
 
 
 
 
Scheme 4. Proposed mechanism for the reaction of KAT II with BCA and the syncatalytic 
inactivation proceeding from the -aminoacrylate intermediate. Adapted from (42). Pirydoxal-5’-
phosphate is bound to the active site via an aldimmine linkage with the -amino group of Lys263 
(species I). Removal of the -substituent from the deprotonated complex (species II) can lead to 
two different reaction pathways: the formation of an -aminoacrylate-enzyme complex (species III), 
which then decomposes to pyruvate and ammonia regenerating the internal aldimine, that can 
catalyze another catalytic cycle. Otherwise, the three-carbon moiety derived from BCA covalently 
binds to a nucleophilic amino acid residue (X) within the active site resulting in the formation of the 
complex IV in which the enzyme is irreversibly inactivated. With aspartate aminotransferase, this X 
was demonstrated to be the -amino group of the lysine residue involved in the formation of an 
aldimine bond with the coenzyme (70,72). The fraction of enzyme that is covalently modified and 
IV 
I 
II 
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therefore irreversibly inactivated depends on the rates of the two different reaction of quinonoide 
intermediate decay. 
 
BCA is considered the best substrate to test for -elimination reaction, as chloride is a good -
leaving group. KAT II -lyase activity was further tested on a different substrate, S-phenyl-cysteine 
(SPC). SPC was chosen as a substrate for -elimination because cysteine S-conjugates are good 
substrates for the -lytic activity of the related enzyme KAT I (43,46) and this activity could have 
important physiological consequences in the bioactivation of both potentially toxic cysteine S-
conjugates or anti-cancer prodrugs. (43,53). As SPC strongly absorbs at 220 nm, the rate of 
pyruvate formation could not be measured by monitoring the absorbance increase at 220 nm. 
Therefore, the -lytic activity of KAT II in the presence of SPC was evaluated by measuring the 
amount of ammonia produced by the Nessler’s method. Moreover, SPC solubility limit did not allow 
for assay concentrations higher than 3 mM. Unlike BCA, SPC is transaminated by hKAT II, as 
measured by the GOX coupled assay that monitors the formation of glutamate. Therefore, in the 
case of SPC, the aminotransferase reaction competes with the -elimination reaction. -elimination 
results in generation of the PLP form of the enzyme, which is free to catalyze another round of -
elimination. A half-transamination reaction converts the PLP coenzyme into its pyridoxamine 5’-
phosphate (PMP) form, which cannot catalyze a -lyase reaction. When transamination competes 
with the -elimination reaction, as in the case of SPC, maximal -lyase activity requires the 
presence of an -keto acid substrate in the reaction mixture. The -keto acid forms a Schiff’s base 
with PMP that is then converted to the corresponding amino acid and PLP. The PLP form of the 
enzyme can then support another round of -lyase catalysis (53). Therefore, in the case of SPC, 
inclusion of KG in the reaction mixture was necessary to ensure maximal -lyases activity. For a 
reaction of KAT II in the presence of 3 mM SPC and 10 mM KG, the specific activity was 42 
pmol/ g∙min. This value is comparable to that measured for rat KAT I/GTK on the same substrate 
(53 pmol/ g∙min) (54). The -lytic activity of Tyr142Phe KAT II was instead undetectable. We 
tested whether also SPC can inactivate hKAT II,  as it was observed with BCA. A solution 
containing KAT II (129 M) was incubated with 3 mM SPC for 60 minutes, at 25 °C. The reaction 
was diluted 200 fold in an assay solution containing 10 mM KYN and 10 mM KG. The activity of the 
enzyme reacted with SPC was found to be about 65% compared to the activity of the unreacted 
enzyme, suggesting that -lytic activity of SPC may lead to syncatalytic inactivation of the enzyme. 
Furthermore, the -lyase catalysis on the natural substrate KYN by KAT II was also evaluated. The 
specific activity measured using 20 mM KYN was 9∙10-6 mol/min∙ g, four orders of magnitude 
lower than that measured on BCA. The activity of the enzyme reacted with KYN was found to be 
identical to that of the unreacted enzyme, indicating that in this case the enzyme was not 
covalently inactivated as a consequence of the occurrence of the -elimination reaction.  
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Discussion 
PLP-dependent enzymes are reported to be quite promiscuous, with reference to both substrate 
and the type of catalyzed reaction. In particular, some ATs are known to be relatively efficient in 
catalyzing -elimination as side reaction on substrates with good leaving groups, such as BCA 
and, more interestingly, on S-substituted cysteine derivatives (42-44,53,62,69,73). Cysteine S-
conjugates -lyase side reactions can have both negative and positive physiological 
consequences. Adverse effects may occur as a result of cysteine S-conjugates -lyases catalysing 
reactions that generate toxic sulphur-containing fragments, whereas possible beneficial 
consequences of cysteine S-conjugates -lyases activity include pharmacological applications in 
cancer therapy via the bioactivation of pro-drugs into anti-proliferative and pro-apoptotic agents 
(43,53-56). In the case of KAT II, the exploration of -lyase activity was particularly intriguing in that 
structural comparisons suggested the presence of features normally observed in -lyases, such as 
the conformation of the N-terminal region and a tyrosine residue in position 142 which is normally 
occupied by a tryptophan or a phenylalanine in most AT (65). We thus investigated the -lytic 
activity of KAT II and Tyr142Phe KAT II with BCA and SPC. Whereas the Tyr142Phe mutation 
does not change the reactivity of KAT II towards AAD and KYN in the presence of KG, it heavily 
influences the -lytic activity of the enzyme. In fact, both the wild type and the mutant are able to 
eliminate chloride from BCA, with production of equivalent amounts of ammonia and pyruvate, but 
Tyr142Phe mutant is twenty times less efficient. One possible explanation is that the tyrosine 
residue in position 142 plays a role in the balance between -elimination and transamination. In the 
conditions tested here we could not reach saturation in a plot of initial velocity against BCA 
concentration. This is consistent with the observation that KM values of transaminases for BCA are 
usually very high, preventing the determination of kinetic parameters. This also hampers the 
calculation of catalytic efficiency for chloride elimination by KAT II and Tyr142Phe KAT II. For this 
reason, we cannot rule out the possibility that the lower rate of -elimination observed for 
Tyr142Phe KAT II is partly due to a higher KM value. The KM values exhibited toward BCA by 
various aminotransferases vary markedly. The values reported for mitAspAT (69), cytAsAT (69), 
AlaAT (42), BCATm (61), AGAT (62,66) are 50, 200, 0.1, 0.6, 0.07-0.1 mM, respectively. Evidently 
BCA binds favorably at the active site of some aminotransferases, but not others. 
Although a detailed characterization of the -lytic activity of this mutant is behind the aim of this 
work, we checked the -lytic activity of wild type KAT II and the mutant enzyme in the presence of 
SPC. Also in this case we observed -elimination with production of ammonia by the wild type 
enzyme but no activity by the Tyr142Phe mutant, a further indication of a reduction of -lytic 
activity brought about by the mutation. Interestingly, the -elimination, although quite inefficiently, 
takes also place on the natural substrate KYN. This unusual -elimination reaction should produce 
ortho-amino benzaldehyde, as already reported in a controversial paper on the activity of 
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kynureninase (74). At present, it is not known whether this reaction has any physiological 
significance or is regulated by any effector, as in the case, for example of the mammalian serine 
racemase (40,41). However, it should be bear in mind that the -elimination reaction requires the 
formation of an -aminoacrylate intermediate that, in the case of KAT II, as demonstrated by 
experiments with BCA, leads to a concomitant syncatalytic inactivation of the enzyme. 
Furthermore, it is unlikely that a very inefficient reaction, when compared to the main one, would 
have any physiological significance, unless it is tuned by effectors and ligands. The understanding 
of this aspect of KAT II mechanism of action is beyond the aim of this work but should deserve 
further attention. 
To date, -lyase activity of hKAT II has not yet been investigated. Our preliminary evaluation 
demonstrates for the first time that hKAT II catalyzes -elimination reactions on BCA and SPC, 
with efficiency comparable to that reported for other aminotransferases. These findings suggest 
further investigations (i.e. the reaction with TFEC, DVCD and other cysteine S-derivatives) to 
extend the specificity of hKAT II as a cysteine S-conjugates -lyase, and, more importantly, to 
assess whether hKAT II might contribute in human brain to bioactivation of potentially toxic 
cysteine S-conjugates and act as a possible target for cysteine S-conjugate prodrugs in cancer 
therapy. It is worth noting that the mercapturate pathway, by which cysteine S-conjugates are 
produced, is most prominent in liver and kidney, but all the constituent enzymes are present in 
most other organs. Thus, many tissues have the capacity to generate cysteine S-conjugates (63). 
Moreover, cysteine S-derivatives that are formed in the liver can be released into the circulation 
and distributed to other organs, including the brain (63). DCVC, for example, is readily transported 
across the blood-brain barrier (75). Human KAT I, like its rat counterpart, has the potential to 
bioactivate DCVC and other halogenated cysteine S-conjugates (43). Better understanding of the 
catalytic properties of hKAT II is crucial not only for expanding the knowledge of its biological 
functions in human brain, but also for improved inhibitor design. 
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CHAPTER 4 
 
 MECHANISMS OF INTERACTION WITH INHIBITORS 
 
Introduction and aim of the work 
Fluctuations in the brain levels of the neuromodulator KYNA may control cognitive process and 
play a role in several neurological brain diseases (1). Since KAT II accounts for the majority of 
KYNA formation in the human brain, a KAT II selective inhibitor is an important pharmacological 
tool to control KYNA levels favouring precognitive effects. The potential harmful complete depletion 
of this neuroprotective molecule would be prevented by the action of other KAT isoenzymes (2). 
Development of isozyme-specific inhibitors is notoriously difficult, especially in the case of PLP-
dependent aminotransferases, since the members of this family share significant conservation of 
the active site (3). To this end, the different geometry of the ligand-binding pocket in KAT I and II 
isozymes was exploited for the synthesis of the first potent and selective rat KAT II inhibitor, (S)-4-
ethylsulfonylbenzoylalanine (S-ESBA), a close structural analogue of KYN that bears a bulky 
substituent on the anthranilic ring (4). ESBA was found to be pharmacologically active on rats KAT 
II but poorly active towards the human ortholog, as signaled by a 20-fold higher IC50 value (4, 5). 
On the basis of the results of a molecular docking approach, it was proposed that this different 
inhibitory activity might arise from the presence in the catalytic site of human KAT II of two 
hydrophobic residues, Leu40 and Pro76, which are substituted by polar serine residues in the rat 
enzyme (5). Recently, a human KAT II double-mutant harboring the serine residues characterizing 
the rat ortholog active site was generated, in order to investigate the molecular basis for ESBA 
species-specificity (2). Unexpectedly, the site-directed mutagenesis approach did not provide 
further experimental support to explain the striking difference in ESBA inhibitory efficiencies toward 
rat and human KAT II, and underlined the need for more in depth biochemical investigation aimed 
at deciphering the mechanism of ESBA inhibition. It is also worth noticing that rat KAT II displays a 
KM for KYN of 0.66 mM (6), a value about ten-fold lower than the value determined for hKAT II (7). 
This observation indicates that the rat enzyme has evolved to recognize the physiological substrate 
KYN with a higher affinity compared with the human KAT II. Interestingly, both KYN and ESBA 
bind more tightly to the active site of the rat KAT II, suggesting that their binding is controlled by a 
similar mechanism. In this respect, it can be noted that S-ESBA retains the general amino acid 
chemical structure, opening the question whether this molecule is actually more a substrate than 
an inhibitor in the case of the human enzyme (2). This hypothesis can be investigated by 
determining the mechanism of S-ESBA action on hKAT II. 
The isotype-specificity of a rat KAT II inhibitor, cysteine sulphinate (CSA), has been demonstrated 
for brain slices (8) and might be the starting point for the development of potent and specific 
inhibitors of the synthesis of KYNA in the brain. In mammals, endogenous sulphur-containing 
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amino acids, such as homocysteine, cysteine sulphinate, homocysteine sulphinate and cysteate, 
display neuroexcitatory actions similar to those of glutamate. These cysteine derivatives were able 
to reduce the production of KYNA in cortical slices in rats, due to their interaction with KATs. Thus, 
they were considered endogenous modulator of KYNA synthesis in the CNS (9, 10). In particular, 
CSA displayed unique specificity, inhibiting only the action of rat KAT II and showing an IC50 of 
approximately 2 M (8), relatively close to the physiological brain level of CSA (11, 12). The 
potency of CSA as an inhibitor of human KAT II has never been evaluated so far. Moreover, the 
mechanisms of both CSA and ESBA inhibition on human KAT II have not yet been studied in 
depth. Therefore, a detailed analysis of the mechanisms of action of these two inhibitors was 
carried out. 
 
 
                                    CSA                                                         ESBA 
 
 
Materials and Methods 
Materials. L-Kynurenine (K8625), CSA (C4418), glutamate oxidase from Streptomyces sp. 
(G5921), peroxidase from horseradish (P8375), o-dianisidine (D9143) were purchased from 
Sigma-Aldrich (St.Louis, MO). ESBA was synthesized as previously described (4, 5) and kindly 
provided by Prof. Roberto Pellicciari. 
 
KAT transamination activity measured by a coupled glutamate oxidase-peroxidase assay. The 
amount of glutamate produced by transamination activity in the presence of KG was determined by 
an end-point assay based on the use of GOX and peroxidase. A reaction mixture containing 10 
mM KG, 40 M PLP and the potential aminogroup donor (CSA or ESBA), was equilibrated at the 
desired reaction temperature (25°C) in 50 mM Hepes, pH 7.5, before starting the reaction with 
addition of 2 M KAT II. Aliquots (20 L each) were removed after an appropriate incubation time, 
and stopped by mixing with 2 L of 1.14 M phosphoric acid (final concentration 14 mM). Each 
aliquot was subsequently mixed with a detection solution containing 0.02 units of glutamate 
oxidase (GOX-Sigma G5921), 3 units of peroxidase (perox-Sigma P8375), 1 mM O-dianisidine 
(Sigma D9143) and 50 mM Hepes pH 7.5, in a final volume of 200 L. The detection mixture was 
incubated at 37 °C for 30 minutes. Finally, the mixture was supplemented with 50 L sulphuric acid 
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(final concentration 3.36 mM) to dissolve the occasional precipitates of oxidized O-dianisidine and 
to increase the sensitivity of the assay (13), before measuring the absorbance at 530 nm to 
quantify the extent of O-dianisidine oxidation. A calibration curve was prepared, using known 
concentrations of glutamate, ranging from 10 to 800 M in the presence of 10 mM KG, 40 M PLP, 
14 mM phosphoric acid, 1 mM O-dianisidine (Sigma D9143), 0.02 units of glutamate oxidase 
(GOX-Sigma G5921), 3 units of peroxidase (Perox-Sigma P8375) and 50 mM Hepes pH 7.5, in a 
final volume of 200 L. The reaction mixture was incubated and treated as above, and the 
absorbance at 530 nm was plotted against the initial amount of glutamate to generate a calibration 
curve. Blanks (control reactions) were set up using the same reagents as for the assay except for 
hKAT II that was replaced by the same volume of buffer.  
 
KAT -elimination activity measured by Nessler’s assay. Reaction mixtures containing 
ammonia produced by -elimination were tested with the Nessler’s assay (14) using a ready-to-use 
solution (Fluka, code 72190). At pH 7.5 98% of ammonia is in the NH4
+ form and the solubility of 
NH3 in water at 25 °C is about 50 % (w/w), thus no significant loss of ammonia by evaporation is 
expected under these experimental conditions. A standard curve was built using ammonium sulfate 
solutions at concentrations in the range 1-20 mM. 40 l of a solution containing ammonia were 
diluted with 860 l of water. 100 l of Nessler’s reagent were added to the mixture and the 
absorbance of the solution immediately recorded at 436 nm.  
 
Determination of CSA inhibition mechanism and dissociation constants. The mechanism of 
inhibition of CSA and its dissociation constants were determined by measuring the initial rate of 
reactions containing 870 nM hKAT II in 50 Mm Hepes pH 7.5 in the presence of 10 mM KG, 40 M 
PLP and concentrations of KYN from 2.5 to 10 mM. The reactions were carried out at 25 °C in 0.1 
cm optical path cuvettes either in the absence or presence of 4 mM and 20 mM CSA. Initial rates 
were measured from kinetic traces collected at 310 nm using the calculated Δ  310 nm = 3625 M
-1 
cm-1 for KYNA.  
Double reciprocal plots for uncompetitive inhibition of KAT II by CSA were globally fitted to linear 
equations of the type (15): 
ii0
K
CSA
1
appV
1
KYN
1
appV
appK
V
1
                                               [1] 
 
where appK and appV are apparent KM and apparent Vmax. The slope is the linking parameter, 
whereas the intercept is allowed to vary. A secondary plot of intercepts of the primary plots versus 
[CSA] gives an estimated Kii as the abscissa intercept. Because the KYN concentration used in the 
assay is close to KM, an approximated value of Ki can be obtained by the following: 
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Determination of kinetics parameters for transamination reaction with ESBA. A continuous 
assay for the determination of kinetic parameters for the transamination reaction of ESBA with 
hKAT II was developed (see Results). Reactions (200 L final volume) containing 50 mM Hepes 
pH 7.5, 10 mM KG, 40 M PLP, and variable concentrations of ESBA (50 M-15 mM) were 
incubated at 25°C. The reaction was started by the addition of 870 nM hKAT II and carried out at 
25 °C in a 0.1 cm optical path cuvette. Initial rates were estimated exploiting the absorbance 
increase at 338 nm due to the accumulation of the ketoacid ESdiOBA (  = 15,400 M-1∙cm-1).  
 
Results 
Reactivity with CSA.  
CSA is a physiological substrate of AspAT (16, 17) due to its structural similarity with Asp. On the 
basis of structural considerations, CSA can, in principle, be a substrate for either transamination 
and -elimination reaction catalyzed by KAT II, being sulfite a good leaving group. The reaction of 
hKAT II with CSA was first analyzed spectroscopically (Figure 1A). hKAT II reacts with 1.8 mM 
CSA showing a slow decrease of the intensity of the internal aldimine band at 360 nm and the 
accumulation of a species, likely PMP, absorbing at 330 nm. The reaction is completed in about 60 
minutes. In the presence of the same enzyme concentration and 10 mM -aminoadipate the 
reaction reaches equilibrium within 8 minutes (see Figure 1C in chapter 2). The occurrence of 
transamination activity on CSA in the presence of KG was demonstrated by a GOX-peroxidase 
coupled assay measuring the formation of glutamate. For the same reaction, the accumulation of 
ammonia was detected by a Nessler’s assay, indicating that also a -lytic side reaction takes 
place. Cysteine sulfinate is thus a poor substrate of KAT II rather than a pure, competitive inhibitor. 
To further investigate CSA mechanism of action, we exploited the new developed continuous 
spectrophometric assay for KYN aminotransferase activity monitoring the absorbance increase at 
310 nm. hKAT II activity assays were carried out at two concentrations of cysteine sulfinate, 
namely 4 and 20 mM. A double reciprocal plot of the initial velocity against KYN concentration 
gave a series of parallel lines, indicative of an uncompetitive inhibition (Figure 1B). Double 
reciprocal plots for uncompetitive inhibition of hKAT II by CSA were globally fitted to equation 1 
with a slope of 392±22 min and intercepts of 47±4, 68±6 and 94±6 mM-1 in the presence of  0, 4 
and 20 mM CSA, respectively. A secondary plot of the intercepts of the first plot versus inhibitor 
concentration gave a straight line, allowing to estimate a Kii for CSA of about 25 mM (Figure 1B, 
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inset) (15). The approximated value of Ki, calculated from equation 2, is 20 M, in good agreement 
with the IC50 value from in vivo experiments on rats (8), which is about 2 M. These experiments 
provide the first information on the mechanism of inhibition of hKAT II by CSA.  
 
 
 
Figure 1. Reaction of hKAT II with CSA 
A Reaction of KATIIwith CSA monitored by absorption spectroscopy. 
Spectra of the reaction mixture containing 7 M hKAT II in 50 mM Hepes, pH 7.5 at 25°C, were 
recorded in the absence (solid line) and presence of 1.8 mM CSA upon 5 (dotted line), 10 (short 
dashed line), 15 (dash dotted line) and 60 (long dashed line) minutes from the addition. Inset: time 
course of internal aldimine disappearance at 360 nm. The solid line represents the fitting to a 
monoexponential equation with k = 0.09 min-1. 
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B Determination of the mechanism of inhibition and inhibition constants. 
The primary double reciprocal plot for KAT II inhibition by CSA was obtained by determining the 
rate of reaction in a mixture containing 870 nM hKAT II in 50 Mm Hepes pH 7.5 in the presence of 
10 mM KG, 40 M PLP and concentrations of KYN from 2.5 to 10 mM. The reaction was carried 
out at 25 °C in 0.1 cm optical path cuvettes either in the absence (closed circles) or presence of 4 
mM (open squares) and 20 mM CSA (open triangles). The solid lines through data points represent 
a global fitting to equation 1 with a slope of 392±22 min and intercepts of 47±4, 68±6 and 94±6 
mM-1 in the presence of  0, 4 and 20 mM CSA, respectively. Inset: secondary plot of the intercepts 
of the primary plot versus CSA concentration. The abscissa intercept, 25 mM, gives an estimate of 
the inhibition constant Kii. 
  
Reactivity with S-ESBA 
ESBA is an aromatic compound analogous to the natural substrate KYN, that absorbs maximally at 
287 nm, with an approximate extinction coefficient of 2050 M-1 cm-1 (Figure 2A, short dashed line). 
ESBA might be either a pure inhibitor, as previously proposed (4), or, more likely, a substrate 
analog. Indeed, the structure of ESBA bearing an amino acid moiety suggests that this molecule 
might be processed by the enzyme.  
The interaction between ESBA and hKAT II was first investigated by analyzing the spectroscopic 
behaviour of the enzyme in its presence. Binding of ESBA to hKAT II, in the absence of 2-
oxoacids, led to marked changes in the absorption spectrum, with intensity increase at 283 nm and 
at around 330 nm. (Figure 2A). The absorption spectrum of the reaction mixture changes with time 
up to 11’ (dashed dotted line), indicating that ESBA is processed by the enzyme. Moreover, the 
final spectrum is similar but not coincident with the spectrum of PMP-KAT II, as collected in the 
presence of AAD (grey solid line). In particular, considering that in the absence of keto acids only 
one transamination cycle can take place, with consumption of an amount of ESBA equal to the 
amount of active sites, the product of the reaction show higher absorbance intensities at around 
300 and 355 nm. The addition to the reaction mixture of 10 mM KG led to the accumulation of a 
species absorbing maximally at 338 nm (Figure 2B), likely the product of ESBA transamination, 4-
(4-(ethylsulfonyl)phenyl)-2,4-dioxobutanoic acid (ESdiOBA) (Scheme 1). Spectral analysis of the 
product, after separation by ultrafiltration from the enzyme, showed a species with a single 
absorption peak centered at 338 nm (data not shown). As most keto acids significantly absorb in 
the 320-340 nm region (18), it seems likely, from its spectroscopic properties, that this product 
represents the keto acid generated by ESBA transamination. As a check, the occurance of 
transamination activity on ESBA was assessed by a GOX-peroxidase coupled assay for the same 
reaction mixture described in figure 2. The amount of ESBA transaminated by hKAT II at 
equilibrium (about 3 hours after the addition of KG) was found to be about the 90 % of the initial 
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ESBA concentration. Thus, the main product of the reaction is ESdiOBA, that is characterized by 
an extinction coefficient at 338 nm of 15,400 M-1∙cm-1.  
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Figure 2. Reactivity of KATII towards ESBA 
A Absorption spectra recorded for a solution containing 8 M hKAT II in 50 mM Hepes, pH 7.5, 25 
°C (black solid line), and in the presence of 100 M ESBA at the equilibrium (dashed dotted line). 
For comparison, a spectrum of a solution containing 100 M ESBA in 50 mM Hepes, pH 7.5 (short 
dashed line), and the spectrum of PMP-KAT II collected in the presence of AAD (grey solid line) 
are reported.  
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B Upon addition of 10 mM KG a series of spectra was collected after 1’ (long dashed line) , 5’ 
(short dashed line), 15’ (medium dashed), 45’ (dotted line) and 185’ (grey dashed dot-dot line). 
Spectra were corrected for KG contribution.  
 
Based on previous experiments carried out in the presence of compounds undergoing -
elimination, it was verify whether a -lytic reaction takes place on ESBA. In fact, it is reported in the 
literature that p-substituted benzaldehyde is produced by the  elimination activity of 
kynureninase on kynurenine (19). If a -elimination reaction on ESBA is taking place, accumulation 
of ammonia is expected and can be compared to the amount of ammonia produced in the reaction 
with the good -elimination substrate BCA. The rate of -elimination was determined by monitoring 
the formation of ammonia as a function of time for a solution containing 2 M KAT II, 8 mM ESBA 
and 10 mM KG (Figure 3). The reaction is linear within 180’, with a slope of 2.5 M/min ammonia 
(e.g. the specific activity is 25 pmol/ g∙min). This rate is expected to be a lower limit, since, for 
substrates with poor leaving groups, transamination reaction, in the presence of 2-oxo acids, is 
favoured with respect to the -elimination reaction. As a comparison, the reaction of KAT II with 5 
mM BCA gave a specific activity of 5 nmol/ g∙min, thus indicating that ESBA is a poor substrate for 
-elimination.  
 
 
 
Figure 3. -elimination kinetics of ESBA by hKAT II  
The amount of ammonia formed in a reaction mixture containing 2 M hKAT II, 8 mM ESBA and 
10 mM KG was determined as a function of time with the Nessler’s assay. The solid line through 
data points represents the fitting to a linear equation with slope 2.5  0.18 M/min. 
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Taken together these findings confirm that, as previously supposed, ESBA is a good substrate for 
hKAT II rather than a pure competitive inhibitor, and indicate two possible pathways for ESBA 
processing by hKAT II, as shown in Scheme 1. The reaction of hKAT II with ESBA proceeds mainly 
via a transamination reaction, producing 4-(4-(ethylsulfonyl)phenyl)-2,4-dioxobutanoic acid 
(ESdiOBA). This reaction is accompanied by a -elimination side-reaction that likely gives a p-
substituted benzaldehyde. Both products are expected to absorb at wavelengths lower than 350 
nm (18, 20) and are merely hypothesized, as any attemps to identify them by mass spectrometry 
failed. 
 
 
 
Scheme 1. Reaction pathways for ESBA (in the presence of KG as amino group acceptor) to give 
either 4-(4-(ethylsulfonyl)phenyl)-2,4-dioxobutanoic acid (ESdiOBA) or 4-
(ethylsulfonyl)benzaldehyde.   
 
We have also assessed whether ESBA or its reaction products inactivate hKAT II, as it was 
observed with BCA. A solution of KAT II (174 M) was incubated with 8 mM ESBA for 60 minutes, 
at 25 °C. The reaction was diluted 200 fold in an assay solution containing 10 mM KYN and 10 mM 
KG. hKAT II reacted with ESBA was found to be two fold less active than the unreacted enzyme, 
suggesting that -lytic activity of ESBA might lead to syncatalytic inactivation of the enzyme. The 
enzyme that reacted with ESBA was unstable, as a PLP-ESBA derivative could not be recovered 
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neither after ultrafiltration nor gel filtration on micro spin columns. This hampered the determination 
of the type of modification by mass spectrometry. 
Unlike in the case of CSA, the mechanism of inhibition of ESBA on hKAT II could not be 
determined, due to the heavy interference of ESBA spectrum with spectroscopic signals used to 
monitor hKAT II activity. However, the affinity of ESBA for hKAT II could be estimated exploiting 
the absorbance increase at 338 nm due to the accumulation of the ketoacid ESdiOBA. Kinetic 
parameters for the transamination reaction of ESBA with hKAT II were determined by collecting 
kinetic traces at 338 nm at different ESBA concentrations. Data were fitted to the Michaelis Menten 
equation with KM = 4.5 ± 0.9 mM and Vmax = 7.8 ± 0.6 M/min (Figure 4). kcat for the reaction of 
hKAT II with ESBA is 9 min-1, only about 2.5 fold less than the value of 25 min-1 for the reaction 
with KYN.  Moreover, the inhibition of hKAT II by ESBA was further assessed by a colorimetric 
hightroughput screening assay, as illustrated in the following chapter. 
  
 
 
 
Figure 4. Dependence of the rate of reaction of hKATnII on ESBA concentration in the 
presence of KG. The reaction mixture contained 870 nM hKAT II in 50 mM Hepes pH 7.5 in the 
presence of 10 mM KG and variable concentrations of ESBA (50 M-15 mM). The reaction was 
carried out at 25 °C in 0.1 cm optical path cuvettes. The solid line through data points represents 
the fitting to the Michaelis Menten equation with Vmax  = 7.8 ± 0.6 M/min and KM = 4.5 ± 0.9 mM.  
 
Discussion 
In vivo experiments have indicated that both CSA and ESBA are inhibitors of KAT II (4, 5, 8), but 
their mechanisms of action were never studied in depth. On the basis of structure-reactivity 
considerations, they might be substrates for either transamination and -elimination reactions. 
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Their interactions with hKAT II were evaluated by both spectroscopic analysis and monitoring the 
accumulation of reaction products. Our findings demonstrate that both CSA and ESBA are 
substrate analogs and not purely competitive inhibitors. 
CSA is a physiological substrate of AspAT that is able to catalyze both the transamination (21, 22) 
of CSA and its -elimination as a side reaction (23). CSA is an effective amino donor substrate for 
AspAT, probably because a product of the aminotransferase reaction, -sulfinylpyruvate, 
decomposes non enzymatically to SO3
2- and pyruvate, and hence the aminotransferase reaction is 
irreversible (21). In the case of hKAT II, cysteine sulfinate is a very slow transamination substrate 
when compared to the natural substrate AAD. Inhibition of hKAT II by CSA was determined to be 
uncompetitive, a quite unexpected finding, considering that CSA is also a substrate of hKAT II, 
converting the PLP form of the enzyme to the PMP form. Uncompetitive inhibition involves the 
exclusive (or predominant) binding of the inhibitor to the enzyme-substrate complex or to any 
intermediate downstream of it (15). This mode of inhibition is quite rare in nature and is particularly 
encountered in multi-substrate reactions (24-29), where the inhibitor is competitive with respect to 
one substrate (S2) but not with respect to another (S1). The reaction scheme is represented by      
 
 
 
 
Inhibition occurs since ES1I is catalytically inactive. As it can not form product, it is a dead end 
complex which has only one fate, to returns ES1. The uncompetitive inhibition is most noticeable at 
high substrate concentrations (i.e. S1 in the scheme above) and cannot be overcome as both the 
Vmax and KM are equally reduced. Normally, the uncompetitive inhibitor also bears some structural 
similarity to one of the substrates. In the case of CSA, uncompetitive inhibition could come from 
preferential binding of CSA to the PMP form of hKAT II, suggesting that CSA might better mimic 
KG than KYN or AAD. 
In the case of ESBA, the mechanism of inhibition could not be determined due to its strong 
interference with the continuous spectrophotometric assay for KYN aminotransferse activity. 
However, the spectroscopic signal generated by the accumulation of the product of the reaction of 
ESBA with hKAT II was exploited to calculate the kinetic parameters for the transamination of 
ESBA by hKAT II and, thus, an approximate affinity of the inhibitor for the enzyme. An apparent KM 
of 4.5 mM is in good agreement with a 64 % inhibition exerted by 1 mM ESBA (5). Any attempt to 
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identify the reaction products by mass spectrometry was unsuccessful. Although the identity of the 
product could not be assessed, it seems likely, from its spectroscopic properties, that it represents 
the -ketoacid generated by ESBA transamination. Occurrence of transamination activity on ESBA 
was confirmed by the detection of the other product of transamination activity, glutamate. As 
expected on the basis of ESBA structure, this substrate analogue is processed by hKAT II mainly 
via a transamination reaction, which is accompanied by a -lyase side activity. A rough estimate of 
the catalytic efficiency for -elimination reaction, based on specific activity at a fixed substrate 
concentration, indicate that ESBA, as KYN, is a poor substrate for -elimination, when compared to 
BCA. However, ESBA, like BCA, is capable of permanently inactivating hKAT II through a 
mechanism that, likely, involves formation of a covalent adduct between the active site lysine 
residue and the –aminoacrylate intermediate, as already reported for alanine aminotransferase 
(30) and AspAT (31) (see Scheme 4 in chapter 3).  
In conclusion, although both CSA and ESBA show good inhibitory properties on hKAT II, with, at 
least for CSA, inhibition constants in the micromolar range, these molecules are actually 
substrates. In particular, the nature of the reaction of ESBA with hKAT II, possibly involving a 
syncatalytic inactivation and a -elimination reaction with production of an aromatic aldehyde, 
suggest caution in the clinical application of this molecule or its structural analogues. 
Understanding the mechanisms of hKAT II inhibitors is important not only to enable the design of 
better hKAT II inhibitors, but also to understand the enzyme reaction mechanisms. Control of 
reaction mechanism is particularly important for PLP-dependent enzymes because it is known that 
they catalyze side reactions at significant rates with substrates analogues or even with their natural 
substrates (3). 
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CHAPTER 5 
 
 DEVELOPMENT OF A HIGH-THROUGHPUT SCREENING ASSAY 
FOR hKAT II INHIBITORS  
 
Introduction and aim of the work  
KYNA is a neuroinhibitory metabolite of the kynurenine pathway acting as an antagonist of both the 
7-nicotinic acetylcholine receptor and the NMDA glutamate receptor (1-3). Since these effects are 
detected at KYNA concentrations found in the mammalian brain, altered KYNA levels could signal 
malfunctioning of neuronal excitability and synaptic plasticity. In particular, chronically increased 
levels of KYNA can lead to hypofunction of glutamatergic and cholinergic neurotransmission, which 
has been proposed to play a causative role in cognitive impairments seen in Alzheimer’s disease 
(4), schizophrenia (5,6) and Down syndrome (7). In the brain as elsewhere, KYNA is formed 
enzymatically by the irreversible transamination of the pivotal kynurenine pathway metabolite 
kynurenine (KYN). At least, four aminotransferases can utilize kynurenine as the amino donor of 
the transamination reaction in the mammalian brain (8). However, only one of them, KAT II, 
accounts for the majority of cerebral KYNA synthesis in rat and human brain tissue (9). Hence, 
selective inhibition of KAT II is an attractive strategy for therapeutically normalization of increased 
levels of KYNA in the diseased brain (10,11). The ability to pharmacologically modulate KAT II has 
been limited, and only a rat-specific KAT II inhibitor, ESBA, with poor potency toward the human 
ortholog, has been reported (12-15). A different rat KAT II inhibitor, BFF 122, has been discovered 
recently (16), exhibiting also activity against human KAT II (17). The mechanisms of action of these 
two inhibitors have been ascertained: BFF 122 forms a hydrazone adduct with PLP and is thus an 
irreversible inhibitor (17), whereas ESBA is actually a substrate undergoing a transamination 
reaction (see above). Thus, although to date available KAT II inhibitors are good in vitro and are 
valuable experimental tools for the elucidation of the role of the kynurenine pathway in brain 
function (12,16), they should be improved for possible future orally administered in vivo drugs. 
Therefore, there is a need for novel and optimized KAT II inhibition structures. To select structures 
leading to potent KAT II inhibitors, it is necessary to develop a simple and sensitive high-
throughput-compatible enzymatic screening tool. In recent years, assaying enzyme-catalyzed 
transformations in high-throughput systems has become crucial to enzyme discovery, enzyme 
engineering and the drug discovery process (18). In most high-throughput enzyme assays, 
catalytic activity is detected using labelled substrates or indirect sensor systems that produce a 
detectable spectroscopic signal upon reaction (19-23). To date, the discovery of KAT II inhibitors 
has been hampered by the inability to use the existing HPLC-based KAT assay for high-throughput 
screening. A very recent study (10) reports a modification of the conventional HPLC fluorescence 
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method that enabled the development of a 96-well microplate fluorescence assay for analysis of in 
vitro human KAT I activity. KYNA enzymatically produced from KYN is measured directly in the 
reaction mixture fluorimetrically ( exc = 344 nm, em = 398 nm). The major advantages of this new 
assay is that it is amenable for high-throughput screening due to its simplicity and low cost 
compared to exiting HPLC method. However, a significant drawback of this assay is that 
compounds that fluoresce at similar wavelengths can be lost. Moreover, another important 
shortcoming of this method is the long incubation time (4 hours at 37°C), which harbours 
significant risks in compounds screening, such as formation of active breakdown products or 
compounds instability. This fluorescence-based method, which was reported for KAT I using KYN 
as substrate, could also detect activity of other KAT isoforms, as they all use KYN as amino group 
donor and have activity at the applied pH range (8,24-26). Therefore, this method is not a KAT II-
specific assay. The lack of a specific assay for each individual KAT represents a significant 
drawback in clinic and pharmacological studies, as it is impossible to ascertain which isoenzyme 
being affected by the action of tested inhibitors. Among KATs isoforms, KAT II is unique in having 
aminoadipate (AAD) aminotransferase activity. We exploited this substrate specificity to develop a 
specific and sensitive method to assay KAT II activity, based on the coupling of KAT II activity to 
two reporter reactions catalyzed by glutamate oxidase and peroxidase. This end-point assay was 
efficiently implemented on a 96-well plate format for rapid high-throughput screening of hKAT II 
inhibitors. To validated the assay, we investigated its ability to differentiate between known KAT II 
inhibitors of various potencies. Although KAT II is considered an interesting drug target in the 
treatment of schizophrenia and other neurological disorders (11,13), only a few compounds have 
been so far described as potent KAT II inhibitors (12-14,16,27-29) (Scheme 1): cysteine sulfinate 
(CSA) on brain slices of rats (27), ESBA in dialysis experiments on rat hippocampus (13), 1-
Methyl-4-phenylpyridinium (MPP+) and 3-nitropropionic acid (3-NPA) on both cortical brain slices 
and partially purified KATs (29), O-phosphoserine (OPS) on rat brain tissue homogenates (28) and 
BFF122 on both rat brain tissue homogenates (16) and recombinant human KAT II (17). MPP+ is 
the metabolite of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a contaminant of “street 
drugs”, whereas 3-NPA is a toxin produced by fungi and plants. Both MPP+ and 3-NPA are 
mitochondrial toxins that inhibit the mitochondrial respiratory complex I and II, respectively (29-33). 
Compromised energy metabolism associated with these two mitochondrial toxins has been 
supposed to increase the vulnerability of neurons to the endogenous glutamate and thus initiate 
changes leading to neurodegeneration (34). Enzymatic studies revealed that MPP+  inhibits the 
activity of rat KAT II, but not the activity of rat KAT I, whereas 3-NPA affects the activity of both 
enzymes (29). Thus, the neurotoxic consequences evoked by MPP+ and 3-NPA may be at least 
partially associated with the decrease of KYNA production. Although MPP+ was proved to be able 
to discriminate between KAT I and KAT II, stimulating the design of isoform-specific inhibitors, the 
use of this compound triggers Parkinsonian symptoms (35). Therefore, we tested only the inhibition 
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activity of 3-NPA.   We tested also the inhibition brought about OPS as in rat brain tissue 
homogenates, some metabotropic glutamate receptor (mGluR) ligands, such as quisqualate and 
OPS, inhibited KAT II activity, but not KAT I, therefore reducing KYNA formation (28). This effect 
should be taken into consideration when novel mGluR ligands are developed for the treatment of 
neurological and psychiatric diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Natural substrates (KYN and AAD) and inhibitors [ESBA (13,14), CSA (27), MPP+, 3-
NPA (29), OPS (28), BFF-122 (16,36)] of KATII.   
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Materials and methods 
Materials. KYN (K8625), AAD (A0637), CSA (C4418), 3-NPA (N5636), OPS (P0878), 
glutamate oxidase from Streptomyces sp. (G5921), peroxidase from horseradish (P8375) and O-
dianisidine (D9143) were purchased from Sigma-Aldrich (St.Louis, MO). ESBA was synthesized as 
previously described (13,14) and kindly provided by Prof. Roberto Pellicciari. 
 
KAT transamination activity measured in a 96-well microplate by a coupled glutamate oxidase-
peroxidase assay (GOX-peroxidase coupled assay). Reactions were performed in 96-well tissue 
culture plate (Sarstedt). According to final optimized conditions, reaction mixtures containing 10 
mM AAD, 10 mM KG, 40 M PLP, 2.2 M hKAT II, 50 mM Hepes, pH 7.5, were incubated at 25 °C 
for 30 minutes. The reactions were stopped with 14 mM phosphoric acid. 0.015 units of glutamate 
oxidase (GOX-Sigma G5921), 2.25 units of peroxidase (perox-Sigma P8375) and 0.75 mM O-
dianisidine were added to the solution. The mixture was incubated at 37 °C for 90 minutes. 3.36 
mM sulphuric acid was added and the absorbance was measured at either 500 or 550 nm using a 
home-developed plate reader. Blanks were set up using the same reagents as for the assay 
except hKAT II was replaced by the same volume of buffer. A calibration curve using known 
concentrations of glutamate, ranging from 10 to 800 M in the presence of 10 mM KG, 40 M PLP 
and 14 mM phosphoric acid, was build to measure the amount of glutamate produced in the 
enzymatic reactions. Inhibition assays were set up by adding in the reaction mixture either cysteine 
sulfinate (CSA), -chloroalanine (BCA), (R)-2-amino-4-(4-(ethylsulfonyl)-4-oxobutanoic acid 
(ESBA), 3-nitropropionic acid (3-NPA) or O-phosphoserine (OPS). CSA, CSA, 3-NPA, OPS and 
ESBA at the same concentrations used for the inhibition assays were also tested for 
transamination activity in the presence of 10 mM KG. All measurements were performed in 
duplicate.  
 
Results                                                                                                                                                     
Because hKAT II is a potential target for pro-cognitive interventions in schizophrenia and other 
neurological disorders, a high-throughput screening assay to identify hKAT II inhibitors was 
developed. The assay implemented on a 96-well microplate format is based on the end-point 
associated with the consumption by glutamate oxidase of glutamate produced during the 
transamination of AAD, or other substrates, in the presence of KG. GOX specifically catalyzes the 
oxidative deamination of L-glutamate with the formation of -ketoglutarate, ammonia and hydrogen 
peroxide (37). The latter reacts with O-dianisidine in the presence of peroxidase to form a stable 
coloured product, absorbing at 530 nm that is proportional to the glutamate concentration. When 
measured in microplate, the oxidized O-dianisidine spectrophotometric signal was linearly 
proportional for a wide range of glutamate concentration (10 M to 800 M), hence fulfilling the 
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requirement for detection system linearity. The conditions of the GOX-peroxidase end-point system 
were optimized to ensure assay sensitivity, reliability and reproducibility, as already described in 
chapter 3. Incubation time and reagents concentrations allow for product to accumulate to readily 
detectable levels in the presence of relatively low substrate concentrations, which in turns helps 
avoid saturation of the reaction. This assay is well suited to monitor both the transamination of 
potential substrates and the inhibition brought about by molecules rationally designed or, more 
importantly, by libraries of compounds to be screened. Using the optimized GOX-peroxidase 
endpoint assay we performed a 96-well microplate assay in order to assess at the same time the 
transamination activity with potential amino donor substrates and the inhibition of AAD 
transamination activity in the presence of compounds which have been described as KAT II 
inhibitors. Results of 96-well plate assay are shown in Figure 1. A mixture containing 2.2 M hKAT 
II and 10 mM KYN, incubated for 30 min, led to the formation of 810 ± 91.9 M glutamate, i.e. 8.1 ± 
0.9 % of KYN was transaminated within the incubation time. When the reaction was carried out in 
solution and the transamination determined directly by the absorption intensity of KYNA ( 310 nm = 
3625 M-1cm-1), the same degree of KYN transamination was measured. The transamination 
reaction in the presence of 10 mM AAD generated a higher amount of glutamate (1.1 ± 0.0997 mM 
) due to the higher catalytic efficiency of KAT II towards AAD with respect to KYN (26). 1 mM 
ESBA, 200 M CSA and 2 mM OPS gave a measurable transamination, which was about 8 ± 0.78, 
1.4 ± 0.07 and 41 ± 4.2 % of the transamination with AAD, respectively (Figure 1B). 
Transamination in the presence of either 5 mM BCA or 50 mM 3-NPA was found to be negligible 
(Figure 1B). Furthermore, the assay allows to identify compounds that specifically inhibit KAT II 
activity. It was found that the presence of either 1 mM or 100 M ESBA leads to 71 ± 4.9 % and 63 
± 1.4  % hKAT II activity inhibition, respectively (Figure 1B), in good agreement with data 
previously obtained (64 % inhibition exerted at 1 mM ESBA) (14). CSA, BCA, 3-NPA and OPS 
inhibition of hKAT II was also measured (Figure 1B) and found to be in good agreement with data 
reported in the literature, showing an IC50 value of approximately 2 M for CSA (27), and inhibition 
of 24% and 38% exerted at 5 mM NPA (29) and 1 mM OPS (28), respectively.   
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Figure 1. Representative 96-well microplate assay for substrates and inhibitors of hKAT II. 
A Each reaction well contained 10 mM KG and 40 M PLP in  50 mM Hepes, pH 7.5. Reactions 
were allowed to proceed for 30 minutes at 25 °C and stopped with phosphoric acid to a final 
concentration of 14 mM. To the reaction mixture, a solution containing 0.75 mM O-dianisidine, 
0.015 U GOX and 2.25 U peroxidase was added. The reaction was allowed to develop for 90 
minutes at 37 °C, and stopped with 3.66 M sulfuric acid. Each reaction well was duplicated (odd 
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and even lines). Wells in lines 1 and 2 were used to build a calibration curve using the following 
glutamate concentrations: 0 (A), 10 M (B), 50 M (C), 100  M (D), 200 M (E), 400 M (F), 800 
M (G). The effect of tested molecules on the reporter GOX-peroxidase reaction is shown in line 3 
and 4. Each well contains 400 M GLU and 10 mM KYN (A), 10 mM AAD (B), 1 mM ESBA (C), 
200 M CSA (D), 5 mM BCA (E), 50 mM NPA (F), 2 mM OPS (G). Wells in lines 5 and 6 are 
blanks containing only tested molecules at the higher concentration. The transamination activity of 
10 mM KYN (A), 10 mM AAD (B), 1 mM ESBA (C), 200 M CSA (D), 5 mM BCA (E), 50 mM 3-
NPA (F) and 2 mM OPS (G) in the presence of 2.2 M hKAT II is shown in lines 7 and 8. In lines 9-
12 each molecule is tested for inhibition of the transamination reaction in the presence of 10 mM 
AAD and 2.2 M hKAT II using the following concentrations of inhibitors: 1 mM ESBA (A9-10), 100 
M ESBA (B9-10), 200 M CSA (C9-10), 20 M CSA (D9-10), 5 mM BCA (E9-10), 500 M BCA 
(F9-10), 50 mM NPA (A11-12), 5 mM NPA (B11-12), 2 mM OPS (C11-12) and 200 M OPS (D11-
12). 
B. Percentage of transamination activity of hKAT II in the presence of either AAD, KYN, ESBA, 
CSA, BCA, NPA, and OPS (black bars) or AAD and ESBA, CSA, BCA, NPA, and OPS (red bars), 
at concentrations shown in the figure. The activities are expressed as a percentage of the degree 
of transamination measured in the presence of 10 mM AAD.  
Discussion                                                                                                                                                     
The high-throughput search for specific and potent enzyme inhibitors strongly takes advantage of 
fast, simple, cheap and reliable activity assays. High-throughput enzyme assays for screening 
large compound libraries are generally set up as endpoints tests with comparatively long reaction 
times (19,38-40), in contrast to rapid kinetic assay systems for IC50 determinations (41-43). Most 
high-throughput assays are based on chromogenic and fluorogenic substrates or sensors. Recent 
advances in the development of high-throughput enzyme assays have identified new labels and 
chromophores to detect a wide range of enzymes activities (18). These conditions allow multiple 
96-well, 384-well, or higher density well plates to be set up in parallel by hand or simple robotics 
(19). Due to the lack of such a method for hKAT II, we developed and validated a simple and 
sensitive enzymatically coupled absorbance assay to enable routine high-throughput screening for 
hKAT II inhibitors. The GOX-peroxidase coupled assay was efficiently adapted to a 96-well 
microplate format and allowed to assess quickly and sensitively both the transamination activity on 
potential substrates and the inhibition potency of selected compounds. The assay is very sensitive 
and is linear in an 80-fold concentration range of glutamate (between 10 and 800 M). 
Furthermore, very low amounts of enzyme are used for the assay. The assay was optimized for 
about 20 g of hKAT II/assay and an incubation of 30 minutes. By increasing the incubation time, 
the amount of enzyme can be proportionally decreased. One of the criteria for high-throughput 
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screening assay is to provide the best sensitivity while using the minimal amount of reagents for 
which supply may be limited, such as enzymes. This assay is therefore compatible with the low 
yields of hKAT II expression. The development of new hKAT II inhibitors can take advantages of 
this high-throughput screening compatible activity assay. Indeed, it is the first KAT II assay 
amenable for high-throughput screening due to its simplicity, quick readout and low cost compared 
to existing HPLC methods. Moreover, it was intended for use in conjunction with the continuous 
spectrophotometric assay monitoring KYNA accumulation at 310 nm. The GOX-peroxidase 
coupled assay implemented on a 96-well microplate allows the fast evaluation of libraries of 
compounds as potential hKAT II inhibitors via an initial visual inspection. Subsequently, for 
compounds showing good inhibitory properties, the mechanisms of inhibition and dissociation 
constants can be estimated with the continuous spectrophotometric assay. Notably, as the GOX-
peroxidase end-point assay works with both AAD and KYN, two different applications are possible. 
First, using AAD as aminogroup donor, only KAT II activity can be specifically assayed. One of the 
main drawbacks of the discontinuous HPLC-based KAT II assay is lack of isoform-specificity (44), 
as under the same assay conditions, also KAT I, III and IV have detectable activity (8,24,25). 
Differently from KYN, that can be used as the amino group donor by all four known KAT 
isoezymes, AAD is efficiently used only by KAT II (26,44). A KAT II-specific activity assay has 
never been reported so far. On the other hand, if KYN is used as amino group donor, the end-point 
assay can also be adapted for use with different members of the KAT superfamily, thus allowing 
the quantitative comparison of substrate preferences among the different isoforms and the 
selectivity of potential inhibitors.  
In conclusion, the assay system we have developed will be a valuable tool to the high-throughput 
screening of large compounds libraries, with the objective to discover currently unknown potent 
hKAT II inhibitors leading to novel drugs for cognitive dysfunction. New hints toward the 
development of a KAT II-specific inhibitor come from the recent observation that large molecules 
with bulky substituents specifically bind to the II-isoform of the enzyme (29,36), probably as a 
consequence of the higher mobility of the N-terminal domain of KAT II with respect to that of other 
aminotransferases (36). These observations together with the tools developed here for the high-
throughput screening of KAT II specific inhibitors will aid in the development of anti-schizophrenic 
and precognitive drugs.  
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CHAPTER 6 
 
OPTIMIZATION OF hKAT II HETEROLOGOUS EXPRESSION 
 
Introduction and aim of the work 
As a part of the activities carried out during the thesis, we report here the attemps to increase the 
expression yield of soluble hKAT II. Recombinant expression of hKAT II was investigated by a 
novel culture method, called EnBaseTM (BioSilta - enzyme-based-substrate-delivery), which 
exploits the principle of fed-batch culture, traditionally used within bioreactors, to provide controlled 
growth at micro-scale by enzymatic substrate release. EnBaseTM (BioSilta) is an enhanced novel 
microbial culture system in which enzyme-based supply of glucose allows a glucose-limited 
growth, providing high cell densities and high recombinant protein yields.  
Culture for recombinant protein production today in laboratory scale is mainly based on shaken 
media which are generally performed in batch (i.e. all nutrients are added at the beginning of the 
process). Shake flask cultures are known to be easy and low cost, but generally their reliability and 
final product yield is poor. Compared to industrial fed-batch processes, shaken cultures are 
characterised by low volumetric cells and product yields (1). Cell cultures in shake flasks often fail 
to reach high cell densities and high protein productivity per cell due to oxygen depletion, lack of 
pH control and the necessity to use low induction cell densities. Shake flask cultures are normally 
run without monitoring and control of any parameters such as pH and the level of dissolved oxygen 
(2). Under such circumstances, high cell densities cannot be reached since the high respiratory 
rate of fast growing bacteria exceeds the oxygen transfer capacity of the medium, and the culture 
is relatively soon depleted of oxygen (3). Under oxygen limitation growth is slow and recombinant 
protein production is poor. Moreover, oxygen limitation leads to anaerobic responses (4, 5), which 
multiply the stress caused by the recombinant protein synthesis. In addition to oxygen limitation, 
uncontrolled batch cultures may suffer from acetate accumulation by overflow metabolism. The 
drop of pH due to accumulation of overflow acetate and anaerobic metabolites impairs cell growth 
and leads to poor recombinant protein formation (2). Uncontrolled cell growth is often associated 
with uncontrolled protein synthesis rate and incorrect protein folding. High local concentration of 
recombinant protein together with insufficient amount of folding-promoting proteins may lead to 
formation of insoluble protein aggregates (inclusion bodies). 
In contrast to variable shaking cultures, in well controlled bioreactor scale cultures, high cell 
densities can be successfully achieved by applying the fed-batch principle, which has been widely 
utilized since late 1980’s (6-8). In most fed-batch processes, a continuous supply of a growth 
limiting substrate (generally glucose) by an external pump provides a metabolic control. In this 
way, the growth rate can be controlled to match the oxygen transfer rate, allowing for the growth to 
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be run in aerobic mode. Higher cell densities (up to 50-200 OD600) are therefore reached compared 
to shake flask cultures. In shaken cultures substrate-limited growth is not commonly applied as it is 
not trivial to implement a continuos well-controlled feed flow in a shaking enviroment. However, 
recently a novel technology to provide feeding without external devices have been developed (1). 
The novel techology, called EnBaseTM (BioSilta), or enzyme-based-substrate-delivery, combines a 
continuos diffusion of a metabolic inactive polymer, starch, from a gel phase into the culture 
medium and the enzymatic conversion by glucoamylase of the starch to glucose substrate. In this 
system, the glucose release rate and the growth rate of the culture can be simply controlled by the 
amount (and principally by the activity) of the enzyme glucoamylase, in a similar way as the pump 
speed of the feed solution is changed to control the growth of cells in a biorector. This solves the 
problems of uncontrolled growth, oxygen limitation and severe pH drop in shaken cultures. The 
enzymatic glucose release principle has recently been developed into a fully liquid phase 
cultivation system, EnBaseTM Flo (BioSilta), where the glucose-releasing polymer is fully soluble 
and no gel phase is necessary (2). This novel method was directly applied in microwell plates and 
shake flasks without any requirements for additional sensors or liquid supply systems. The 
feasibilility of this method was demonstrated by overproduction in Escherichia coli of three different 
recombinant proteins, the A-domain of human protein disulphide isomerase (PDI), alcohol 
dehydrogenase (ADH) from Lactobacillus and a multifunctional enzyme from Drosophila 
melanogaster (2). In this study, these three proteins were expressed in EnBaseTM Flo (BioSilta), 
conventional Luria-Bertani (LB), Terrific Broth (TB) and mineral salt medium. By examination of cell 
growth, medium pH development and protein yields, results demonstrated that sigificant 
improvements in protein yield can be achived by this new cultivation method. With EnBaseTM Flo 
(BioSilta), the final cell densities were typically 10 times higher compared to the standard cultures 
in LB, TB and mineral salt medium. The enzymatic glucose release system together with a well-
balanced combination of mineral salts and complex medium additives provided high cell densities, 
high protein yields and a considerably improved proportion of soluble proteins in harvested cells. 
This increase was coupled with equal or improved yields of soluble recombinant proteins. This 
improvement is thought to result from a well controlled physiological state during the whole 
process. Indeed, this novel culture method consist of two phases (figure 1): in the first step cells 
grow in fed-batch like mode controlled by the activity of amylase, and, in the second phase, 
addition of medium boosters together with an inducer guaranties stable pH conditions and 
balanced supply of extra energy source for optimal protein expression. The boosting step is 
followed by a slow growth period during which the recombinant protein is slowly synthesized and 
folded.  
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Figure 1.  Schematic picture of the EnBaseTM (BioSilta) culture principle (1).  
Phase 1 = controlled culture in optimized mineral salt medium with a low concentration of complex 
additives (peptones, yeast extract). Phase 2 = induction with IPTG and addition of complex 
nutrients (booster mixture). Phase 2a of increased growth rate is followed by phase 2b of low 
growth rate and slow production of soluble protein. 
 
EnBaseTM Optiset (BioSilta) is a handy tool to select an optimal culture medium for the production 
of the target recombinant protein. It includes a total of 4 different culture media. For each medium 
variant, the conditions for testing can be differentiated by the presence of absence of inducer and 
medium boosters. One of the test media is the medium routinely used for recombinant protein 
production. The other culture options utilize the patented EnBaseTM media of Biosilta. EnBaseTM 
media are based on an optimised mineral salt medium (MSM) composition, where small amounts 
of complex medium additives (yeast extract and peptones) have been added to ensure a fast 
adaptation of cells to the medium.  
 
The expression system for recombinant human KAT II production has been developed and 
optimized by Proff. Franca Rossi and Menico Rizzi (University of Piemonte Orientale), but is still 
poor, yielding about 1.5 mg of soluble protein from 2 litre culture broth, as most of the enzyme is 
inside inclusion bodies. The search for specific and potent hKAT II inhibitors will strongly take 
advantages of an optimized recombinant expression process enabling to obtain higher volumetric 
protein yields (i.e. soluble or active protein per culture volume) compared to the standard shake 
flask protocol. Therefore, we tested hKAT II heterologous expression in a 24-wells plate culture 
format using two versions of EnBaseTM Optiset (BioSilta). The first version of EnBaseTM Optiset 
included two gel-based Enbase media (MSM2 and MSM10) and a liquid EnBaseTM Flo medium. 
Recently, the EnBaseTM Optiset was updated by BioSilta so that the gel-based media were 
excluded. The most recent EnBaseTM Flo Optiset contains three different variants of the liquid 
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EnBaseTM Flo medium (Flo-02, Flo-10 and Flo-20). These three culture media differ from each 
other only in the amount of complex nutrients.  
  
Materials and methods 
Standard protocol for hKAT II expression and purification. The E.coli strain BL21(DE3) 
expressing human KAT II was constructed by Prof. Franca Rossi, Università Piemonte Orientale. 
The DNA fragment coding for the His-tagged hKAT II sequence was ligated into the pET16b 
expression vector (Novagen). The resulting pET16b-hKAT II construct was transformed in 
BL21(DE3) competent bacteria for the expression of native enzyme. pET16b-hKAT II transformed 
BL21(DE3) bacteria were inoculated in 1 liter of LB medium (50 g/mL ampicillin); bacterial culture 
was grown at 22°C under vigorous shaking, omitting the addition of IPTG. 18-20 post-inoculation, 
bacteria were collected by centrifugation (11,000 x g for 15 min. at 4°C), washed once in PBS and 
flash frozen in liquid nitrogen for storage at –80°C until subsequent use. Bacterial pellet from 1 liter 
of native hKAT II expressing culture was dissolved in 40 mL of buffer A (20 mM Tris-HCl, pH 8.0, 
50 mM NaCl, 40 M PLP and a commercial proteases inhibitors cocktail from Sigma) and 
disrupted by sonication. The clarified bacterial lysate was added with 50 mM imidazole and 
incubated with 5 mL of drained Ni-NTA Agarose resin (Quiagen) for 1 hr at 20° C, under gentle 
agitation. After extensive washes in buffer A containing 75 mM imidazole, the elution of the 
absorbed protein was obtained at 200 mM imidazole in buffer A. Pure hKAT II containing fractions, 
as determined by standard SDS-PAGE analysis, were pooled, dialyzed against buffer A and 
concentred using a 30,000 MWCO disposable device (Vivascience) to a final protein concentration 
 10 mg/mL, as determined by Bradford assay (Sigma), using bovine serum albumin as standard. 
Aliquots of hKAT II were frozen at -80 °C for long term storage.  
 
Expression of hKAT II with EnBaseTM Optiset (BioSilta). The pET16b-hKAT II construct, 
provided to us by Proff. Franca Rossi and Menico Rizzi, Università Piemonte Orientale, was 
transformed in E.coli Tuner (DE3) (Novagen) competent bacteria. Tuner (DE3) bacteria encoding 
pET16b-hKAT II were inoculated in four different culture media: 1) Luria-Bertani (LB) medium, 
which is the standard medium for hKAT II heterologous expression; 2) EnBase gel with mineral salt 
medium (MSM2), 3) EnBase gel with balanced medium (MSM10) and 4) EnBase Flo medium. The 
media composition is reported in (2). Culture procedures were carried out as indicated in the user 
manual included in BiosiltaTM Optiset kit. E.coli cells expressing hKAT II from premade glycerol 
stocks were streaked on a LB-agar plate (50 g/ml Amp) and incubated overnight at 37°C. All the 
cells from the LB-agar plate cultured overnight at 37°C were collect by rinsing with 3-4 mL of 
EnBase medium for dilution. The optical density of cell suspension was measured at 600 nm with a 
Cary 400 Scan spectrophotometer (Varian Inc.). To each bottle of culture medium a volume of 
inoculum was added in order to obtain an initial OD600 of 0.15. Supplements including ampicilline 
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(50 g/ml final concentration), thiamine, magnesium, inoculum and the enzyme glucoamylase, 
were aseptically added to the medium bottles according to the user manual. Bottles were carefully 
mixed after supplements addition. The plastic storage seal was removed from the 24-wells plate 
and 3 mL of each medium-cell mixture was dispensed per well as indicated with colours in the 
plate layout 1:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enbase gel with MSM2 medium: wells A1, A2, A3, B1, B2, B3, green. 
EnBase gel with MSM10 medium: wells C1, C2, C3, D1, D2, D3, red. 
EnBase Flo medium: wells A4, A5, A6, B4, B5, B6, yellow. 
Standard medium (LB): wells C4, C5, C6, D4, D5, D6, white. 
 
The plate was sealed with an oxygen permeable membrane and the culture was immediately 
started at 30°C, 200 rpm on a shaker with amplitude of 30 mm.  
After 2 hours, IPTG (15 M final concentration) and a mixture of medium booster were added to 
the wells containing the LB standard medium, as marked on the plate layout 1. Growth was 
continued at 30°C. Samples of LB cultures for protein analysis were harvested at 3-4 hours after 
IPTG addition. For total protein analysis, aliquots corresponding to a 500 L culture with OD600  of 
0.7 were pelleted by centrifugation (13 000 rpm for 10 min. at 4°C), supernatants were discarted, 
the pellets were resuspended in 40 L of sample buffer and further analyzed by SDS-PAGE. For 
the analysis of the soluble and insoluble fractions after cellular lysis, aliquots of 500 L were 
collected from each well. The samples were pelletted by centrifugation (13 000 rpm for 10 min. at 
4°C), supernatants were discarted and the pellets were frozen at –20°C. 
1                       2                         3                         4                         5                       6 
LB medium + 
medium boosters 
+ IPTG 
 
LB medium + 
medium boosters 
+ IPTG 
 
LB medium + 
medium boosters 
EnBase MSM10 
+ medium 
boosters +  IPTG 
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+ medium 
boosters +  IPTG 
 
EnBase MSM10 
+ medium 
boosters 
 
LB medium + 
IPTG 
 
LB medium + 
IPTG 
LB medium  EnBase MSM10 
+ IPTG 
 
EnBase MSM10 
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IPTG 
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D 
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After overnight growth (16-20 hours), the EnBaseTM cultures were supplemented with a “booster 
solution”, providing additional complex medium additives and glucoamylase; product synthesis was 
simultaneously induced by addition of IPTG (15 M final concentration). 24 hours after induction, 
aliquots of the EnBaseTM cultures were withdrawn for OD600 measurement. For total protein 
analysis, aliquots corresponding to a 500 L culture with OD600 of 0.7 were harvested and treated 
as descibed for LB samples. For the soluble and insoluble fractions analysis, the volume of each 
EnBaseTM sample was calculated so that the resulting cell density was the same in all LB and 
EnBaseTM samples. The samples were pelletted by centrifugation (13 000 rpm for 10 min. at 4°C), 
supernatants were discarted and the pellets were frozen at –20°C. 
 
Expression of hKAT II with EnBaseTM Flo Optiset (Biosilta). Four different media were used for 
bacteria growth: 1) Luria-Bertani (LB) medium; 2) EnBase Flo-02 medium, 3) EnBase Flo-10 
medium and 4) EnBase Flo-20 medium. For each medium variant, the conditions for testing were 
differentiated by the presence or absence of inducers (IPTG or lactose) and medium boosters. 
Therefore, 24 different growth conditions were tested, as indicated with colours in the plate layout 
2:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enbase Flo-02 medium: wells A1-A6, green. 
EnBase Flo-10 medium: wells B1-B6, yellow. 
EnBase Flo-20  medium: wells C1-C6, red. 
Standard medium (LB): wells D1-D6, white. 
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medium bosters 
+ IPTG 
 
EnBase Flo-02 + 
medium boosters 
+ lactose  
EnBase Flo-02 + 
medium boosters 
A 
 
 
 
 
B 
 
 
 
 
C 
         
 
 
 
D 
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The growth process was the same as that described above, except for the incubation temperature 
and time. Growth was carried out at 15°C and induction with IPTG or lactose was at 2 hours and 
about 18 hours for the control (LB medium) and the optimized EnBaseTM Flo media, respectively. 
Cell samples were harvested at 4 hours and about 48 hours after induction for the control and the 
optimized EnBaseTM Flo media, respectively. For each growth conditions, samples for total and 
soluble protein analysis were collected as previuosly described. 
 
Analysis of the soluble fraction after cellular lysis. Cell pellets were suspended in 500 L of 20 
mM Tris-HCl, pH 8.0, 50 mM NaCl, 40 M PLP and then disrupted by three freezing (-20°C) and 
thawing (42°C) cycles. Cellular lysis was then carried out by adding to each sample 50 L of a 
fresh made 10 mg/mL lisozyme solution, samples were incubated at 37°C for 20 minutes. 
Complete cells disruption was ensured by one minute of sonication on ice. To obtain the soluble 
protein fraction, the disrupted cell solution was centrifuged at 13,000 rpm for 10 min. at 4°C. 
Pellets were resuspended in 50 L of sample buffer, whereas supernatants were concentrated 
using Vivaspin 10,000 (Sartorius) up to 30 L final volume; then 20 L of sample buffer were 
added to the concentrated supernatants and soluble protein fractions were analysed by SDS-
PAGE and Western Blotting.  
 
Western Blotting procedure. Sample proteins were first separated by SDS-PAGE, then blotted 
using Chemichrome Western Control (Sigma C4236) or ProSieve Color Protein Markers (Lonza 
50550) as control. A sheet of nitrocellulose membrane and four pieces of filter paper were soaked 
in transfer buffer (48 mM Tris, 39 mM glycine, 1.3 mM SDS, 20 % methanol, pH 9.0-9.4). The gel 
and membrane were gently pressed together by using a Pasteur pipette as a rolling pin to avoid 
the occurence of air pockets between the “sandwich” layers. By applying electric current (30 
minutes at 10 Volt), proteins were trasferred from the gel to the nitrocellulose membrane, retaining 
the same separation pattern they had on the gel. The blotted membrane was washed with TBST 
solution (Sigma T94447) and then incubated overnight at room temperature with a commercial 
solution containing milk proteins (TBS with 3% fat milk, Sigma T8793). TBS solution was then 
discarted and the membrane washed with TBST solution. The colorimetric detection of the target 
recombinant protein was carried out using monoclonal anti-polyHistidine antibodies conjugated 
with peroxidase (dilution 1:20 000) and TMB as substrate (Sigma PQ0101). 
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Results 
Expression of hKAT II with EnBase Optiset (BioSilta). 
The growth process was performed as indicated in the protocol included in the kit, inoculating the 
24-wells plate with cells obtained from a fresh-made LB-agar plate. LB broth was used as standard 
medium. For each medium variant, protein expression was tested either in the absence and 
presence of medium boosters and IPTG. Therefore, 16 different growth conditions were tested, as 
marked in plate layout 1. Growth was carried out at 30°C and induction with IPTG (15 M final 
concentration) was at 2 hours and about 18 hours for the control and the optimized EnBaseTM 
media, respectively. Cell samples were collected after 4 hours and about 18 hours induction for the 
control and the optimized EnBaseTM media, respectively. The presence of the target protein was 
assayed by SDS-PAGE and Western Blotting on the total amount of cellular proteins and on the 
soluble and insoluble fractions. The volume of each sample was calculated so that the resulting 
cell density was the same in all samples. Therefore, protein productivity per cell in different 
samples can be directly compared on the basis of the protein band thickness. EnBaseTM Optiset 
allowed a 5-fold increase in the amount of cells present at the end of the induction. Normalized 
results show a further 2-3 fold increase in the amount of total protein. Taken together these data 
indicate a 10-15 fold increase in protein yield. Results demonstrated that sigificant improvements in 
protein yield can be achieved by this new culture method, but unfortunately, the analysis of the 
soluble fractions (figure 2) showed that almost all the target protein was in the pellet. As also the 
standard medium LB did not show any protein in the soluble fraction, the growth temperature 
(30°C) was likely too high with respect to that normally used, 22°C. Therefore, we repeated the 
expression tests at a lower temperature (15°C), using an updated version of Opiset BioSilta, which 
contains no more gel-based media, but three different variants of the liquid EnBase Flo medium. 
Low temperature may trigger the production of intracellular chaperone type proteins, which may 
further improve protein folding during synthesis or refolding after synthesis. 
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Figure 2.  Analysis of the soluble and insoluble fractions after cellular lysis. 
Recombinant hKAT II was produced in EnBaseTM Optiset (Biosilta) 24-well plate format using 4 
different culture media. To facilitate direct comparison between different culture media, all samples 
were diluited to equal cell concentration before cell lysis and loading on a gel. M = ProSieve Color 
Protein Markers (Lonza 50550). His-tagged recombinant proteins were used as control: AGXT = 3 
g of alanine-glyoxilate aminotransferase, hKAT II = 7 g of recombinant hKAT II. The different 
growth conditions are indicated in plate layout 1 (A1=MSM2, A2=MSM2 + IPTG, B1= MSM2 + 
booster mixture, B2=MSM2 + booster mixture + IPTG. C1=MSM10, C2=MSM10 + IPTG, 
D1=MSM10 + booster mixture, D2=MSM10 + booster mixture + IPTG. A4=Flo, A5=Flo + IPTG, 
B4=Flo + booster mixture, B5=Flo + booster mixture + IPTG. C4=LB, C5=LB + IPTG, D4=LB + 
booster mixture, D5=LB + booster mixture + IPTG). For each growth condition, soluble and 
insoluble fraction are indicated as “S” and “P”, respectively.  
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Expression of hKAT II with EnBaseTM Flo Optiset (Biosilta). 
Expression procedures were carried out following the usual protocol, inoculating the 24-wells plate 
with cells coming from a fresh-made LB-agar plate. Growth was carried out at 15°C and induction 
with IPTG or lactose was at 2 hours and about 18 hours for the control (LB medium) and the 
optimized EnBaseTM Flo media, respectively. Cell samples were harvested at 4 hours and about 48 
hours after induction for the control and the optimized EnBase TM Flo media, respectively. In 
addition to decreasing the culture temperature, we tried induction with lactose (0.5 mg/mL final 
concentration), instead of IPTG. Some limited data (private comunications from BioSilta company) 
indicate that lactose might be a slower inducer than IPTG, and this could be beneficial for soluble 
expression of the target protein. As in the Optiset 24-wells plate there are three parallel wells for 
each medium variant, we omitted the addition of inducer in one well, induced with lactose in one of 
them and with IPTG (15 M final concentration) in the last one. Therefore 24 different growth 
conditions were tested, as shown in plate layout 2. For each growth condition, total and soluble 
protein samples were analyzed by SDS-PAGE and Western Blotting. EnbaseTM Flo Optiset allowed 
a 3-fold increase in the amount of cells present at the end of induction. Normalized results show a 
further 2-3 fold increase in the amount of total protein. Taken together data indicate a 6-9 fold 
increase in protein yield. Unfortunately, the analysis of the soluble fraction after cellular lysis (figure 
3), showed that even at decreased temperature almost all the target protein aggregated in 
inclusion bodies. Thus, reducing the growth temperature is not an adequate strategy to improve 
the expression of our target protein in a soluble form. Different strategies aimed at optimizing the 
heterolous expression of recombinant hKAT II in a soluble form should be taken into account. 
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Figure 3.  Analysis of the soluble and insoluble fractions after cellular lysis. 
Recombinant hKAT II was produced in EnBaseTM Flo Optiset (Biosilta) 24-well plate format using 4 
different cultivation media. To facilitate direct comparison between different cultivation media, all 
samples were diluited to equal cell concentration before cell lysis and loading on a gel. M = 
Chemichrome Western Control (Sigma C4236) or ProSieve Color Protein Markers (Lonza 50550). 
The different cultivation conditions are indicated in plate layout 2 (A1=Flo-02 + booster mixture, 
A2=Flo-02 + booster mixture + lactose, A3= Flo-02 + booster mixture + IPTG, A4=Flo-02, A5=Flo-
02 + lactose, A6=Flo-02 + IPTG. B1=Flo-10 + booster mixture, B2=Flo-10 + booster mixture + 
lactose, B3=Flo-10 + booster mixture + IPTG, B4=Flo-10, B5=Flo-10 + lactose, B6=flo-10 + IPTG. 
C1=Flo-20 + booster mixture, C2=Flo-20 + booster mixture + lactose, C3=Flo-20 + booster mixture 
+ IPTG, C4=Flo-20, C5=Flo-20 + lactose, C6=Flo-20 + IPTG. D1=LB + booster mixture, D2=LB + 
booster mixture + lactose, D3=LB + booster mixture + IPTG, D4=LB, D5=LB + lactose, D6=LB + 
IPTG. For each cultivation condition, soluble and insoluble fraction are indicated as “S” and “P”, 
respectively.  
  
Discussion   
The expression system for hKAT II synthesis in bacterial host has been developed and optimized 
by our collaborators Proff. Franca Rossi and Menico Rizzi, Università Piemonte Orientale. 
However, the protein yield (about 1.5 mg from 2 litre culture broth) is still too low and most of the 
protein is inside inclusion bodies. As a part of the activities carried out during the thesis, we have 
carried out several unsuccesful attemps to increase the expression yield of hKAT II in a soluble 
form. The avaibility of higher amounts of hKAT II, together with the activity assays previously 
described, are useful in the development of anti-schizophrenic and pro-cognitive drugs. 
Cultures for recombinant protein production in shake flasks as a batch process often lead to 
oxygen limitation, medium acidification, and overflow metabolism. High cell densities are not 
routinely reached in this batch process and consequently low product yield rates occurs. By 
contrast, in the feed-batch process used in industrial bioreactors, the microbial growth is controlled 
by substrate limitation to avoid inhibitory effects and provide high cell densities and high product 
yields. In typical bioreactor process the main substrate feed, mostly glucose, is added by a pump. 
In EnBaseTM  no external glucose feed is required, but glucose is released in into the growth 
medium by enzymatic degradation of starch. Starch is supplied directly dissolved in the medium or 
embedded in a gel from which it slowly diffuses into the growing culture suspension. The potential 
of the system is that the microbial growth rate and oxygen consumption can be simply controlled 
by the amount, and principally by the activity, of the starch degrading enzyme glucoamylase. By 
utilising controlled growth within EnBaseTM, accumulation of growth limiting compounds from 
overflow metabolism, and oxygen starvation can be significantly reduced or eliminated. The 
EnBaseTM technology based on catalytically controlled glucose delivery results in controlled growth 
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of E.coli to high cell densities and enhanced protein production. The 24-deep well plate of the 
Optiset enables a direct comparison between the traditional expression method and three different 
EnBaseTM media and also includes growths with an additional boosting step. We tried the first 
version of BioSiltaTM Optiset for the expression of hKAT II. Results indicated a 10-15 fold increase 
in protein yield, therefore sigificant improvements in protein yield can be achieved by this new 
culture method. Unfortunately, we did not succeed in the expression of the target soluble protein as 
all the proteins accumulated in inclusion bodies. One possible reason for this was the induction 
temperature: the standard protocol is optimized at 22 °C for 48 h, while we have tried Optiset at 30 
°C, following exactly the protocol of the kit. Inclusion bodies are insoluble aggregates of misfolded 
protein lacking biological activity. Although the reasons for inclusion bodies formation are not well 
understood, two factors that might contribute are the rate of translation and the rate of protein 
folding, which are almost an order of magnitude faster in E.coli as compared with eukaryotic 
systems (9). It is well known that a reduced growth rate usually leads to more soluble expression 
and hence reduces the tendency to form inclusion bodies. A well known technique to limit the in 
vivo aggregation of recombinant proteins consist of growth at low temperature (10). Moreover, 
aggregation reactions are in general favoured at higher temperatures due to the strong 
temperature dependence of hydrophobic interactions that determine the aggregation reactions 
(11). In order to improve the fraction of soluble protein, we tried the recent version EnBaseTM Flo 
Optiset, using a lower temperature, 15 °C and collecting samples after 48 hours of induction. Final 
protein yield with EnBase Flo media was about 6-9 fold higher than that obtained with the standard 
medium LB, but, even with growth at reduced temperature, the formation of inclusion bodies 
occured. EnBaseTM guarantees more cells, due to the enzymatic glucose release and a well-
balanced combination of mineral salts and complex medium additives, which provide high cell 
densities. The increased specific protein yield, measured as soluble or active protein per cell and 
better solubility, is depending on the expression system. If the reason for inclusion bodies 
formation is the stress due to oxygen limitation or too fast growing cells, then EnBaseTM might be 
the solution for improvement of solubility. With EnBaseTM the following parameters can be 
optimised to increase the solubility: inducer concentration, temperature (EnBaseTM is working up to 
10°C), medium composition (percentage of complex additives) and growth rate (controlled in a fed-
batch manner by glucoamylase concentration). Should these modifications prove insufficient to 
increase soluble expression, more comprehensive strategies can be considered. These include the 
use of fusion tags, co-expression with chaperones or other folding-machinery components, and the 
use of an alternative host organism. Another possible strategy is refolding from inclusion bodies, 
but this procedure is in many cases considered undesiderable. The major obstacles are the poor 
recovery yields, the requirements for optimization of refolding conditions for each target protein and 
the possibilty that the resolubilization procedures could affect the integrity of the refolded proteins. 
In addition, the purification of highly expressed soluble protein is less expensive and time 
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consuming than refolding and purification from inclusion bodies (10). One of the most successfull 
methods used to improve soluble expression of aggregation prone proteins consist in engineering 
the target protein with solubility fusion tags (12). These tags are protein or peptides that are fused 
to the protein of interest and, in the best case, help to properly fold their partners leading to 
enhanced solubility of the target protein (13, 14). Among the most potent solubility enhancing 
proteins characterized to date are the E.coli maltose binding protein (MBP), N-utilizing substance A 
(NusA), thioredoxin (Trx) and glutathione-S-trasferase (GST). Both MBP and GST have an 
additional benefit in that they can function as affinity tags to facilitate the purification process. 
However, E.coli MBP proved to be a much more effective solubility partner than the highly soluble 
GST and thioredoxin proteins (15). A precise mechanism for the solubility enhancement of MBP 
has not been found. However, MBP might act as a chaperone by interactions through a solvent 
exposed “hot spot” on its surface which stabilizes the otherwise insoluble target protein (16, 17). 
Numerous examples of MBP and NusA as functional solubility enhancers are found in the literature 
(10, 18, 19). Aggregation of recombinant proteins overexpressed in bacterial cells could results 
either from accumulation of high concentration of folding intermediates or from inefficent 
processing by molecular chaperones. Another possible strategy for the prevention of inclusion 
body formation is the co-overexpression of chaperone encoding genes and the recombinant target 
protein. Some chaperones drive folding attemps, whereas others prevents protein aggregation (20-
22). Numerous E.coli specialized host strains have been developed to improve soluble expression 
of aggregation prone proteins. Recently, a novel improved BL21(DE3) host strain, called 
SoluBL21, has been developed and it’s now commercially available by amsbio (AMS 
Biotechnology). The SoluBL21 strain contains mutations that make this strain able to express 
insoluble proteins in a soluble form, fully or partially, in most tests conducted. 
In conclusion, hKAT II recombinant expression with EnBaseTMTM Optiset demonstrated that 
sigificant improvements in protein yield can be achieved by this new culture method. Nevertheless, 
other steps are necessary in order to overcome the protein propensity for aggregation in inclusion 
bodies. One or more strategies listed above could be applied in the future to enhance protein 
solubility. 
 
Optimization of hKAT II heterologous expression      
 139 
REFERENCES 
 
1. Panula-Perala, J., Siurkus, J., Vasala, A., Wilmanowski, R., Casteleijn, M. G., and 
Neubauer, P. (2008) Enzyme controlled glucose auto-delivery for high cell density 
cultivations in microplates and shake flasks, Microbial cell factories 7, 31. 
2. Krause, M., Ukkonen, K., Haataja, T., Ruottinen, M., Glumoff, T., Neubauer, A., Neubauer, 
P., and Vasala, A. A novel fed-batch based cultivation method provides high cell-density 
and improves yield of soluble recombinant proteins in shaken cultures, Microbial cell 
factories 9, 11. 
3. Vasala, A., Panula, J., Bollok, M., Illmann, L., Halsig, C., and Neubauer, P. (2006) A new 
wireless system for decentralised measurement of physiological parameters from shake 
flasks, Microbial cell factories 5, 8. 
4. Overton, T. W., Griffiths, L., Patel, M. D., Hobman, J. L., Penn, C. W., Cole, J. A., and 
Constantinidou, C. (2006) Microarray analysis of gene regulation by oxygen, nitrate, nitrite, 
FNR, NarL and NarP during anaerobic growth of Escherichia coli: new insights into 
microbial physiology, Biochemical Society transactions 34, 104-107. 
5. Salmon, K. A., Hung, S. P., Steffen, N. R., Krupp, R., Baldi, P., Hatfield, G. W., and 
Gunsalus, R. P. (2005) Global gene expression profiling in Escherichia coli K12: effects of 
oxygen availability and ArcA, The Journal of Biological Chemistry 280, 15084-15096. 
6. Jung, G., Denefle, P., Becquart, J., and Mayaux, J. F. (1988) High-cell density fermentation 
studies of recombinant Escherichia coli strains expressing human interleukin-1 beta, 
Annales de l'Institut Pasteur 139, 129-146. 
7. Konstantinov, K., Kishimoto, M., Seki, T., and Yoshida, T. (1990) A balanced DO-stat and 
its application to the control of acetic acid excretion by recombinant Escherichia coli, 
Biotechnology and bioengineering 36, 750-758. 
8. Shiloach, J., and Fass, R. (2005) Growing E. coli to high cell density--a historical 
perspective on method development, Biotechnology advances 23, 345-357. 
9. Chatterjee, D. K., and Esposito, D. (2006) Enhanced soluble protein expression using two 
new fusion tags, Protein expression and purification 46, 122-129. 
10. Sorensen, H. P., and Mortensen, K. K. (2005) Soluble expression of recombinant proteins 
in the cytoplasm of Escherichia coli, Microbial cell factories 4, 1. 
11. Kiefhaber, T., Rudolph, R., Kohler, H. H., and Buchner, J. (1991) Protein aggregation in 
vitro and in vivo: a quantitative model of the kinetic competition between folding and 
aggregation, Bio/technology (Nature Publishing Company) 9, 825-829. 
12. Esposito, F., Fogliano, V., Cardi, T., Carputo, D., and Filippone, E. (2002) Glycoalkaloid 
content and chemical composition of potatoes improved with nonconventional breeding 
approaches, Journal of agricultural and food chemistry 50, 1553-1561. 
Optimization of hKAT II heterologous expression      
 140 
13. Makrides, S. C. (1996) Strategies for achieving high-level expression of genes in 
Escherichia coli, Microbiological reviews 60, 512-538. 
14. Sorensen, H. P., and Mortensen, K. K. (2005) Advanced genetic strategies for recombinant 
protein expression in Escherichia coli, Journal of Biotechnology 115, 113-128. 
15. Kapust, R. B., and Waugh, D. S. (1999) Escherichia coli maltose-binding protein is 
uncommonly effective at promoting the solubility of polypeptides to which it is fused, Protein 
Sci 8, 1668-1674. 
16. Bach, H., Mazor, Y., Shaky, S., Shoham-Lev, A., Berdichevsky, Y., Gutnick, D. L., and 
Benhar, I. (2001) Escherichia coli maltose-binding protein as a molecular chaperone for 
recombinant intracellular cytoplasmic single-chain antibodies, Journal of Molecular Biology 
312, 79-93. 
17. Fox, J. D., Kapust, R. B., and Waugh, D. S. (2001) Single amino acid substitutions on the 
surface of Escherichia coli maltose-binding protein can have a profound impact on the 
solubility of fusion proteins, Protein Sci 10, 622-630. 
18. Smyth, D. R., Mrozkiewicz, M. K., McGrath, W. J., Listwan, P., and Kobe, B. (2003) Crystal 
structures of fusion proteins with large-affinity tags, Protein Sci 12, 1313-1322. 
19. Goh, L. L., Loke, P., Singh, M., and Sim, T. S. (2003) Soluble expression of a functionally 
active Plasmodium falciparum falcipain-2 fused to maltose-binding protein in Escherichia 
coli, Protein expression and purification 32, 194-201. 
20. Hartl, F. U., and Hayer-Hartl, M. (2002) Molecular chaperones in the cytosol: from nascent 
chain to folded protein, Science (New York, N.Y 295, 1852-1858. 
21. Mogk, A., Mayer, M. P., and Deuerling, E. (2002) Mechanisms of protein folding: molecular 
chaperones and their application in biotechnology, Chembiochem 3, 807-814. 
22. Schwarz, E., Lilie, H., and Rudolph, R. (1996) The effect of molecular chaperones on in 
vivo and in vitro folding processes, Biological Chemistry 377, 411-416. 
 
 
LIST OF PUBLICATIONS 
 
Elisabetta Passera, Barbara Campanini, Franca Rossi, Valentina Casazza, Menico Rizzi, 
Roberto Pellicciari, and Andrea Mozzarelli. Human kynurenine aminotransferase II: 
reactivity with substrates and inhibitors. Manuscript submitted. 
 
Ileana Ramazzina, Stefano Amato, Elisabetta Passera, Stefano Sforza, Gianni Mistrello, 
Rodolfo Berni and Claudia Folli. Recombinant production and characterization of the lipid 
transfer protein from pear (Pyr c 3), an allergen with an in vivo low allergenic potential. 
Manuscript submitted. 
 
 
